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RESUMO 
O objetivo deste trabalho foi o de elaborar e validar um novo método de rastreio de fármacos e 
drogas presentes em amostras de sangue. Rastreios direcionados, semi-direcionados e não-
direcionados foram realizados em 55 amostras de sangue proveniente de casos forenses. Todas as 
matrizes provieram de relatórios medico-legais de casos antemortem and postmortem. 
Ionização por electrospray, no modo positivo, foi util izada como fonte de iões. A deteção foi 
feita com base numa aquisição de alta resolução de massa exata realizada por um espectrómetro de 
massa de tempo-de-voo. Todos os dados foram processados com recurso ao UNIFI1.7
TM
 e adquiridos 
através de uma abordagem de varredura completa, com base numa aquisição independente de 
dados. 
No rastreio direcionado, uma biblioteca comercial de 1030 compostos de relevância fármaco-
toxicológica foi adotada. Um total de 231 ocorrências possibilitou a identificação de 103 fármacos, 
drogas e metabolitos. 119 ocorrências foram confirmadas por análises paralelas de triplo quadrupólo. 
O método foi avaliado em termos de sensibilidade e especificidade.  
Uma biblioteca semi-direcionada contendo 1392 compostos de relevância fármaco-toxicológica 
não-comuns foi estruturada com base nos resultados do rastreio direcionado. O tempo de retenção foi 
excluído da informação dos compostos considerados para análise. Os compostos suspeitos foram 
recolhidos a partir da literatura e de outras fontes científicas/recreativas. No rastreio semi-direcionado 
foram identificados 15 compostos suspeitos, distribuídos por 21 ocorrências. A presença de 3 dos 
suspeitos foi confirmada pela análise das respetivas soluções padrão. A capacidade de previsão do 
padrão de fragmentação por parte do UNIFI1.7
TM
 foi avaliada. Uma ocorrência suspeita provou ter 
elevada probabilidade de corresponder a uma “designer drug”.  
Um rastreio não-direcionado adquiriu a massa exacta correspondente a ocorrências 
desconhecidas. Uma pesquisa invertida foi aplicada às massas exactas através da predição de 
fórmula molecular por parte do UNIFI1.7
TM
. As estruturas moleculares de um composto endógeno e 
de um composto de relevância fármaco-toxicológica foram elucidadas. 
 
Palavras-chave: rastreio direcionado, rastreio semi-direcionado, rastreio não-direcionado, espectrometria de massa de 
tempo-de-voo, alta resolução, massa exata, aquisição independente de data, fármacos, drogas de abuso, “designer drugs”. 
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ABSTRACT 
The objective of this work was to formulate and validate a new screening method for 
legal and illegal drugs, which presence is in whole blood. Targeted, semi-targeted and non-
targeted screenings in 55 blood samples from forensic cases. All matrixes were provided 
from medico-legal antemortem and postmortem case reports. 
Electrospray ionization (ESI), in positive mode, was used as ion source. Detection was 
based on a high resolution accurate mass (HR/AM) acquisition provided by time-of-flight 
mass spectrometry (TOF/MS). All data was processed using UNIFI1.7TM and acquired 
through a full scan approach based on data-independent acquisition (DIA). 
In targeted screening, a commercially available library containing 1030 common 
pharmaco-toxicological relevant compounds (PTRCs) was adopted. A total of 231 hits made 
possible the identification of 103 drugs and metabolites. 119 hits were confirmed by parallel 
analysis with triple quadrupole (MS/MS). The method was evaluated in terms of sensitivity 
and specificity. 
A semi-targeted library containing 1392 non-common PTRCs was assembled, 
excluding retention time (RT) from the information of the compounds considered for analysis. 
Suspects were gathered from literature and other scientific/recreational sources. Semi-
targeted screening identified 15 suspect compounds, distributed by 21 hits. 3 compounds 
were confirmed by the respective pure standards. UNIFI1.7TM capacity of fragmentation 
pattern prediction was evaluated. A highly probable designer drug hit was semi-targeted 
identified. 
A non-targeted screening acquired exact mass of unknown hits. A reverse search was 
applied in AMs by prediction of molecular formula by UNIFI1.7TM. The molecular structures of 
one endogenous compound and one PTRC were elucidated. 
 
Key-words: targeted screening, semi-targeted screening, non-targeted screening, TOF/MS, HR/AM, DIA, PTRC, 
designer drug. 
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1 INTRODUCTION 
1.1 RKA 
This project was carried out in the Section of Forensic Chemistry, Department of 
Forensic Medicine, University of Copenhagen or simply abbreviated RKA. 
The department provides a wide offer of toxicological analysis. As such, it undergoes 
about 600 medico-legal autopsies per year, analyzes about 1800 driving under the influence 
of drugs (DUID) cases, in complementarity to around 10000 driving under the influence of 
alcohol cases. 
Additionally, the department examines around 1000 police drug related seizures and 
about 400 violence and rape cases. 
The geographical area covered by 
RKA comprehends eastern Denmark 
(Zealand, surrounding islands and Bornholm) 
highlighted in dark green in Figure 1.1. 
The population served by this 
forensic department is of approximately 2.4 
million, from a total of 5.6 million that 
represent all of Denmark and its 
dependencies. 
The biological matrixes toxicologically analyzed in a routinely basis are blood, urine, 
muscle and hair samples. 
It is expected that a toxicological analysis covers all compounds and to achieve the 
closest results to that premise a conjugation of methods is performed. As a standard 
screening setup, two methods based on liquid chromatography time-of-flight mass 
Figure 1.1 Map of Denmark. 
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spectrometry (LC-TOF-MS) are coordinated to provide unambiguous detection and 
identification of pharmaco-toxicologically relevant compounds (PTRC). 
With respect to whole blood samples, the 5 validated and routinely used methods for 
screening are present in Figure 1.2’s diagram. 
The green segment of Figure 1.2 is what was meant to be upgraded in the project. At 
first instance, the main improvements were the reduction of the needed sample volume (pre-
sample preparation) from 200 μL to 100 μL; the increase of compounds in the targeted 
database, from 400 to 1030 basic drugs; and the implementation of semi and non-targeted 
screening approaches. 
 
1.2 Systematic Toxicological Analysis 
Systematic toxicological analysis (STA) is the general search for pharmaco-
toxicologically relevant compounds in a biological sample. The array of matrixes comprises 
human blood, urine, organ tissue and hair. The screening is performed without prior 
analytical information concerning the presence and category of the xenobiotic poison [1-5]. 
Due to the enormous number of possible PTRCs and their metabolites (most of the times 
present in very low concentrations) and because of the complexity of the matrixes, general 
unknown screening (GUS) is credited as one of the most difficult tasks in the field of 
analytical chemistry 
[1]
. 
It is possible to categorize PTRCs in 4 groups: toxic gases, volatile substances, metal 
ions and, the largest category (and the one of relevance for this thesis), organic compounds 
with low volatility. To the latter subdivision it can be appointed: pesticides, chemical reagents, 
alkaloids and drugs for therapeutic uses and purposely synthesized or traded with illegal 
intentions [1]. 
This project´s targeted screening is restricted to scan for small molecules pertaining 
to the drugs (of abuse/legal) sub-category. Complementarily, the semi-targeted and non-
targeted approaches provide a screening platform for all types of organic compounds with 
low volatility. 
Figure 1.2 Outline of five different methods employed for screening and quantification purposes in toxicological analysis of 
whole blood samples. 
Targeted, semi-targeted and non-targeted screening for drugs in whole blood by UPLC-TOF-MS 
with data-independent acquisition (DIA) 
3 
Today, STA of non-volatile organic small molecules starts with an appropriate and 
fast sample preparation for wide extraction of as many compounds as possible from the 
complex and frequently complicated matrixes [1]. Most remarkably, the analytical process that 
follows has suffered a great degree of alteration in the past few decades [1-5]. 
Nowadays, forensic samples will initially be directed to immunochemical techniques, 
including non-instrumental on-site (performed by police officers) and instrumental format. 
This initial stage is not limited to immunoassays, being complemented by more capable 
screening techniques employing gas chromatography with mass spectrometry (GC-MS) and 
high performance liquid chromatography with diode array detector (LC-DAD) [5] and more 
recently LC-MS [1-6]. These screening procedures mainly concern is to provide a yes or no, 
rapid-response based on threshold concentration; or the provision of more elaborated 
qualitative and even semi-quantitative information, in the case of chromatography-detector 
methods. Especially when employed LC-MS methods [6]. 
In the case of a positive result in the screening step, an additional 2nd stage is 
employed were the same sample is subjected to a confirmatory method that provides a 
higher level of confidence in the result. Generally, the additional selective confirmation and 
quantification is carried out by GC-MS or LC-MS/MS [6]. 
From the conjugation of high sensitivity and selectivity of their MS detectors and the 
availability of extensive libraries of standardized electron impact (EI) mass spectra, GC-MS 
has long been considered as the gold standard for STA [5]. 
Nevertheless, the application of the method above is confined to the screening of 
volatile, thermally stable and non-polar compounds. For instance, analysis of urine (that 
along with blood is the most relevant toxicological matrix) is impaired due to its richness in 
polar metabolites [2]. 
Indeed, an additional and related disadvantage of GC-MS is the time-consuming and 
labor-intensive compound derivatization needed for analysis of low-volatile and polar 
analytes [2]. The previously stated HPLC-DAD may alleviate the referred GC-MS constrains, 
however at the cost of detection power, as DAD is not as specific as MS detectors. 
Additionally sensitivity may also be compromised as DAD fails to detect molecules with no or 
little UV (ultra-violet) absorbance [5]. To troubleshoot this impasse, in the last decade several 
advances have been made in liquid chromatography (LC) combined with mass spectroscopy 
(LC-MS or/and LC-MS-MS) and with convenient ions sources such as electron spray 
ionization (ESI) or atmospheric pressure chemical ionization (APCI) [1]. 
Although LC-MS GUS has become well accepted as a confirmatory tool, screening 
methods employing this instrument are not as established as the two previous methods [5]. 
Several methodologies have been published such as single-stage MS detection (LC-MS) 
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combined with reference libraries [7]; ion trap (LC-IT/MS) [4] and tandem mass spectrometry 
(LC-MS/MS) [8]. However no single technique has conciliated sufficient specificity and the 
capability of screening for complete unknown chemicals. The majority of LC-MS approaches 
simply targets chromatographic and spectral information against a panel of compounds and 
their respective nominal masses. The reduced number of commercial libraries and their 
incompatibility for instruments of different brands, further complicates targeted screening. 
Additionally, one of the limitations of using nominal mass is that not enough resolving power 
is provided for an efficient non-targeted screening 
[1, 2, 5]
. 
In an attempt to address the issue, time-of-flight/mass spectroscopy (TOF/MS) 
technology have been developed in order to provide compatibility of this instrument with the 
STA context. The interest on this method derives from the TOF/MS capability to assign mass 
to charge ratio (m/z) to four decimal places. Additionally and very importantly, for the non-
targeted screening, the analyzer/detector has the ability to provide m/z values to unknown 
compounds with a mass error interval of less than 5 millidalton (mDa) [9]. This provides the 
possibility to assign a unique elemental molecular formula based on the mass sufficiency of 
each constituent atom and on the pattern between the isotopes of the protonated ion present 
in the spectrum [5]. 
With the highlighted properties, methods 
like the one developed in the this thesis, which 
employed instrumentation and software present 
in Figure 1.3, are expected to provide 
systematic toxicological analysis (same as 
general unknown screening) with a compound 
identification confidence and selectivity that not 
only rivals but surpasses the other 
“mainstream” LC-MS screening methods. 
 
1.3 Pharmaco-Toxicologically Relevant Compounds 
PTRCs comprise all the pertinent small molecules that should be identified in a 
general unknown screening. The less ambiguous categorization format of these compounds 
is based on their presence in the annual reports of the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) [10] and simply the amount of knowledge available concerning 
their chemical properties. 
Figure 1.3 UPLC-qTOF/MS. 
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As for this, three categories can be delineated: Pharmaceuticals, Drugs of abuse 
(catalogued) and Designer drugs (some catalogued but the vast majority absent from the 
EMCDDA “black list”). 
For agreement with this project, the three categories were converged into two, where 
the differentiation criterion was the compound’s presence/absence in the library used for 
targeted screening. 
 
1.3.1 Pharmaceuticals and drugs of abuse 
1.3.1.1 Pharmaceuticals 
Most of compounds detected in STA correspond to medical prescribed and over-the- 
counter drugs. Their molecular ions and respective metabolites corresponded to the bulk of 
the positive hits in this thesis. 
A short list of commonly identified compounds in a STA, in the forensic context, is 
present in Table 1.1. 
 
Table 1.1 Common pharmaceuticals detected in a STA. 
Pharmaceutical Toxicological information 
Paracetamol Widely used over-the-counter analgesic and antipyretic. Deliberate or accidental 
overdoses are not uncommon, probably due to w ide availability [11]. 
Diazepam A benzodiazepine w ith anticonvulsant, anxiolytic, sedative, muscle relaxant, and 
amnesic properties and a long duration of action [12]. Although not usually fatal w hen 
taken alone, overdose can ultimately lead to a state of comma [13]. 
Citalopram/Escitalopram Antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) [14]. Overdose 
deaths have been reported. It is the most dangerous of SSRIs in overdose [15]. 
Chlordiazepoxide A benzodiazepine w ith sedative/hypnotic properties. The f irst benzodiazepine 
discovered by serendipity. The drug is frequently involved in drug intoxication, 
including overdose [16]. 
Zuclopenthixol Potent neuroleptic drug of the thioxanthene class. Despite rare, occurrence of fatalities 
have been reported due to neuroleptic malignant syndrome, induced from over dosage 
[17]. 
 
Additionally, as an example of a toxicological relevant 
pharmaceutical, quetiapine is hereby illustrated (molecular 
structure displayed in Figure 1.4) in function of its importance 
for this thesis. 
Quetiapine possesses antipsychotic properties 
normally prescribed in the treatment of schizophrenia [18] and 
Figure 1.4 Quetiapine chemical 
structure. 
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bipolar disorder [19]. Additionally it acts as an antidepressant, regularly used in the treatment 
of major depressive disorder. Its major active metabolite is 7-OH-quetiapine. [20]. 
Acute over dosage generally translates in sedation and tachycardia. However, 
cardiac arrhythmia, coma and death have been reported [21]. 
 
1.3.1.2  Common drugs of abuse 
The other group of compounds screened for are drugs which are used for a 
nontherapeutic effect, which may lead to organ damage, addiction, and disturbed patterns of 
behavior. The most common are alcohol, nicotine, marijuana 
[22]
. These were not taken into 
account in this method. 
The most relevant common “street” drugs considered for this screening method were: 
opiates, opioids  and cocaine (see Table 1.2) [22]. 
 
Table 1.2 Example of common drugs of abuse. 
Class Example Toxicological information 
Opiates Morphine Main psychoactive chemical in opium and the gold standard in commercialized 
analgesics [23]. It acts directly in the central nervous system (CNS). Overdose 
cause asphyxia and death by respiratory depression [24]. 
Codeine Methylated morphine w hich occurs naturally and has a w ell-defined and 
regulated range of therapeutic applications [23]. Deaths by overdose have been 
reported due to its potential misusage for recreational purposes [25]. 
Opioids Heroin Diacetylmorphine w ith no direct psychoactive effects. It is its metabolization, in 
the brain, into 6-monoacetylmorphine (6-MAM) and morphine, that induces the 
acute transcendent state of euphoria [26]. 
Methadone Therapeutically used as an analgesic and anti-addictive in opioid detoxif ication 
[27]. Deaths of patients using prescribed methadone are normally attributable to 
combined intake w ith alcohol and/or other drugs [28]. 
Tropane 
alkaloids 
Cocaine Pow erful CNS stimulant. Biologically it functions as a SSRI and as a nonspecif ic 
voltage gated sodium channel blocker, w hich in turn causes the compound to 
produce anesthesia at low  doses [29]. Cocaine intake in high doses instigates the 
compound´s blocking effect on cardiac sodium channels and overdose may 
result in sudden cardiac death [30]. 
 
1.3.2 Designer drugs 
1.3.2.1 Designer drugs of abuse 
Per definition, designer drugs are synthetic compounds that do not occur naturally, 
which is also a characteristic of most pharmaceuticals and widely legislated drugs of abuse. 
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However the structure backbone of all three categories is often based on the structures of 
naturally occurring compounds [10]. 
What is distinctive in designer drugs is that they are a result of a chemical 
adulteration of other drugs already known to be on the illicit marker circuit (see Figure 1.5 to 
Figure 1.12). There are 8 principal classes of designer drugs: aminoindanes, synthetic 
cathinones, phenethylamines, phenylcyclohexylamines, piperazines, pyrrolidinophenones, 
synthetic cannabinoids, tryptamines. Descriptive diagrams for each group are presented in 
next section: “Designer Drug Classification” [31]. 
The development and synthesis of novel drugs is either performed (inadvertently) by 
the pharmaceutical industry in the search for new pharmaceuticals or by illegal laboratories 
and vendors that intentionally seek to circumvent the legislation, as new drugs per definition 
are legal until they are classified illegal 
[10, 31]
. 
The main social impact of these “new” drugs is their availability on the Internet, sold 
as “legal highs”, “spices”, or “bath salts” in order to conceal their illegal nature [32-34]. Most 
importantly, these drugs represent a risk to abusers as there are numerous reports of 
accidental overdoses after ingesting tablets or powders with different content and/or 
repercussions not anticipated by the consumer [35-43]. 
As an example, the effects of synthetic cannabinoids (Figure 1.11) are largely similar 
to those of tetrahydrocannabinol (∆9-THC), as they have affinity for the cannabinoid 
receptors, CB1 and CB2 
[44]. However, the over-dosage risk increases with the designer drug 
intake due to their enhanced affinity with the receptors, and potency, when compared with 
natural occurring cannabis [45]. Additionally, the fact that the content of synthetic 
cannabinoids in herbal mixtures often differs from batch to batch increasing their clinical 
unpredictability, which may ultimately lead to over dosages [46]. 
In GUS context, the problem rises as in general these drugs cannot be detected in 
common drug screening assays, mainly because the respective pure standards are not of 
easily availability (if ever synthetized). The problem is aggravated by the fact that, as 
substances become known and consequently banned, new analogues replace them making 
identification of designer drugs a challenge. This thesis will ultimately function as a new 
attempt to screen for these substances. 
 
1.3.2.2  Designer drug classification 
The hereby displayed designer drug classification provided the foundations for the in-
house assembled library in the ambit of the semi-targeted screening stage of this project 
(see section 3.2.1). 
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Aminoindanes 
Nine compounds are known to be part of this class and all of them derive from the 2-
aminoindane (2-AI) structure. The two most 
relevant designer drugs of this class are 
illustrated in Figure 1.5 along with the referred 
precursor drug [47]. 
The toxicological effect of compounds of 
this class has been reported to be entactogenic 
(empathogenic). It is very similar to the 
distinctive emotional (feeling of empathy) and 
social effect that usually follows ecstasy 
(MDMA) intake [47].  
 
 
Synthetic cathinones 
Officially reports state that there are 44 synthetically derivative compounds from 
cathinone. The small structure of this well documented illicit drug provides a good platform 
for chemical adulteration [48]. 
Synthetic cathinones are frequently found in products sold in powder, pill or capsule 
and labeled as “plant food”, “bath salts” or “glass cleaner”. The “new age” synthetic drugs of 
this class are: mephedrone (“m-cat” or “miaow”) 
and methylone (“top cat”); both present in 
Figure 1.6 with the respective base structural 
compound [48]. 
The two drugs are usually available as 
white or brown powders or in the form of pills 
that are often sold as ecstasy, as their 
psychoactive effects mimic those of a 
phenethylamine. Mephedrone is commonly 
nasally insufflated, injected, ingested by swallowing a powder wrapped in paper (“bombing”), 
or mixed in a drink [48]. 
  
Figure 1.6 Cathinone based designer drugs. 
Figure 1.5 Aminoindane based designer drugs. 
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Phenethylamines 
Comprising more than 100 compounds, this category of designer dugs is probably the 
largest and the most relevant in regard to drug abuse cases, as this class is the most often 
encountered in forensic cases (RKA context) [6]. 
Compounds of this class are 
well known for their stimulating and 
hallucinogenic psychoactive effects 
[47]. 
The backbone of this category 
is shared by both phenethylamine and 
amphetamine, whose structures are 
present in Figure 1.7, along with 
some of their most relevant 
derivatives [47]. 
 
Phenylcyclohexylamines 
The backbone of this class is the 
molecular structure of 
phenylcyclohexilamine. Phencyclidine (PCP) 
and ketamine (illegal and pharmaceutical, 
respectively) are the most relevant 
phenylcyclohexanamine derivatives [2]. The 
referred compounds and other of relevance 
are present in Figure 1.8 [31]. 
This category comprises around 55 
drugs but only 8 have been reported in drug 
abuse related cases. Designer drugs of this 
class interact with many different receptor 
systems; however the predominant psychotropic effects are the anesthetic and 
hallucinogenic [31]. 
  
Figure 1.8 Phenylcyclohexilamine based designer drugs. 
Figure 1.7 Phenethylamine/Amphetamine based designer drugs. 
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Piperazines 
Benzylpiperazine (BZP) and Phenylpiperazine (PP) are the precursor small 
molecules behind the 11 designer drugs of this class reported so far. An example of structure 
adulteration for each parent compound is 
provided in Figure 1.9 [49]. 
Their stimulating and 
hallucinogenic psychotropic effects mimic 
those of the phenethylamine/amphetamine 
class. Indeed, piperazines are often 
encountered in MDMA tablets, either with 
sole chemical activity or in combination 
with ecstasy 
[49]
. 
 
 
Pyrrolidinophenones 
The compound that functions as 
base for this class, alpha-
pyrrolidinopropiophenone (α-PPP) is itself 
a synthetic cathinone. However, because 
at least 12 different drugs of abuse have 
been described as direct chemical 
adulterations of α-PPP, a sole class may 
be considered. Figure 1.10 illustrates the 
parent drug and the two most pertinent 
pyrrolidinophenone based designer drugs. 
The para position of the phenyl ring and 
the length of the alkyl chain (up to 6 
carbons) are the unique structure substitution sites, reported so far [50]. 
From the twelve drugs listed to be part of this class, all demonstrated to have the 
same stimulating and euphoric effects as phenethylamines. Likewise, interferences with the 
norepinephrine and dopamine neurotransmitter systems mediate the activity of psychotropic 
compounds of this class of designer drugs [50]. 
  
Figure 1.9 Piperazine based designer drugs. 
Figure 1.10 Pyrrolidinophenones based designer drugs. 
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Synthetic cannabinoids 
The chemical activity of drugs pertaining to this class is referenced to be fully or 
partially agonist for the same receptors targeted by ∆9-THC. However, the latter and its 
synthetic counterparts seldom share the same core structure (examples presented in Figure 
1.11); and accordingly to the molecular shape, 4 sub-categories can be delineated [31]: 
 
 ∆9-THC analogues, classical 
cannabinoids (e.g. HU-211) [31]; 
 “JWH” compounds, comprising 
naphthoylindole, naphthoylpurrole, 
or naphthalene structure (e.g. JWH-
007) [51]; 
 Cyclohexylphenols, e.g. CP55,940, 
inadvertently synthetized by Pfizer 
[31]
; 
 All other compounds that do not fit 
into the structural description 
mentioned in the previous groups 
but with similar psychoactive activity 
(e.g. Pravadoline) [31]. 
 
Tryptamines 
Although tryptamine itself (an endogenous neurotransmitter) does not hold a drug of 
abuse potential, its derivatives (25 different drugs reported so far) had proved otherwise. In 
this class about half of the compounds naturally occur in plants, fungi or animals. In Figure 
1.12 4 examples of non-synthetic 
tryptamine based designer drugs 
(DMT, Psilocybin, 5-MeO-DMT and 
Butofenine) and one last, 5-MeO-
DIPT, of synthetic origin are present 
[52]. 
Most of the tryptamine 
derivative drugs are substituted at the 
aromatic ring and/or at the amine 
positioned in the end of the aliphatic 
chain [52]. 
  
Figure 1.11 Synthetic cannabinoids designer drugs. 
Figure 1.12 Tryptamine derivate designer drugs. 
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1.4 Method theory 
The diagram of Figure 1.13 demonstrates the comprehensiveness of the combination 
of instruments and techniques required for the development of the projected screening 
method.  
Each topic is individualized and theoretically stressed along this chapter. 
1.4.1 Sample preparation- Automated protein precipitation 
As referred, a STA covers an array of different biological matrixes, and considering 
those that a priori are in the liquid phase, it would be inappropriate to directly inject them into 
a GC or LC system (in the case of a GUS that employs chromatography) [53]. This 
inconvenient is justified by the composition of the biological samples, where high contents of 
phospholipids (PhPL) are a major source of matrix effects (ME) in ESI [54]. Other interfering 
compounds are present in these matrixes such as salts and endogenous small molecules, 
irrelevant for the analysis, which diminish separation efficiency. However, the most relevant 
interference presence in biological matrixes is its protein content [53, 55]. 
Especially when working with plasma or whole blood, both with high amount of 
proteins, liquid chromatography columns are prone to wear because of occurrence of protein 
precipitation in the mobile phase [53, 56]. Additionally, for analyte identification and 
quantification, it is needed to intermit the protein-drug binding so the compounds of interest 
can be extracted for further analysis [57]. 
Figure 1.13 Summary diagram of instrumentation, software and methods adopted in this thesis. 
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For this reason, sample preparation is an essential part of GUS in biological matrixes, 
where the focus is to isolate analytes of interest from the unwanted remains of biological 
material. Today, the conventional techniques for the effect are: protein precipitation (PPT), 
liquid-liquid extraction (LLE) and solid phase extraction (SPE) [53, 57]. 
PPT, the technique adopted for this experiment, is the simplest, fastest and in 
controlled conditions, the most effective of the three options for STAs [58]. 
There are four different variants of this sample preparation; either by addition of 
organic solvent, acid, salt or metallic ions. Nevertheless, the first is the most widely employed 
[4, 5] and was the one adopted in this project. 
Acetone, acetonitrile (ACN), and methanol (MeOH) are common organic solvents 
used for PPT [4]. The three are miscible with water, capable of lowering the dielectric constant 
of the solution, which results in attraction between macromolecular structures, and 
consequently, electrostatic interaction between proteins will augment. Supplementary, by 
displacement of water molecules, these solvents minimize hydrophobic interactions of the 
proteins which further increase the predominance of electrostatic interactions between these 
macromolecules, ultimately causing their aggregation. Then after a centrifugal step, clear 
distinction between a precipitated protein layer below an organic phase is achievable [53, 56, 57]. 
LLE and SPE are accounted to normally provide cleaner extracts than PPT [58]. 
However under automated conditions, this disadvantage is minimized to the point that the 
latter yield better analyte extraction than its counterparts [59]. 
In this work a Tecan Freedoom Evo 200TM, a fully-automated robot represented in 
Figure 1.14, was used for the performance of all liquid handling required in a PPT sample 
preparation. In addition to the drastic decrease of time consumption and labor intensity, this 
fully-automated liquid handling also increases the extraction efficiency and the pipetting 
reproducibility, since the robot perform the task in the same way, every time. 
 
 
 
 
 
 
 
 
For further details on the operation of the robot, see section 2.3.1. 
Figure 1.14 Tecan Freedom EVO 200TM. 1, Robotic manipulator arm; 2, carrier for 96-well 
plates; 3, weighing-machine; 4, liquid Handling arm; 5, washing and tips waste station; 6, racks 
with disposable tips; 7, carrier for tubes; 8, shaking platform; 9, carrier for troughs; 10, plate 
sealer; 11, centrifuge; 12, evaporator; 13, vacuum station [59]. 
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1.4.2 Ultra-Performance Liquid Chromatography 
Chromatography is the method of choice in bio-analytical laboratories. To satisfy the 
search for a fast and controlled analyte separation, new trends of liquid chromatography 
have been employed in recent years. They involve monolith technology, fused core columns, 
high temperature liquid chromatography and ultra-performance liquid chromatography 
(UPLC). Recently, the latter has become a wide-spread separation option with focus on fast 
and sensitive assays, and was the selected chromatographic technique to tandem the 
analyzer adopted for this thesis [58]. 
UPLC is a part of the liquid chromatography category. This technology provide 
analytical access to about 80% of the chemical universe, unreachable by GC and indirectly is 
also the main responsible for the phenomenal growth and interest in mass spectroscopy [60].  
In its simplest form, LC relies on the ability to reproduce, with great precision, 
competing interactions between analytes, the eluent (the mobile phase) and a bed of packed 
particles (the stationary phase) 
[60]
. 
Over the past few decades, technological developments allowed better sealing and 
pumps, able to hold higher pressures, enabling UPLC columns to be packed with sub-2-
micron (µm) particles [58]. 
Accordingly to van der Deemter, Giddings and Knox theories, efficiency expressed as 
the height equivalent to a theoretical plate (H) is proportional to particle size squared. Hence, 
it is inversely proportional to the particle diameter (dp), as expressed in equation (1.1) 
[58]. 
Therefore UPLC columns, now with the possibility of being packed with particles with 
a diameter down to 1.7 µm, provide a well suited solution in the quest to improve 
chromatographic performance [58, 60]. 
 𝐻 = A +
𝐵
𝑢𝑥
+ 𝐶𝑢𝑥 = 2𝜆𝑑𝑝 +  
2𝛾𝐷𝑀
𝑢𝑥
+
𝑓(K)𝑑𝑝
2𝑢𝑥
𝐷𝑀
 (1.1) 
 
Where 𝑢𝑥 symbolizes the linear flow rate or velocity, 𝜆 the structure factor of the 
column packing material, 𝛾 is a constant termed tortuosity or obstruction factor, K is the 
retention factor for an analyte and DM is the analyte diffusion coefficient 
[58]. 
A, B and C are constants and respectively relate to multiple flow paths, longitudinal 
diffusion and finite equilibration between phases. The first term arise because molecules of 
the same analyte can elute at different times, as they can flow through different paths along 
the column. This results in band broadening and reduced efficiency. The employment of 
particles with low diameter can circumvent this problem, as it allows a more uniform flow 
through the column, thereby reducing the multiple path term (A) of equation (1.1) [61]. 
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B or longitudinal diffusion related to the analyte diffusion along the axis of the column, 
from areas of high concentration to areas where it is lower. Thus the increasing of 𝑢𝑥 will 
result in the decrease of B, as the analytes will spend less time in the column, reducing this 
term of the equation [61]. 
Finite equilibration between phases, simply called mass transfer (C), corresponds to 
the analyte equilibrium between the mobile and stationary phases. Small particle diameter 
will reduce the band broadening which exists in high performance liquid chromatography 
(HPLC) owing to the fact that analyte diffusion is not homogeneous. This occurs in certain 
larger particle size columns and lower pressure providing instruments, as some analyte 
molecules are retained in the stationary phase, whereas others continue moving forward, 
resulting in an unwanted larger value of C [61]. 
Concluding, by employing particle with lower dp, will directly reduce the constants A 
and C from equation (1.1). Additionally, it will indirectly reduce the constant B as the 
instrument is technologically capable of providing high pressure to the chromatographic 
column [61]. 
Altogether, this will result in lower values for H (also known as HEPT), which leads to 
a higher efficiency [58, 60, 61]. 
As illustrated in Figure 1.15, the efficiency of columns with smaller particles changes 
less dramatically, when the flow rate is increased. This enables a reduction in analysis time 
and enhances efficiency 
in UPLC, when 
compared to HPLC [58]. 
As provided by 
the illustration, columns 
with particles with 
diameters of 1.7 µm 
provide a higher 
efficiency than any 
other used in HPLC 
systems. 
The highest chromatographic efficiency for UPLC systems is within the mobile phase 
and analytes flow rate velocity interval comprehended between 3 to 7.5 mm/s [60]. 
Contextualizing with this project, UPLC introduced in 2004 by Waters under the 
trademark UPLCTM, offers enhanced chromatographic resolution and more intense peaks. 
This reduces the risk of peak co-elution and provides a reduced analysis time [62]. This 
minimizes one of the main constrains that influences accurate mass acquisition by a TOF 
Figure 1.15 Variation of efficiency (HEPT) in function of 𝑢𝑥 
[60]. 
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analyzer: the minimum number of points, i.e. minimum acquisition width which defines a 
peak [63]. Summarizing, narrower chromatographic peaks contribute for a more reliable and 
accurate mass (AM) detection. 
 
1.4.3 Electrospray Ionization 
In the context of LC-MS, within the ionization chamber (Figure 1.16) which is at 
atmospheric pressure, the LC eluent containing analyte and solvent molecules is introduced 
in the source, usually at the same flow rate of that selected in the LC run [64]. The typical ESI 
flow rate for toxicological analysis ranges from 0.1 to 0.6 mL/min [6, 8, 9, 59, 65, 66]. 
The eluent passes through the capillary/needle that has a high potential difference 
applied to it, opposite to that of the counter electrode and within the range of 2000 to 5000 V. 
The voltage applied in the needle will define either if the eluting analyte and solvent 
molecules will be positive or negatively ionized [64, 67]. 
The liquid protrudes from the ESI capillary metallic tip in a cone shaped fashion 
denominated “Taylor cone”, which has an excess of “molecular ions” with the pre-selected 
charge sign. The uninterrupted 
flow of charge from the metallic 
contact to the sample solution 
occurs via an electrochemical 
reaction at the surface of the 
needle. In positive ion ESI the 
dominant reaction is oxidation, 
whereas in negative ion ESI it is 
reduction [64]. 
In order to ensure analytical accuracy and reproducibility, a lock spray needle is 
present in the ion source, from where a lock mass compound is sprayed at the same time 
analyte and solvent molecules enter the chamber. Lock mass compounds are of known 
concentration and mass and are injected at a flow rate several times smaller than of that 
applied in LC and in the ESI capillary [9]. 
Currently, modern apparatus have being developed and successfully applied in order 
to avoid the drawback that the lock mass approach can originate, like ion suppression, 
potential mass interferences and solvent gradient effects [68]. 
 
Figure 1.16 Overall illustration of an electrospray ionization chamber in 
positive mode. 
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Due to the electric field gradient between electrodes and the electrostatic repulsions 
between the charged molecules within the Taylor cone, its surface reaches a tension limit, 
designated “Rayleigh” limit (Figure 1.17). At this point Coulombic repulsion of the surface 
charge will be equal to the surface tension of the solution. This event will force the charged 
particles to exit the cone. 
agglomerated in the form of 
droplets. The difference of 
potential within the ESI 
source will make the droplets 
traverse the space between 
the two electrodes 
[61, 64]
. 
The desolvation 
process and ultimately the 
formation of free analyte ions can be explained by two different but equally accepted 
mechanisms: Coulomb fission or ion evaporation [64]. 
Similarly to what takes place in the “Taylor cone” the Coulomb fission explanation 
assumes that, along the chamber’s atmosphere, the increased charge density due to solvent 
evaporation causes droplets to divide gradually into smaller ones, which eventually will only 
consist of single ions with the intended charge. The second mechanism supposes that the 
increased charge density that also results from solvent evaporation will originate Coulombic 
repulsions to overwhelm the tension in the liquid’s surface. This will ultimately release gas 
phase ions from droplets’ surface [61, 64]. 
The ion source does not only produce condensed and ultimately gas-phased charged 
analytes ([M+H]+ or [M-H]-), but also neutral species and clusters of ions containing neutrals. 
To achieve optimal desolvation, separation of the interferences and the analytes, and to 
introduce them into the vacuum at the MS entrance, two flows of neutral gas are 
continuously introduced at both ends of the ionization chamber: the sheath gas and the 
“curtain” gas [61, 64]. 
The first consists in a flow of neutral specie in the gas phase that round the needle 
tip. Strategically off-axis positioned, it contributes to the separation of ions from neutrals in 
the outer region of the spray, generally constituted by smaller, lighter and more desolvated 
droplet. This way, additionally to its role in the desolvation per se, the off-axis positioning 
maximizes the amount of desolvated analyte that enters the mass spectrometer while 
selecting against the unevaporated droplets [61, 64]. 
At the other opposite of the capillary the “curtain” gas flows between both sides of the 
MS entrance. Normally composed by molecular nitrogen, it “screens” the ionized species at 
atmospheric pressure into the MS vacuum. Furthermore, it drives neutral species away from 
Figure 1.17 Schematic of the mechanism of ionization in positive ion mode. 
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the MS orifice, and allow the entrance of charged species, as they are impelled by the 
stronger electrostatic effect induced by the referred electric field gradient [64]. 
Generally, in electrospray little fragmentation of analyte occurs and mass spectra are 
simple. However, fragmentation by ESI can be intentionally increased by collisionally 
activated dissociation, achieved by adjusting the voltage at the counter-electrode cone. This 
enables the introduction of fragments into the MS vacuum for mass analysis, which can be 
useful, for example, in determining the identification of an analyte. However, the resulting 
product ion spectra are known to be of complicated interpretation [61]. 
The ESI ionization mode duality in toxicological analysis is greatly inclined for ESI 
positive mode, as most of known toxicologically relevant compounds have basic properties. 
The negative mode is mostly used for diuretics, barbiturates, some organophosphates and 
pesticide 
[69]
. 
 
1.4.4 StepWave™ 
The analyzer employed in this thesis encloses a feature that maximizes sensitivity 
and robustness of the analytical process. The StepWaveTM assembling is based in the 
stacked ring ion guide technology. Figure 1.18 (Top) depicts an internal longitudinal plan of 
the off-axis design of this part of the instrument [70]. 
The device maximizes ion 
transmission from the ion source to the 
first quadrupole (Q) by exhausting 
neutral contaminants, excess solvent 
and high gas flow, illustrated by the red 
pointed arrows in the illustration [70]. 
This filtering step maximizes 
sensitivity by increasing the passage 
exclusivity for analyte charged 
molecules (blue pointed arrows) to the 
mass analyzer, resulting in an 
enhancement of the overall signal to 
noise ratio (S/N) up to 25 times [70]. 
The analyzer robustness is also increased as the filtration for instrument hazardous 
contaminants “sterilizes” the upper ion guide (blue arrows), which increases the longevity of 
the devices that constitute the mass spectrometer and detector [70]. 
Figure 1.18 UPLC-ESI-TOF/MS schematics with an in focus of a 
longitudinal cut view of the Off-Axis StepWaveTM [70]. 
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1.4.5 Time-of-Flight and High Resolution Mass Spectrometry  
In contrast to tandem MS instruments, TOF/MS instruments make possible a 
comprehensive registration of data. Targeted as well as non-targeted search procedures for 
drug screening can be performed on the same set of data [71]. 
TOF analyses involve accelerating a group of ions, in a brief burst, towards a 
detector. Figure 1.19 illustrates, in this experimental context, what is expected to happen 
within the analyzer. 
 
After a previous filtering by the StepWaveTM, the positively charged molecules 
originated in the source (ESI) enter the Q where each ion’s potential simply accelerates, as 
optionally, the capability to filter specific ions was not adopted in this experiment [60]. 
Then, in the collision cell two types of fragmentation energies will be applied upon the 
entering analytes (subject covered in section 1.4.6). Finally, after passage through the 
hexapole the ions enter the TOF per se. There the charged particles will be fired into a 
vacuum by a pusher. This stage is not so linear and can raise resolution problems which will 
be addressed later in this section [60]. 
In the tube, because all charged ions are subjected to the same electrical field, those 
with lower masses evidence grater velocity and a lesser time interval travelling a stipulated 
“flying” distance before striking the detector (see, equations (1.2) to (1.7)) [60]. 
The represented equation system, mathematically elucidates the role of mass (𝑚), 
time (t) and distance (d) in the detection. 
Equation (1.2) plots the kinetic energy (1/2 𝑚𝑣2, where 𝑣 is the velocity) applied by 
the pusher with an “equal” intensity to all particles, at a certain momentum or “push”. 
 
1
2
𝑚𝑣2 = 𝑞𝑈 (1.2) 
Figure 1.19 TOF/MS analyzer and the route taken by ions inside the Xevo G2-S QTofTM. 
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In theory this kinetic energy is equal to the potential energy (𝑞𝑈) of each specimen, 
being 𝑞 the individual charge of a particle and 𝑈 the electrical potential difference (or voltage) 
that should be the same at the pusher stage. However this is not strictly observable, which 
may raise problems in resolution (discussed later). 
 
Equation (1.2) can be rewrote in the form of equation (1.3) that depicts the equation 
in order to 𝑣. 
 ⇔ 𝑣 = √
2𝑞𝑈
𝑚
 (1.3) 
 
Given that  𝑣 is equal to the distance travelled over time (𝑑/𝑡), further modification of 
the equation to 𝑚 is described in equations (1.4) and (1.5). 
 √
2𝑞𝑈
𝑚
=
𝑑
𝑡
 (1.4) 
 ⇔ 𝑚 =
2𝑞𝑈
𝑑2
𝑡2 (1.5) 
 
In equation (1.5) the term 
2𝑞𝑈
𝑑2
 may be grouped as an unit-less constant if the 
molecule is in a neutral environment in terms of charge. However, in a mass spectrometer, 
molecules are ionized (in the ion source) and there is a charge gradient along the analyzer, 
turning 𝑞 into a variable. Hence, at equation (1.6) exclusively  𝑈 and 𝑑 are grouped so they 
can be simplified to the unitless constant 𝑘. 
 ⇔
𝑚
𝑞
= 𝑘𝑡2 (1.6) 
 
As for that, in equation (1.7) it can be stated that the mass with an attributed charge 
varies with the square of time. 
 
𝑚
𝑞
∝ 𝑡2 (1.7) 
 
So if a certain charged particle has a relative large mass in comparison to others, in a 
mixture, it will take more time for it to travel 𝑑. 
Concluding, the segregation and separation of the mixture of charged particles are 
made in terms of mass-to-charge ratio (m/z). The change form 𝑞 to z marks the transition 
from coulombic to the dimensionless quantity formed by dividing the mass number of the ion 
by its charge number, which is used for data presentation in a mass spectrum. 
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However, because 
in the source (ESI) the 
voltage is not evenly 
distributed along its area 
where ionization occurs, as 
illustrated in Figure 1.20, 
there will be occasions 
where particles of the same 
species, sharing the same exact mass, will travel in the vacuum at different velocities. This 
contradicts what was represented in the previous set of equations, which states that to 
particles with same mass, it will be attributed a similar kinetic energy 
[72]
. 
As illustrated by Figure 1.20, there will be peak multiplicity in the spectrogram as 
molecules with same m/z will be detected at different times. This will influence the resolving 
power (RP) of an instrument [72]. 
Certain precaution can be adopted to avoid this effect, such as application of a pulse 
with the lowest duration possible (in the order of the nanosecond) or to provide a source of 
ions that provides the nearest to uniform equipotential conditions [72]. 
All the referred features introduced by a reflectron contribute to the exponential 
increase of the resolution and the RP 
[72]
. 
RP is the ability of a mass spectrometer to separate ions with different m/z values 
measured having in reference the full width half maximum (FWHM). The latter, expressed in 
equation (1.8) is applied to a wide variety of MS analyzers including the TOF/MS [5]. 
 
RFWHM =
m/z
∆m/z
=
𝑡
2∆𝑡
 (1.8) 
 
Where 𝑡 is the flight time of the ion and ∆m/z and ∆𝑡 are the peaks widths at 50 % 
level on the mass and time scales [73]. 
Another option is the introduction of a reflectron (see Figure 1.19) which functions as 
an electrostatic mirror to compensate the disparity of the kinetic energy. This will not 
equilibrate the energy at the source, but will decrease the flight distance for ions with less 
energy at the pulse and the reverse for the others with higher energies, as illustrated in 
Figure 1.21. Simultaneously, it will comprehensively decelerate ions with higher kinetic 
energy, until the velocities of the homologous ions reach equal intensity [72]. 
An apparatus with a reflectron, as that used in this work, also increases (doubles) the 
flight distance which, alone, increases the resolution of chromatograms and spectra [65]. 
Figure 1.20 Schematic of a linear TOF and flight of 3 ions with equal mass [72]. 
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High MS resolving power 
is necessary to separate 
adjacent peaks from one 
another and to ensure that only 
one kind of ion contributes to the 
measurement. Several key 
factors must be optimized and 
considered to achieve high mass 
accuracy with good precision. 
These factors include peak shape, ion abundance, the referred RP, and calibration [73]. 
Resolution of a TOF is typically comprehended between 15000 to 26000 (
m/z
∆m/z
). 
Hence the problem raised by interfering peaks of ions with the same nominal mass, but 
different exact masses of intended analytes, may be solved partially or completely. It also 
allows the determination of the charge state of multiple charged ions from their isotopic mass 
spacing in isotope pattern studies. Additionally the S/N is improved owing to the grouping of 
ions into narrower peaks, which increases the peak height. 
In sum, the greater the resolution the better, if it does not interfere with sensitivity [73, 
74]. Additionally TOF detectors are the cheapest high-resolution mass spectrometers 
(HR(MS)), with consistent unique features in terms of acquisition speed and m/z range 
[74]
.
 
 
All the above characteristics provide TOF the technology to produce a full-scan, 
independent of set masses, with a molecular weight (MW) detection capability to the nearest 
0.001 Da (dalton), compared with 1 Da in conventional MS [65]. 
Theoretically, this LC-HR(MS) has the requirements for a sensitive screening of 
(polar) targeted compounds and/or their metabolites, and to discover non-targeted 
compounds that can be of toxicological relevance in complex mixtures. 
 
1.4.6 Data-Independent Acquisition  
Unbiased data-independent acquisition (DIA) strategies attempt to overcome the 
disadvantages of its counterpart, data-dependent acquisition (DDA), in what concerns STA 
screening [75]. Differences between these two techniques will be discussed in section 1.6. 
In summary, DDA consists in a pre-selection of a nominal or exact m/z, provided by a 
MS scan cycle, and then through an additional multiple reaction monitoring (MRM) cycle it is 
acquired the intended fragmentation spectrum.[62,69] This approach raises limitations such as 
irreproducibility of precursor ion selection, underdamping and long instrument cycle times [75]. 
Figure 1.21 Schematic of a TOF equipped with a Reflectron and the 
principles that are applied with it: Acceleration, Reflection and Deceleration 
[72]. 
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Whereas for DIA experiments, two almost simultaneous and intercalated acquisition 
functions with different collision energies are configured in the collision cell. The low energy 
function (LE) and the high energy (HE) functions with a collision ramp energy, are depicted in 
Figure 1.22 [76]. 
The analyzer/detector 
illustration describes a parent 
ion scanning, being the energy 
in the collision cell low enough 
not to fragment the charged 
particles (blue and red circles). 
The lower illustration describes 
the ensuing HE function. In 
this case, the smaller circles 
illustrate the respective 
product ions and their relative 
“flying” velocities towards the detector, when compared to their parent ions. 
In the detector, data being collected will be then separated into two data channels, 
with the instrument spending not more than 0.1 s on data acquisition for each channel [77]. 
Hence two alternating MS spectrums (I and II) are algorithmically displayed (see Figure 
1.23) providing AM, intended isotopes, adducts and, most relevantly, fragmentation 
information of a targeted compound or of an unknown [6]. 
In the case of usage of a quadrupole TOF analyzer (qTOF/MS) instrument, as it was 
the case in this thesis, because no qualifier parent ion is selected in DIA, the first quadrupole 
is set to static mode.  
As it is observable, the data 
treatment software employed in this 
project enabled compound specific DIA 
results. The upper spectrum is relative to 
the LE data channel result, providing the 
exact molecular mass of the parent ion 
(304.15441 m/z), isotopes (305.157316 
m/z and 309.157316 m/z) and sodium 
adduct of cocaine (326.15444 m/z). 
The lower spectrum depicts the HE spectrum which provides fragments exclusively of 
cocaine, algorithmically placed to the left of the parent ion peak. In this spectrum cocaine´s 
peak has decreased in detector counts when comparing to those of the LE spectrum, which 
Figure 1.22 Route of charged particles in a (HR)TOF/MS analyzer with DIA. 
Figure 1.23 Cocaine DIA spectra of a real forensic case, 
displayed in UNIFI1.7TM software. 
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evidences loss of precursor ions for this compound, as a substantial amount was fragmented 
into product ions (fragments 1 to 4 in Figure 1.23 (II)). 
 
1.4.7 UNIFI1.7™ 
UNIFI1.7TM is a software tool from Waters CorporationTM. This version (beta) is 
exclusively compatible to Windows 7TM, 64-bit operating system (OS) and is still in 
development by the manufacturer. Hereby it is presented some of its more innovational 
features in the context of STA [78]. 
The software controls instrument systems and devices, and performs all data 
acquisition, analysis, processing, reporting, and other information management functions [78]. 
It allows the study of old samples as a database is maintained in a server and stores 
raw data and content items including results, sample identifiers, methods, and reports in a 
relational database management system [78]. 
It directly influences instrument robustness, contributing to its maintenance through a 
console of functions. With this application the operator can configure the instrument settings, 
monitor performance, perform diagnostic tests and maintain the instrument system and its 
modules [78]. 
This tool provides the possibility to create individual methods for instrument control 
and lists them for future use (see Figure 1.24) [78]. 
The “analysis method” acts as a shortcut in which it is stored all trial conditions, 
instrument control parameters, and data processing parameters. Additionally, a series of 
methods can be stored for future application, depending on the context of the analysis [78]. 
Figure 1.24 “Analysis method” window of UNIFI1.7TM. 
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A list of identified compounds, indicated by (i) and denominated “Component 
Summary” is displayed with relevant information such as molecular formula, retention time 
(RT), status of identification (analyte presence in library or not), the exact mass of the 
protonated molecule and the mass deviation of the acquired spectrographic peak, relatively 
to the stored information in the library. There are other criteria possible to be displayed on 
the list (ii), which is dependent in the selected “view”. 
“Analysis methods” specifies the following features [78]: 
 The type of analytical experiment it is wanted to run; 
 The compounds in one or more samples that are wanted to analyze. For 
example, in the case of the “exclusion” of compounds from the targeted library 
in the method specificity studies. The compounds to be “hidden” are those 
present in the “excluded” library (discussed in section 3.1.4); 
 The instruments to use for data acquisition; 
 The instrument control settings and parameters; 
 The parameters that define how to process the data for analysis. This 
application defines the filter criteria to be applied in the data process. Again, 
this is of relevance for specificity studies, highlighted in section 3.1.5[78]. 
When reviewing old data, the software 
is able to assign different “views", which are 
dependent on operator’s preferences for data 
interpretation (see Figure 1.24 (ii)) [78]. 
Among the already referred and other 
capabilities, the software is able to assign 
filters with a list of criterions possible to be 
inter-correlated, in order to provide a more 
specific list of compounds (see Figure 1.25). 
Hence, it is possible to attain a narrower list of chemicals which chromatograms and 
spectrograms are to be assessed, without compromising the sensitivity of the analysis. 
Another property of this software is 
the ability of providing a compound specific 
qualitative and quantitative (in terms of 
response/detector count) comparison tool, 
designated “summary plot”. 
In Figure 1.26, it is illustrated an 
example of an endogenous substance 
(nicotinamide) present in the library of 
Figure 1.25 UNIFI1.7TM “Edit filter” box. 
Figure 1.26 UNIFI1.7TM “Summary Plot”. 
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compounds adopted in this thesis. From the plot it is possible to conclude that the referred 
substance is in every sample. Each column represents the nicotinamide response (for each 
injection). This catalogs the compound as a non-pharmaco-toxicologically relevant 
compound and promotes subsequent listing in the “excluded” library (see section 3.1.4). 
Another feature to be presented is the capability of this software to import molecular 
structures as a .mol file. This format is directly downloadable from ChemSpiderTM or can be 
provided by any chemical drawing software. 
This particularity is of high importance in the development of the semi-targeted 
screening method, as the software has the ability to attribute molecular structure to product 
ions, which are displayed in the HE spectra of an unknown not present in the library of 
compounds. In Figure 1.27 it is 
given the example of N-dealkyl- 
hydroxyquetiapine, a non-targeted 
metabolite of quetiapine, identified 
with resource to the highlighted 
feature. 
In the image, (a) is 
correspondent to the low collision 
energy spectrum and (b) 
corresponds to the high collision 
energy spectrum. 
Another important property is the ability of displaying chromatographic peaks of 
product ions that are common to different compounds present in the same sample. Figure 
1.28, illustrates a real forensic case where cocaine was identified. The chromatographic 
information reveals that there are 4 fragments of cocaine that are common to other 
chemicals present in the sample. 
Graphic I corresponds to the total ion chromatogram (TIC) in which all the detected 
peaks are displayed, irrespectively of being present in the database of compounds, or 
absent, being accounted as unknown small molecules. Scheme II is the extracted ion 
chromatogram (XIC) for every component with m/z equal to 304.1544. 
Graphics III to VI are the XICs of fragments of the pharmaco-toxicologically relevant 
compound present in II (cocaine in this case). Respectively, they correspond to the product 
ions with 182.1172, 82.0647, 105.0327, 150.0909 m/z. 
In Figure 1.28 the fragments present in IV, V, VI are both product ions of cocaine 
and benzoylecgonine, which eluted at the minute 2.98. 
 
Figure 1.27 N-dealkyl-hydroxyquetiapine molecular (above) and 
product (below) ion structures. 
Targeted, semi-targeted and non-targeted screening for drugs in whole blood by UPLC-TOF-MS 
with data-independent acquisition (DIA) 
27 
Normally the non-targeted peaks (eg. substance eluting at 4.94 min in Figure 1.28) 
correspond to non-listed metabolites of the compound being analyzed. However, there is 
always the probability of those complete unknown peaks to correspond to PTRCs which 
identification is of utmost importance for the forensic report. 
This is the problematic that fueled the need for the assembling of the semi and non-
targeted screening methods, developed in this project. 
 
1.4.8 Targeted Screening 
Due to several hundreds of thousands of intoxications per year with drugs of abuse 
and pharmaceuticals, fast screening methods are a necessity for the determination of these 
xenobiotics in forensic intoxication cases [79]. 
In the last 10 year, the development of HR/MS instruments allow the provision of high 
mass accuracy and resolution in full scan mode, enabling AM screening of a theoretically 
unlimited number of polar organic pharmaco-toxicologically relevant compound [79, 80]. 
This section describes the first of the three screening methods introduced by Krauss 
et al. [81]: target, semi-targeted and non-targeted screenings [81]. 
The classical automated targeted analysis approach uses pure standards to serve as 
reference while the MS full scan is taking place. Those reference standards provide the RT 
information of the intended compounds, which is stored in a database (named targeted 
library for simplification). These libraries are normally in-house customized but the bulk is 
often commercially acquired. In addition to RT they might store information of the exact 
mass, fragmentation from tandem mass spectrometry (MS/MS), molecular structure, and 
other information [82]. 
Figure 1.28 UNIFI1.7TM common product ion appointment tool. 
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A targeted library can contain up to several hundred substances [83], which make it a 
resourceful tool for practical screening of PTRCs where reference standards are 
commercially available [82]. 
Indeed, Gregov [84], resorting to a conjugation of results from distinct STA methods 
(GC, GC/MS, HPLC-MS/MS) reported that, between 2000 and 2003 only 80 common drugs, 
to which respective pure standards were available, covered 87% of all findings in the forensic 
laboratory where the experiment took place [84]. 
The utility of these databases is mainly justified because of the knowledge of the RTs 
obtained under the method´s specific chromatographic conditions [84]. 
However, if not obtained commercial source, the database assembling is very 
laborious and costly as all reference standards have to be purchased and the RT individually 
measured. Additionally, not always the substances to which RT measurement is required are 
easily provided by synthesis laboratories, as is the case of drug metabolites [84] and designer 
drugs. 
 
1.4.9 Semi-Targeted Screening 
As stated in the last section, HR/MS enable the differentiation of thousands of peaks 
form the background noise, which largely surpass the target compound library range. As for 
that, those peaks remain unidentified and might be correspondent to non-relevant chemicals, 
such as endogenous compounds, or they simply might be a result of analytical interferences. 
However they also might correspond to a PTRC hit [79, 80]. 
As for that, in a semi-targeted (also referred to as “suspect”) screening, it is attempted 
the identification of those non-identified but detectable peaks 
[82]
. 
In this screening step a library of compounds called semi-targeted library is 
assembled with the ultimate objective of providing all the information that a target library 
would provide, except for compounds´ RTs. Hence it is called “semi” because even though 
all the compounds to screen for are known beforehand, it lacks the reference standard 
information [82]. 
In this screening method, with resource to specific software, chromatographic peaks 
with exact mass are correlated to the AMs present in the semi-targeted database. These 
AMs derive from imported molecular formulas and are compound specific (except in 
isomerism situations). Parent ion peak and suspect compound affinity is corroborated by the 
agreement between measured fragments´ exact mass and the suspect fragment´s AM stored 
in the database [82]. 
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It has been reported (Kern et al. [85] and Gómez-Ramos et al [86]) that confirmation 
of suspect-library hits can be performed by further analysis of suspect´s retention behavior; 
by expert comparison of spectra acquired by multiple fragmentation energy mass 
spectrometry (MSn) methods; and by knowledgeable judgment of spectra obtained in both 
ionization polarities 
[85, 86]
. 
If such a screening strategy is feasible, it will alleviate the dilemma of requiring 
reference standards a priori and opens the door for the fast detection of compound classes 
for which reference standards are not easily accessible [82]. 
However, in the context of this thesis, the rule followed was that, for unambiguous 
confirmation of the presence of the suspects, it is always needed to calibrate the LC-MS 
system with an isolated pure standard of the compound of interest [82]. 
Additionally, the semi-targeted screening was performed as a post-targeted screening 
step, in which the results of the first will complement the positive hits obtained in the latter [81]. 
 
1.4.10 Non-Targeted screening 
Traditional targeted approaches provide good sensitivity and reliable identification 
(and quantification) of the targeted compounds and have successfully been applied for 
several decades. However, database based screenings account for a major drawback, as all 
the compounds which are absent from the selected compound list will always be missed in 
the analysis [87]. 
Nowadays, HR(MS) and AM acquisition permit the automated detection of the “true” 
unknown compounds and further enable the deconvolution of the respective chromatogram 
peaks into spectra. 
However the resulting raw total chromatogram will reveal several thousands of 
unknown peaks in a single whole blood sample [88]. 
In order to mine these chromatograms for useful information, powerful software tools 
became a necessity. Programs such as UNIFI1.7TM provide the resources to filter down the 
“true” unknowns list to a feasible quantity for further analysis [89]. 
Most importantly, the program enables the examination of old full scan data files in a 
retrospective way, in order to look for pharmaco-toxicologically relevant candidate peaks in 
whole blood samples. Without this feature, non-targeted screening would not take place to 
start with [87]. 
For a question of semantics and to avoid confusions, unknowns being treated in non-
targeted screening will be denominated “candidates”. 
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Hence, a candidate is a complete unknown chromatographic peak, to which 
molecular formula can be attributed from the derivatization of both obtained exact mass and 
isotope pattern (to be discussed in section 3.3.2) [90]. 
The next stage of the non-target screening corresponds to the elucidation of the 
chemical structure, as a large number exist for each calculated molecular formula [88]. Hence 
the procedure develops with the searching, in the Internet, for possible structure identities in 
general databases [89], such as ChemSpiderTM. To assist the structure characterization, the 
obtained high and low collision energy spectra are compared with in the Web databases 
containing MS/MS fragment ion spectra with AM [89], such as mzCloudTM. However, the use 
of mass spectral libraries for confirmation of compounds is still limited for certain vendors of 
LC-HR(MS) (Thermo Fisher ScientificTM in the case of mzCloudTM). Hence, at this stage, 
mass spectra libraries are small and the compatibility of spectra is limited between different 
instruments [91]. 
Reverse search has not been fully recognized and valued to this point [87]. The current 
study took full advantage of this possibility and attempted to evaluate the contribution of its 
application in a STA context. Additionally, this will be the ultimate tool for the search of the so 
called “designer drugs” discussed in section 1.3.2. 
 
1.5 Additional theory for method evaluation 
In this section definitions that were employed in the evaluation procedures will be 
clarified. These experiments had as main purpose the elaboration of an objective insight of 
the inherent quality of the GUS method developed in this project. 
1.5.1 LOD, LOF and LTC 
This project didn’t cover PTRC’s upper limits of both detection and identification. 
Subsequently, for disambiguation, “limit” throughout this thesis signify “lower limit”. 
The definition of limit of detection (LOD) was fixed by the Conference Report II as 
“the lowest concentration of an analyte in a sample, in which the bioanalytical product can 
reliably be differentiated from background noise” [92]. Its value is always inferior to the lower 
limit of quantification (in studies where it is of relevance). The most common approach for 
LOD definition, in an experiment, is to set the detector to exclusively consider the peaks with 
heights (signal) equal, or greater than the amplitude between the highest and lowest point of 
the baseline (noise) [93]. 
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In this work´s screening method, LODs of a selection of 198 PTRCs were determined 
and the results were correlated with each compound’s respective lower therapeutic 
concentration (LTC). The latter is defined as the reported minimal concentration, in whole 
blood, in which a drug will manifest its therapeutic properties in the user [94]. 
Limit of identification (LOI) is the concentration at which chromatographic and 
spectral information meet enough criteria in order to be appointed as unambiguously preset 
in the sample. The criteria are subjective and are either defined by operator’s toxicological 
knowledge and/or through application of software filtering tools [95]. 
In this thesis context, for an estimative 95% of the PTRCs accounted for in the 
developed overall screening, compound identification was confirmed through the analysis of 
fragmentation patterns. Hence, limit of fragmentation (LOF) was the main criterion adopted 
for peak identification. It is defined as the concentration limit at which a selected PTRC 
provides fragment(s) in the DIA’s HE function spectrum. 
To increase result robustness, at least 3 distinct but compositional homologous 
matrices should be analyzed and the mean of the resulting data calculated for LOD and LOF 
unambiguous determination [6]. 
 
1.5.2 UP, FP, FN, CP 
For evaluation of the method´s targeted screening, four possible types of results were 
delineated: 
1) UNIFI1.7TM positive (UP): were results that, after instrument´s detection, were 
identified as positive hits by the operator. 
2) False Positive (FP): which comprehended results that, regardless of detection 
by the instrument, were appointed as false hits. These chromatographic/MS 
peaks did not satisfy the identification criteria, such as peak shape, provision 
of fragment ions, satisfactory m/z and RT errors, presence of metabolites/ 
precursor compounds and presence of adduct(s). 
3) False Negatives (FN): which corresponded to small molecules that were not 
detected by the method´s software or were classified as FP. However, these 
substances were identified and quantified by parallel methods and presented 
in the RKA´s laboratory information management system (LIMS). 
4) Confirmed Positives (CP): UP results that were corroborated by parallel 
methods were designated as CP. This classification was implemented with 
regard to cross evaluation between results obtained from UNIFI1.7TM and 
those from other instrumentation considered in the LIMS. 
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1.5.3 False positive frequency and sensitivity 
The Instrument´s targeted screening capability was evaluated in terms of FP 
frequency and sensitivity. Additionally, validation of software filters was performed. 
FP frequency, expressed in equation 1.9, is presented as the quotient between the 
total of instrument detections classified as FPs and the sum of all the hits [96]. 
FP frequency =
FP
(FP+UP)
 (1.9) 
 
Roman et al [71] stipulate that in a targeted screening employing a library of 
compounds comprising 240 drugs, it was acceptable a FP frequency of 5% [71]. 
Sensitivity, expressed in equation 1.10, is the ability of the method to correctly 
identify small molecules, without missing any PTRC [96]. It consists in the quotient between 
the number hits classified as positives (UPs) and the sum of UPs with the total PTRCs 
missed in the screening (FNs). 
Sensitivity =
UP
(UP+FN)
 (1.10) 
 
Accordingly to Roman et al [71] it is expected that a screening method in a STA 
should provide a sensitivity of 100% [71]. 
 
1.6 Literature review 
To better comprehend LC-MS based broad screening procedures, able of covering a 
wide range of toxicological relevant compounds, hereby are presented two independently 
related dualities: STA based on product ion spectra vs GUS based in high resolution 
accurate mass detection (HR/AM); and DDA vs DIA [69]. 
For the first two different general screening approaches, the one based on product 
ion involves the usage of triple quadrupole, linear ion trap (LIT) (illustrated in Figure 1.29) 
and hybrid mass spectrometers (quadrupole ion trap or QIT). Any of them can provide 
information rich fragment ion spectra, to which can be applied search against libraries of 
reference product ion (fragment) spectra. These references are previously recorded on the 
actual or on a similar type of instrument, as there are reproducibility limitations in what 
concerns spectra results between LC-MS apparatus [4, 5, 7, 8, 83, 98]. 
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The other GUS approach is based on 
HR/AM and it is performed either by TOF 
mass spectrometers (see section 1.4.5) or by 
orbitrap instruments [99]. In this case the 
compounds are identified by comparison of 
exact masses with accuracy of at least 4 
decimal houses. Databases can be obtained 
commercially, recorded from available pure 
standards, or built based on theoretical data. 
The latter provides its main advantage which 
is the fact that accurate mass databases are 
reproducible as a PTRC´s molecular formula is [2, 3, 6, 73, 75-77, 99-106]. 
For instance, the instrument’s software used in this thesis is able of calculating the 
exact mass and isotope pattern of intended compounds exclusively by importation of their 
molecular formulas. The reverse is also possible through usage of software tools that can 
probabilistically correlate an exact mass to hypothetical molecular formulas, while accounting 
information from isotope and fragmentation pattern. This is important for the identification of 
drug candidates in the chromatogram and is discussed in section 3.3.2. 
Despite not being used in this thesis, the ion trap apparatus presented in Figure 1.29, 
is described in literature as somehow a screening counterpart to the method developed in 
this study, so its operating description is hereby briefly described. Although being capable of 
providing broad fragmentation information, this instrument is exclusive for product ion spectra 
acquisition methodologies. Hence, it provides nominal and not exact m/z values for parent 
and fragments ions displayed in its spectra [3, 107]. 
LIT process starts when charged particles, exited from a previous part of the 
instrumentation, enter the ion-trap which consists of a grouping of three electrodes: two 
endcaps electrodes and a central ring electrode to which variable voltage intensity is applied. 
The trapping stage commences when the 1st endcap electrode is charged by an alternate 
current (AC) and the polarity of the current is what will determine the entrance of the ions into 
the ion trap. However, their flux is conditioned mainly by the detector data acquisition and 
processing capability. Afterwards, the trapping gas molecules will stabilize the ions 
accordingly to a m/z determined by the voltage applied in the central ring electrode. After the 
ion trapping stage is completed, the 2nd endcap electrode initiates the detection stage by 
mediating the injection to the transducer, through a technique designed mass-selective ion 
injection. This consists in a sequential ejection of ions according to their mass by voltage 
increase in the ring electrode. This procedure is cyclical and it is what makes possible the 
MSn scanning capability to every intended analytes trapped in the chamber [107]. 
Figure 1.29 Ion Trap Spectrometer [107]. 
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Ion trap apparatus can provide either enhanced MS survey scan or (more 
importantly) enhanced product ion (EPI), or even both in the same analytical run, in the case 
of a hybrid triple quadrupole linear ion trap instrument (Qtrap). The main advantage provided 
by this instrument is its MSn capability, which provides multiple product ion chromatograms 
for the same ion specie at different collision energies, increasing the “richness” of 
fragmentation information in the spectra [107]. 
The second duality is more software driven than instrument dependent. As an 
introduction, one of the main differences between DDA and DIA is the fact that the first is well 
established with both GUS based on product ion spectra and STA based on HR/AM 
acquisition, whereas DIA is rather limited to HR/AM acquisition based screening [2-4, 6, 76, 77, 100, 
106, 108]. An exception is exemplified by Humbert, et al. [62], and discussed later in this review 
[62]. 
The favoring of HR/AM acquisition is explained by the deconvolution of 
chromatographic data into mass spectra in DIA (illustrated in Figure 1.30). It requires mass 
assignment to four decimal places, so the fragment ion spectrum may be correctly correlated 
with the parent ion spectrum. This way, accurate mass acquisition is convenient to 
differentiate between isobaric compounds of the same nominal, but differing exact masses [5, 
8, 73, 83, 98, 101, 102]. 
The DIA feature of the 
software used in this thesis permited 
that, even when chromatographic 
peaks co-elute (see Figure 1.30 
(II)), the deconvolution algorithms 
was able to align the parent ion in 
the low energy spectra (e.g. A1 and 
B1 in the upper spectrum) with the 
homologous ions present (now with 
less intensity) in the high energy 
spectra (e.g. A2 and B2 in the lower 
spectrum). More importantly, it 
allowed the correct allocation of the 
product ions (e.g. FA1 and FA2 for A1) 
in the high energy spectrogram. 
In a different way, DDA 
functions as an artificial intelligence-
based on parent ion scan mode 
providing automatic and real-time 
Figure 1.30 Deconvolution of chromatographic data into mass spectra in 
DIA. (I) Example of peaks with distinct RTs. (II) Example of co-eluting 
peaks with a correct spectra alignment (homologous to those of (I)) 
possible due to specific deconvolution algorithms. 
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MS to MS/MS switching. This way, as in the case of DIA, there will be (at least) two spectra, 
one resulting from a low collision energy revealing the parent ion that will then activate a 
comprehensive MRM function in order to provide the respective product ion spectrum [75, 83]. 
The main difference between this approach and DIA is the fact that DDA defines the interval 
or the intended m/z it is wanted to analyse, whereas DIA provides an option of analysis that 
do not require any kind of narrow criteria prior fragmentation. Ultimately, this DIA capability is 
what makes it such a powerful tool for the tentatively identification of non-targeted 
compounds, and the “power” of this tool was assessed in the non-targeted screening 
(section 3.3 of this work) [5, 8, 73, 83, 98, 101, 102]. 
Although very popular, there are some inherent limitations to the DDA approach, such 
as irreproducible precursor ion selection, undersampling and long instrument cycle times. For 
this reason, unbiased DIA strategies try to overcome those limitations [75]. 
As the subject is now finally presented, some examples will be shown to provide 
information about the screening methods and compare those in literature with the 
methodology developed in this thesis. 
The literature study covers screenings techniques from a LC/ESI-MS method with 
intelligent data acquisition [7], to a state of the art UPLC-TOF-MS employing a STA screening 
HR/AM acquisition with DDA [6, 109]. 
The paper of Lafaye, et al. [7] describes a methodology not fully contextualized with a 
GUS procedure, as it does not describe a method to screen for drugs in a forensic or clinical 
context. However, as the study was in a metabolomics context to screen rat urine for 
targeted metabolites, which presence wasn’t reportedly expected by the researcher, this 
method proved to be a good starter to introduce the subject [7]. 
The group’s study dealt with the usage of liquid chromatography coupled to 
electrospray ion trap mass spectrometry for analysis of rat urine metabolome. The objective 
of Lafaye’s team was to study how QIT instruments are well adapted to a first step of 
metabolism profiling. In the meanwhile, they developed a DDA technique from information 
rich MSn spectra (providing nominal mass of parent and product ions), made available by QIT 
for further structural characterization of biomolecules [7]. 
Despite the well-established assumption of ESI spectra complexity (when applied 
high collision energies), as several dozen of m/z ratios may be recorded in a single 
chromatographic peak, the instrument’s ion source exclusively provided the low energy 
function spectra [7]. 
To counterbalance the hypothetical spectral complexity which would result from a 
high collision energy function of the ESI, the team adopted instead a data-dependent 
MS/MS acquisition using a QIT analyzer to differentiate, in real time, metabolite form 
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fragment data, which dramatically simplified the database search. An example of the 
identification procedure is presented in Figure 1.31, which describes the identification of a 
fragment ion (not a phase II metabolite) of a phase I metabolite with a nominal mass of 
385.0 m/z [7]. 
The previous figure exemplifies the worth of DDA mode, has it made possible the 
identification of the fragment with the mass ≈192 m/z, attained in the MS2 spectrum displayed 
in Figure 1.31 (III). However, it also evidenced some of the disadvantages of this intelligent 
data acquisition with product ion spectra (with nominal mass) as reference in the targeted 
screening. For instance, there is loss of RP when comparing Lafaye’s method against a 
HR/AM based screening 
[2,6
 
7,109]
. 
Another broad screening example is presented in the study of Dresens, et al. [8], 
which in 2009 reported on the identification of 700 drugs by multi-targeted screening with LC-
MS/MS system and library searching. The library was in-house built based on electrospray 
ionization–MS/MS spectra and containing over 1250 spectrums, which included drugs of 
abuse, pharmaceuticals and toxic compounds of forensic and clinical relevance. Their 
approach comprehended a “scheduled” survey scan though 700 MRM cycles, DDA and 
usage of EPI spectra from a QIT scanning at three collision energies of 20, 30 and 50 eV [8]. 
As the library had spectral information about the product ion, for correct identification 
of the parent ion, this method exemplified a STA based on product ion spectra, in which it 
was used a DDA for data treatment facilitation [8]. 
The DDA software feature enabled a scheduled MRM (sMRM), which allowed the 
setting of time windows for transitions monitored in the survey scan. This is used to 
automatically select precursor ions as soon as they have been detected within the selected 
Figure 1.31 Lafaye, et al. [7] DDA procedure. (I) Total Ion Chromatogram (TIC) with intended RT interval of interest 
highlighted; (II) corresponding deconvolution into ESI-MS low voltage spectrum (MS1); and (III) MS2 (QIT) product ion 
spectrum of the peak with 385 m/z of MS1 spectrum. The dashed blue lines represent the deconvolution from chromatography 
to MS data [7]. 
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time window where they were expected to be detected. All was done within the same 
analytical run [8]. 
Drensens research revolutionized through the employment of a MRM instead of using 
less resolved ESI or single MS scans which provide less efficient analyte detection. 
However, the method was not immune to sensitivity impairments [8]. 
In occasions the DDA mode was not activated even if the precursor ion was 
genuinely present in the sample and caught in the survey scan. In other occurrences, 
sensitivity was lowered because EPI spectra resolution was insufficient to unambiguous 
detect the parent ion from the survey, resulting in impairment of further sMRM fragmentation 
[8]. 
Another drawback was the limited number of spectra of metabolites in their library, 
which could be of contribution for the unambiguous identification of their parent drug [8]. 
Additionally, the protracting time-lapse of polarity switching, in many times raised the 
need of an additional run [8]. Nevertheless, comparing with the method developed in this 
thesis, the availability of “real time” polarity switching is an advantage, as this option wasn´t 
adopted in this projects´ screening method. 
Finally and as well related to the analysis duration, the usage of MRM for parent ion 
scanning limited the number of compounds in their target library. Although 1250 spectrums is 
a considerable number, for further compound inclusion in the database, a longer 
chromatographic run should be adopted, which isn´t in accordance with the time efficiency 
goal of a STA. 
Dularent, et al. [4] proposed an additional mean of employing a GUS based on 
product ion spectra in conjugation with DDA. This screening is different from the previously 
mentioned as it used a dual product ion library approach. The libraries together contained 
spectra directly related to 320 pesticides and metabolites. Dularent´s spectra libraries were 
generated by a LIT instrument. The MS2 spectra library was generated using the base peak 
ions of the parent full-scan spectra library (MS1), which contained the precursor ions. 
Therefore, the MS2 product ion spectra library contained 450 fragment ion spectra of the 320 
pesticides and metabolites (precursor ions), available as pure solutions [4]. 
Additionally, for the MS3 spectra library, the precursor ions were those generated in 
the MS2 scan. This resulted in an additional 430, second ion trap cycle, fragment ions 
acquired form the first 450 ion trap cycle (MS2) fragment ions [4]. 
This approach’s main strength resided in the availability of the well-developed 2nd IT 
cycle product ion library (MS3), which functioned as an additional confirmation criterion for 
identification purposes. Supplementary, the capability of using data-dependent scanning and 
polarity switching after each cycle, in the same trial, proved to be very resourceful [4]. 
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Another example of a STA based on product ion spectra but without resource to any 
artificially intelligent data acquisition is the work of Liu, et al. [98]. His paper highlights a new 
developed analytical feature that corresponded to a, at the time, novel fragmentation 
approach which consisted in providing voltage ramping and broadened mass window for 
activation (or fragmentation width) 
[98]
. 
Their targeted library was based on the analytes’ retention data and in “information-
rich” MS/MS spectra of 780 standard drugs and toxic compounds. It was meant to screen for 
drugs in postmortem specimens (urine, serum and whole blood) using an ion trap mass 
spectrometer [98]. 
The “information rich” product ion spectrum contained fragments ranging from low to 
high m/z, provided by the higher voltage and lower voltage, respectively. The affinity between 
the product ion spectra empirically obtained and spectra in library was mediated by the NIST-
based search algorithm. The latter also demonstrated high reproducibility between reported 
data from old cases and data gathered 6 months later from newer cases [98]. 
Their ramping voltage CID provided a significant number of product ions, which 
facilitated the characterization of analytes and lowered their limits of detection. As for that 
Liu, et al. [98] LC-MS/MS library search approach proved highly effective for broad 
preliminary screening and confirmatory analysis of drugs and toxic compounds [98]. 
In the context of GUS based on high resolution accurate mass detection (HR/AM), 
the paper in the literature with the largest compound library is that of Polettini, et al. [106]. 
The library was composed by approximately 50500 PTRCs (parent drugs and metabolites). 
The author took to the full extent the reproducibility of compound accurate molecular mass 
and its easy and free availability in million compound databases present in the internet [106]. 
Polettini’s library is a subset of the Internet library “PubChemTM” assembled by the 
National Center for Biotechnology Information (NCBI). Their approach attempted to 
overcome the main limitation of the usage of commercial libraries for the screening 
procedure in their capillary-electrophoresis (CE)-ESI-TOF/MS instrument, which was simply 
the fact that their limited compound content understates the RP capability of the instrument 
[106]. 
The group’s library building strategy consisted in narrowing down the criteria normally 
present in commercial libraries to only molecular formulae, that provide modern high 
resolution mass spectrometers with information to calculate intended AM and isotopic pattern 
[106]. 
After testing the library in real postmortem cases from urine, blood and hair samples, 
the team reported that due to the large quantity of compounds in the database, to each 
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spectrographic peak it could be appointed 1 to 39 identical molecular formulae from those 
present in the database [106]. 
Concluding, in none of their samples a compound could be unambiguously identified 
due to lack of discrimination between isomers. This leaded to the assumption that AM and 
isotope pattern alone are not enough for identification purposes and additional criteria should 
be provided in the database. As for that, the same research group purposed a 
“metabolomics” approach to shorten the compound hit list with the addition of a criterion that 
regarded the presence of metabolite [3, 106]. 
This complementary approach used 108 compounds from the same generous 
database of 50500 compounds from the previous research. Those selected compounds were 
proved to be present in the postmortem cases by parallel LC-TOF-MS or CE-TOF-MS trials 
[3]
. 
With resource to a software tool “E-Dragon software” it was possible to correlate AMs 
to pre-defined biotransformations (i.e. hydroxylation, oxidation, demethylation, glucoridation, 
etc.) that are commonplace in metabolism phase I and II [3]. 
This permitted to screen for the 108 compounds plus the major metabolites for each 
parent compound. Hence, while rescreening the samples, the group proved that the 
simultaneous presence of the parent compound and metabolite molecular formulae reduced 
the average number of hit for each peak present in the spectrum [3]. 
On the other hand, the still considerable amount of possible hits for each molecular 
formulae failed to provide unambiguous results. So the author concluded that it is necessary 
to introduce another criterion for the search strategy and suggested a theoretical calculation 
based on physicochemical properties of the molecules in order to obtain an in silico RT [3]. 
Despite not providing any unambiguous results, these two last papers made a 
statement of the advantages that HR/AM provides. It allows a much broader screening for 
PTRCs than screening approaches based on library search on product ion mass spectra 
databases. Additionally, technological development (especially in computation performance) 
that took place since the publication of these 2 researches, allows today the storage of 
information rich TICs and respective spectra information of all chemical intervenients capable 
of being detected by HR/MS [6, 109]. 
With a comparatively less ambitious database Lee, et al. [2] took part in an inter-
laboratory research involving 6 investigation groups (including RKA´s). Their method used 
different instrumentation than the one used in this thesis, but it applied the same 
methodology concept. A “real-time” acquisition of low and high fragmentation spectra in the 
same analysis was described in their study [2]. 
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It used a database containing monoisotopic exact mass, RT and nominal 
fragmentation pattern. Accordingly to the author, with the latter it was possible to attain an 
optimal fragmentation by increasing the voltage on Aperture 1 (located within the transfer 
optics of the instrument ion source) from 10 eV to 45 eV. An example for 2 chemically distinct 
analytes is present in Figure 1.32 
[2]
. 
Function 1 spectra were collected under low energy fragmentation at mild conditions 
within the source region and provided information of the intact protonated molecular species. 
Function 2 spectra ware collected using higher fragmentation conditions. Both fragmentation 
functions were provided by ESI in positive mode [2]. 
 
A third spectra acquisition function (not illustrated) of the approach developed in their 
study, implied the recording of data of the reference mass of leucine enkphanin, which was 
used to verify mass accuracy throughout Lee et al. research [2]. 
For better specificity, the group took full advantage of exact mass determination and 
the ability to measure the mass of an analyte to four decimal places, which provided a very 
high confidence of identification and a small amount of peaks to consider in the analysis. 
However their work failed to provide adequate sensitivity to the method, even after attempts 
of converting the data (recorded in monoisotopic exact mass) to nominal mass. Which 
accordingly to the author, would minimize the possibility of analytes being excluded (or 
missed altogether), in the eventuality of their exact masses being compromised. However, in 
the end, this conversion applicability wasn’t successful [2]. 
Figure 1.32 Function 1 and 2 spectra for EDDP and Nortriptyline [2]. 
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Another example of STA based on HR/AM acquisition and DIA was the research of 
Pedersen, et al. [6], which took place in the RKA laboratories. The UPLC-(HR)TOF-MS 
instrument used in the research was one edition older than the one used in this thesis 
experiment. Their targeted screening procedure was very similar to the one used in this 
present method and the validation of Pedersen´s methodology was of most importance for 
comparative reason with this project [6]. 
Their database was constituted by 5 internal standards (IS)s and 256 PTRCs. The 
information stored in their method´s targeted library was the same of that employed in this 
project´s targeted compound database: parent ion exact mass, isotope pattern, theoretical 
RT, and exact mass of the most abundant fragment ions for each analyte (limited to the a 
maximal fragmentation voltage of 40 eV) [6]. 
The author carried out a representative number of STAs comprising 1335 authentic 
forensic traffic cases by screening for the intended 256 drugs. 
DIA is nearly always associated with HR/AM acquisition [2, 6, 75-77, 109]. However, 
Humbert, et al. [62] proposed a GUS based on DIA by gathering parent and product ion 
spectra (nominal mass) for further correlation with a targeted library containing itself spectral 
data [62]. 
The GUS comprehended 500 PTRCs, a target database with 2975 spectra, and used 
a UPLC-MS/MS for a 15 min cycle analysis. For each run, ESI functioned as a positive and 
negative ion source. To each polarity different cone voltages were applied, resulting in the 
collection of 6 different product ion spectrums for each targeted PTRC. Consequently, each 
intended compound could be characterized by a combination of two criteria: RT and up to a 
maximum of 12 spectra (combination of [M+H]+ and [M-H]- modes) [62]. 
Despite “DIA” has not been mentioned in this literature, Humbert´s methodology 
suggests this acquisition mode usage as it was reported that, for each single run, multi-
acquisition data were acquired in full scan mode from 80 to 650 m/z and the scan speed was 
around 7000 Da per second. For instance, scans with positive voltage in the ion source cone 
covered the CID energies of +20 V, +35 V, +50 V, +65 V, +80 V and +95 V. For negative 
polarity the applied CID energies where symmetrically homologous [62]. 
This was a possibility with regard to the software (ChromaLynxTM) capability of 
preforming an automated integration of the component peaks at each discrete cone voltage 
(see Figure 1.33). ChromaLynxTM also permitted the application of deconvolution techniques 
for removal of non-specific background ions from the spectra [62]. 
The figure exemplifies oxazepam (a metabolite of diazepam) which ionizes in both 
positive and negative CID polarities, yielding fragmentation data for the maximum 12 
different cone voltages. In both charges it is possible to attain the disappearance of the 
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parent ion, as the fragmentation pattern for the compound is revealed as the energy 
increases [62]. 
Additionally, and enforcing 
the statement of DIA, Humbert, et 
al. [62] concluded that in contrast 
to classical MS/MS screenings, the 
full scan approach (the same used 
in this thesis) can produce a wealth 
of dimensions for unambiguous 
identification of unknowns. In 
opposition, triple quadruple 
screening monitors for previously 
selected protonated molecular 
species (known as qualifiers). Then 
a DDA mode is activated, but 
normally it is limited to acquisition 
of solely 2 product ions [62]. 
Notwithstanding, the main 
disadvantage of their method 
raised when candidate (metabolite 
or drug candidate) structures were to be structurally elucidated, despite the author´s 
estimation that their method would be able to provide candidate structure based on 5 to 8 
fragments. However the researcher concluded that, for unambiguous identification of a 
complete unknown in a non-targeted screening, in addition to fragmentation pattern, it was 
needed accurate mass acquisition [62]. 
Paul, et al. [109] is probably one of the most recent papers to cover a screening 
method for identification of unknown peaks. The research employed a UPLC-qTOF-MS and 
performed a GUS based on a HR/AM acquisition with application of non-targeted DDA. The 
biological matrix of relevance was urine [109]. 
As their screening was based on DDA, the qTOF device was used to its full capacity. 
So the first quadrupole served for isolation of precursor ions in DDA mode (auto-MS) and a 
linear hexapole collision cell (with N2 as collision gas) was used for precursor ion 
fragmentation. The method was applied to 76 real case urine samples [109]. 
Their screening was divided into two. The first was a MS scan for precursor ions and 
the second scan produced MS/MS spectra rich in fragment ions. The 2nd cycle was mediated 
upon the data acquisition of targeted parent ions in the MS scan. However, this was already 
reported in works such as of Broecker, Lafaye, Muller, Rosano, and Paul [1, 7, 83, 101, 109]. The 
Figure 1.33 Spectra of oxazepam in positive and negative CIDs (left and 
right, respectively) [62]. 
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innovative mark left by Paul et al. study was the fact that it goes beyond the simple 
acquisition in data-dependent auto-MS mode. 
When a standard screening with auto-MS is adopted, data is generated statistically 
and is dependent on strict criteria, like precursor ion abundances, making the resulting 
spectra of targeted screening often complicated to interpret.[1]. Given that and the fact that 
the author was searching mainly for unknown metabolites, in the referred research it was 
combined a first screening based on precursor abundance of 49 compounds present in a 
“preferred” targeted list, with a data-dependent MS/MS spectra generation of even not listed 
targets (i.e. completely unknown metabolites). The latter MS/MS scan was not based upon 
precursor ion abundance and as for that the product ion spectra provided broad 
fragmentation pattern information as seen in Figure 1.34. There, graphic information 
exemplifies the approach used by author to identify unknown metabolites, by utilizing to the 
fullest the instrument´s HR/AM acquisition capacity [109]. 
The figure demonstrates that even without possession of the corresponding 
metabolite´s pure standard, the DDA method was able to deliver data thereof. In fact, in 
Figure 1.34 (I) it was attained the presence of an unknown peak that was found to be a co-
elution of two unknown compounds. To structure elucidate these peaks, MS/MS spectra was 
took at where the red rhombuses are assigned in Figure 1.34 (I). Exemplary, MS/MS 
spectra of dehydronorketamine was recorded and displayed in spectrums Figure 1.34 (II) 
and Figure 1.34 (III). In this case the MS/MS spectrum was recorded though the metabolite 
was not listed in the preferred table of the data acquisition tool [109]. 
Figure 1.34 (I) Extracted chromatogram displaying an IS (mephedrone-D3), ketamine and 2 coeluting unkown metabolites that 
proved to be norketamine and dehydronorketamine; (II) MS precursor ion scan for dehydronorketamine (III) MS/MS product 
scan for dehydronorketamine  [109]. 
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Guided by literature information about expected metabolites of ketamine, the author 
was able to identify a fragmentation pattern that put in evidence the presence of the referred 
metabolite. Hence, it was proposed a fragmentation pathway for the MS/MS spectrum of 
dehydronorketiapine (see Figure 1.34 (III). The base peak at m/z 142.0772 (Frag.2) was 
explained by the elimination of a chlorine radical from m/z 177.0469 (Frag.1). This way, two 
fragments were able to be identified, which enhanced the structure elucidation of the peak 
eluted at 5.061 min (Figure 1.34 (I) [109]. 
A similar approach was used for the structure elucidation of norketamine (spectra not 
available) [109]. 
Concluding, Paul et al approach was able to ensure the positive identification of 
ketamine and its metabolites in urine, even without the use of expensive pure standards [109] 
This review cannot be completed without summarizing the vast work produced by the 
group of Ojamperä [73,102,110-112]. 
The first to apply the concept of high-resolution mass spectrometry to general 
unknown screening in forensic toxicology, Ojamperä, et al. [110] primordial procedure 
involved a database assembling containing theoretical accurate masses of toxicologically 
relevant compounds and for some cases, their respective metabolites [110]. 
After their early approaches, the author concluded the necessity of including RT [111], 
metabolite exact mass [66, 97] and most importantly, additional structure information of 
compounds, provided by CID fragmentation spectra [73, 112]. 
Despite all their work being based on HR/MS acquisition, none of the researchers 
employed DIA, failing to explore this new capability for STA. 
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2 EXPERIMENTAL 
2.1 Solutions 
Ultrapure water was prepared with a Milli-Q system (Millipore, Denmark). MeOH and 
ACN (LC-MS grade) were obtained from Fisher Scientific (Leicester, United Kingdom). 
Ammonium formate was supplied by Sigma-Aldrich (Steinheim, Germany). 
All reference compounds, present in BAMBS, TOF mix 1 and TOF mix 2 were 
purchased from Lipomed GmbH (Bad Säckingen, Germany), Cerilliant, (Round Rock, Texas, 
USA), or Toronto Research Chemicals (Toronto,Canada). BAMBS stands for Beta-agonister 
Astma Misbrugsstoffer Benzodiazepiner Specielle (Beta-agonists Asthma Drugs of abuse 
Benzodiazepines Special, in english). Additionally, the preservative sodium fluoride was 
purchased from BD (Plymouth, United Kingdom). 
Purity of the reference standards was ≥ 98%. All 5 deutered ISs, amphetamine-D5, 
diazepam-D5, morphine-D6, methadone-D3, and mianserine-D3 were purchased from 
Cerillant (Round Rock, Texas, USA). 
Two mixtures, TOF mix A and TOF mix B, containing 98 and 100 PTRCs respectively 
were prepared as a stock solution in MeOH, yielding a concentration of 10 mg/L. From the 
stock, working solutions were acquired for further laboratory application by dilution in 50% 
MeOH in water. The stock solution was stored at -80 °C and the diluted working solutions 
(50, 100, 500, 1,000 and 5,000 ng/mL) were stored at -25 °C. 
A single solution containing all 5 IS was prepared in MeOH, with an individual final 
concentration ranging from 0.1 to 4 ng/mL. The solution was divided in ampoules of 1 mL 
and stored at -80°C. 
4 stock solution in MeOH of 4 designer drugs (Pyrovalerone, 5-FUR-144, 5-F-AKB48, 
α-PVP), each at a concentration of 1.0 mg/mL were stored at -20ºC. 
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Stock solution in MeOH of E-OH-nortriptyline and Z-OH-nortriptyline, each at a 
concentration of 1.0 mg/mL and stored at -20ºC. 
Stock solution in MeOH of 7-OH-quetiapine at a concentration of 1.0 mg/mL, stored at 
-20 ºC. 
 
2.2 Materials 
Strictly for blank samples, whole blood was obtained from the Blood Bank at the 
Copenhagen University Hospital (Copenhagen, Denmark). The biological matrix was 
preserved by the RKA staff with 1 % sodium fluoride. The blood will subsequently be referred 
to as blind blood. Additionally and for the same effect, antemortem and postmortem blood 
was also acquired from archived and compound negative forensic cases. Storage was made 
at -20 °C until use. 
Whole blood samples acquired from autopsied and living persons, implicated in open 
and closed forensic cases, were analyzed. 
 
2.3 Method 
2.3.1 Sample Preparation 
The sample preparation of choice was PPT and the liquid handling, which included 
pipetting steps, centrifugation and evaporation, was entirely performed by a Freedom EVO 
200 robot from Tecan Group Lts (Männedorf, Switzerland). 
The procedure within the instrument was as follows: 
(1) From each sample’s total whole blood, the liquid handler transferred 100 mg 
to a hole in a 96 well plate; 
(2) One ampoule with the IS solution, referred in section Erro! A origem da 
referência não foi encontrada., was added to each sample of 100 mg by, the 
liquid handler; 
(3) 700 μL of ACN was added and further shacking precipitated the matrix; 
(4) After precipitate formation, a centrifugation step at 3600 rotations per minute 
(rpm) for 10 minutes took place; 
(5) Further pipetting separated the supernatant from the denser protein 
precipitate; 
(6) In a new vial the supernatant’s organic solvent molecules were evaporated by 
a stream of nitrogen at a temperature of 35 °C, until container was free of 
moisture; 
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(7) In the dried vial, reconstitution was attained by addition of 0.1 mL of 25 % 
MeOH in water containing 0.1 % of formic acid and the solution was shacked; 
(8) The resulting solution was then transferred for a 96 well plate. At this point the 
sample was ready for chromatography injection, which had a volume of 5 μL. 
 
2.3.2 Liquid Chromatography 
The chromatography was performed using a Waters Acquity UPLC system from 
Waters Corporation (Milford, MA, USA). 
The instrument setup was based on the same employed by Humbert, et al. [62], 
Rosano, et al. [101] and application notes provided by Waters
TM
. 
Separation was performed in a hollow structure section (HSS) C18 column (150 mm x 
2.1 mm x 1.8 µm) from WatersTM and maintained at 50 ºC, with an uniform flow rate of 0.4 
mL/min.  
During the UPLC binary solvent run, the mobile phase was composed by a gradient 
of 2 solvents. Solvent A was constituted by an aqueous solution ammonium formate with 
concentration of 5 mM. pH was adjusted to 3 by formic acid addition. Solvent B was 
composed by 0.1% (v/v) formic acid in ACN. 
Table 2.1 provides the binary solvent composition during the 15 minutes 
chromatographic run. 
 
Table 2.1 UPLC gradient over time. 
Time (min) Solvent B (%) 
0.00-0.5 13 
0.5-10 13-50 
10-10.75 50-95 
10.75-12.25 95 
12.25-15 13 
 
2.3.3 Mass Spectrometer 
The ion source/analyzer/detector used in this thesis was a Xevo G2-S QTOF from 
Waters (Waters MS Technologies, Manchester, United Kingdom). The detection type 
involves charged particles orthogonal acceleration and measurement of their “time-of-flight”. 
Exclusively positive mode ESI (z-spray) was employed, although negative mode is an 
option provided by the instrument. Ion source settings were as follows: capillary/aperture 
voltage was set to 800 V; voltage applied at the cone was 25 V; nebulation gas flow rate was 
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1000 L/h at a temperature of 400 °C; cone gas flow was set to 10 L/h; argon was used as 
collision gas; and the overall temperature at the ion source chamber was 150 °C. 
As highlighted in section 1.4.6 a DIA experiment, trademarked as MSe by the 
instruments manufacturer, was delineated. At this stage two different collision energies 
functions (LE and HE) were used in the collision cell of the analyzer. The fragmentation at LE 
function was effectuated at 4 eV whereas HE function involved a ramping from 10 to 40 eV. 
The operation resolution was set to be higher than 18000 at FWHM. For resolution 
measurement and assurance of reproducibility and accuracy, a LockSprayTM was utilized. 
Leucine-enkephalin parent ion with 556.2766 m/z was used as lock mass. The LockSprayTM 
solution with a concentration of 400 ng/mL and a spraying flow rate of 10 μL/min was used 
for all analysis. 
Data acquisition was performed in continuous mode and encompassed the mass 
interval from 50 to 950 m/z. In the detector, for both LE and HE functions, each data channel 
collection was performed at 0.20 s/scan, intercalated by an inter-scan delay of 0.024 
seconds. Hence, each DIA cycle lasted 0.424 seconds. Relatively to the total 15 min 
chromatography run time, data acquisition started at minute 0.9 and lasted until minute 13. 
 
2.4 Software 
2.4.1 UNIFI1.7™ 
The data processing software employed in this project was UNIFI1.7 (Waters 
Corporation, Milford, Massachusetts, USA). This tool performed data acquisition and storage 
for posterior analysis. Dependently of the screening method applied (targeted, semi-targeted 
or non-targeted) several parameters were altered accordingly to the circumstances. In this 
section it is discussed the used databases for unknown identification or for candidate 
structure elucidation. Additionally, it is highlighted the criteria that directly influenced the 
overall sensitive and specificity of the screening. Both varied accordingly to the amount of 
available data about what was to be screened for. 
Hence, in targeted screening the identification criteria were: exact mass < 3 mDa 
(mass error ± 3 mDa); experimentally acquired RT within ± 0.45 min from the library value 
provided (RT error) and a response threshold down to 114. The targeted database of 
compounds utilized was a Waters Toxicology LibraryTM (Waters Corporation, Milford, 
Massachusetts, USA) containing, among other information the molecular formula (exact 
mass and isotope pattern) of 1030 parent ions. Additionally, for each compound the 
respective product ions exact mass (if applicable) was also provided. 
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In semi-targeted screening, criteria that define the listing of the suspected hits in the 
“analysis method” compound list were as follows: mass error ±3 mDa; and response 
threshold up to 1000. The employed library (see, section 3.2.1) was a 1392 compound 
database in-house assembled storing, between other parameters: common name; molecular 
formula (exact mass) of compound and fragmentation pattern obtained either by direct exact 
mass plotting or through importation of molecular structure. The feasibility of these last two 
approaches is discussed in section 3.2.3. 
Non-targeted screening identification criteria corresponded to a mass error of ± 3 
mDa and to a higher response threshold of 30,000. No internal library of compounds was 
used. The external and online reference libraries used for structure elucidation were: 
ChemSpider (Royal Society of Chemistry, UK) and m/zCloud (HighChem LLC, Slovalkia). 
 
2.4.2 ACD/MS Fragmenter™ 
Fragmentation prediction based on in silico conditions for HE collision functions was 
executed by ACD/MS Fragmenter 11.01 from Advanced Chemistry Development 
laboratories (ACD/labs, Toronto, Canada). The software is a fragmentation prediction 
program based on established MS fragmentation rules from literature. For each predicted 
fragment it produced a three-structured presentation. Additionally this tool provided detailed 
information on the routes of fragmentation and all possible structure candidates for a specific 
mass. The exact masses of the fragments were provided automatically [97]. 
The settings adopted for this study were as follows: 
 In this context, the ionization type selected was API (ESI) in positive mode;  
 Charges from multicomponent structures and processing of salts were removed 
when possible; 
 Only hydrogen shift was allowed in the prediction, in detriment of double bonds 
cleavage, triple bond cleavage and saturated rings cleavage; 
 The reactions took into account for fragment formation were resonance and 
hydride shifts, as ring formation was not considered; 
 Exclusively acyclic bonds were selected to be cleaved; 
 The “Maximum Fragments Generated on Each Step” was set to 10; 
 The “Number of Fragmentation Steps” was set to 2; 
 The “Minimum Mass Value” for a fragment to be displayed was of 50 m/z. 
2.4.3 Additional software 
Fragmentation studies prediction and molecular structure drawing were performed by 
ChemBioDraw Ultra 12.0 (CambridgeSoft, Cambridge, Massachusetts, USA). 
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2.5 Databases 
2.5.1 LIMS 
LIMS is an in-house built RKA database which conciliates the results of several LC-
MS/MS and TOF/MS methods for each sample analyzed. The LC-MS/MS methods perform: 
quantification of barbiturates in hair; quantification of antipsychotics; quantification of exotic 
drugs; quantification of drugs present in very low dosages; and quantification of all common 
PTRCs such as amphetamines, opiates, opioids, benzodiazepines (see section 1.3.1). 
Additionally, a Q ExactiveTM is used to screen for synthetic cannabinoids. 
The other non-LC-MS/MS instrument that contributes for the results provided in the 
LIMS corresponds to the previous version of the TOF/MS instrument employed in this thesis 
and it screens exclusively for barbiturates, and its ionization polarity is set in negative mode. 
 
2.5.2 ChemSpider
TM
 
This on-line free chemical structure database provides a fast and free access to over 
32 million structures, properties, and associated information. It integrates and links 
compounds from approximately 500 data sources [113]. 
 
2.5.3 mzCloud
TM
 
A mass spectral database provided in Internet containing a freely searchable 
collection of accurate mass spectra. This was used for analytically assist on the identification 
of library absent compounds [114]. 
This tool was used in the last stage of non-targeted screening. It was used to search 
for m/z by correlating the analytically acquired three most intense product ion peaks of 
intended unknown compounds, with the AM spectra present in the on-line database [114]. 
The “Peak Search” parameters were: 
 “Search Type” was “MSn”; 
 “Libraries” field was set to “Reference”; 
 “Ionization Mode” imaged the one used in this project and was exclusively set to 
“positive”; 
 The “Search in” field was set to “Filtered Spectra” and “Recalibrated Spectra”; 
  “Precursor m/z” was compound dependent; 
 “Peak List” report was compound dependent and the “m/z Accuracy” was set to 
0.009 Da. 
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3 RESULTS AND DISCUSSIONS 
55 whole blood samples were screened for PTRCs by the three staged method. 
These samples pertained to antemortem and postmortem cases analyzed in the RKA 
between 1 October 2013 to 31 December 2013. 
In this chapter all steps of the developed method will be described and explained. 
The examples will contain a degree of continuation and correlation between the different 
stages of the method. This is particularly evident between the targeted and the semi-targeted 
analysis. 
Evaluation and case sample analysis procedures will be integrated in this chapter, as 
there is interdependency between both studies. 
3.1 Targeted screening 
3.1.1 Detection, Filters and Identification criteria 
The interpretation of chromatographic and spectral data using UNIFI1.7
TM 
was the 
first step of the analysis. The data treatment was guided by three factors: detection criteria, 
filtering criteria and identification criteria. 
 
Detection 
This factor corresponded to the instrument/software capability of detecting any peak 
in the analysis. Its sole criterion was that any chromatographic peak would be considered as 
a hit if its signal was 3 times higher than the baseline noise. Given the high RP of the 
analytical instrument employed in this project, the detected chromatographic peaks were in 
the order of the thousands per injection. A DIA cycle was performed at each detected peak. 
The resulting raw chromatograph didn´t display any additional information, such as peak 
identification. 
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Filters 
In order to narrow down the number of hits in every blood sample´s chromatogram 
and for effective compound identification, targeted screening had to be implemented. It 
consisted in limiting the data to be provided in the “Analysis Method” view (see Figure 1.24) 
to that of analytes listed in a targeted database. This process was done by automatically 
correlating empirically acquired data with information plotted in a commercially acquired list 
of compounds. The used targeted library contained 1030 compounds and enclosed 
information such as: compound name, molecular formula, expected RT, molecular s tructure 
and exact mass of fragment(s). The fragmentation information was strict to that predicted at 
a collision energy ramping from 10 to 40 eV. Hence for some analytes there wasn´t present 
any fragment information, as they fragment at different energies from those applied in this 
thesis´ DIA function. 
The basic filter provided by the instrument is denominated “identified”, which 
contained the following default filtering settings: 
 Only compounds present in the targeted database are accounted for in the 
screening (identification status = identified); 
 The difference between the acquired exact mass and the mass stored in the 
library (mass error) had to be lower than 3 mDa; 
 The difference between the acquired RT and the RT stored in the library (RT 
error) had to be within +/-0.45 min. 
However, because of the broad criteria used by the “identified” filter, the FP rate was 
very high, which hampered a time effective sample analysis. In order to reduce the number 
of detected compounds that corresponded to FPs, filters with narrower criteria were 
developed. The filter development study is described in section 3.1.5. 
Contingent upon the filter employed, there was a variation in the number of 
compounds to be classified has FP or UP listed in the “Analysis Method” window of the 
software. 
 
Identification criteria 
Identification criteria are what guided the operator to classify each hit as falsely (FP) 
or truly (UP) present in the sample. The filter criteria varied along the study, however, 
identification criteria, despite prone to subjectivity, corresponded to a more static set of rules: 
 The presence of adducts (Na+ and K+) in addition to the protonated (H+) ion 
enhanced the hypothesis of the hit to be an UP; 
 The exclusive presence of adduct(s) without the presence of the protonated ion in 
the LE spectrum categorized the hit as a FP; 
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 The presence of the parent drug and its metabolites in the same sample further 
regarded the hit as an UP; 
 In the same sample, the presence of compounds of the same chemical class or 
with similar toxicological effects classified the hit as UP; 
 The presence of fragments was accounted as the most important parameter to 
classify the hit as an UP. Especially if the product ion was exclusive to the 
compound in analysis or if the fragment was shared between a parent drug and 
its metabolites. 
 
3.1.2 Method evaluation: LOD, LOF and LTC 
The fragmentation pattern was of upmost importance for the identification of PTRCs 
in this thesis. Hence, it was implemented a procedure to empirically attain information about 
the LOD, LOF and LTC of 198 PTRCs from the targeted library. 
LOF corresponded to a narrower re-definition of LOI, as it exclusively provided the 
approximate blood concentration at which a chemical entity fragments, within collision 
energies ramping from 10 to 40 eV. 
This experiment consisted in spiking samples of 100 mg of blind blood with 198 
compounds divided into two mixtures, TOF mix A and TOF mix B, at different concentrations. 
The assembly of these mixtures was part of a protocol delineated by the RKA in order to 
implement a comprehensive method that will screen for the 300 most commonly identified 
PTRCs. 
The PTRCs concentrations accounted for were 0.001, 0.002, 0.005, 0.01, 0.02, 0.05 
and 0.1 mg/Kg. In order to consistently determine the LOD and LOF values, for each 
concentration, TOF mix A was spiked into three homologous blind blood samples. Therefore, 
globally 21 blind whole blood samples were spiked with 98 PTRCs contained in TOF mix A. 
The same methodology was implemented for TOF mix B, which contained the remaining 100 
compounds. 
The sole detector response and fragmentation information for each PTRC was 
acquired by comparison of the three homologous samples´ results. The criteria were as 
follows: 
 For each compound, the response for each concentration was the mean of the 
three trials; 
 If in any one of the three samples, for each concentration, at least one didn’t 
provide fragment(s), the overall result was set to “no fragmentation”. 
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The filter used in this procedure was the “identified” and the resulting table is 
presented in the Appendix I. 
Additionally, LTC values were attributed to a representative portion of the compounds 
present in the table. The values were provided by the literature, with clear relevance to 
Baselt [21]. 
The LTC contributed to qualify the importance of AM acquisition of product ions. 
Additionally it was of upmost importance in the method´s sensitivity evaluation, discussed in 
section 3.1.6. 
 
3.1.3 Sample analysis 
The results from the procedure discussed in the previous section revealed that from 
the 181 compounds, to which LTCs were determined, 43 did not fragment at concentrations 
below (or at) the LTC. Additionally, 4 out of the total 198 PTRCs weren´t detected and 9 
didn´t provide product ions below the highest concentration considered in the study (0.1 
mg/Kg). 
These results revealed that, despite an important tool for peak identification, 
fragmentation couldn’t be the sole criterion to be taken into consideration in the analysis. For 
cases where product ions weren´t provided, the remaining identification criteria listed in 
section 3.1.1, had to be considered. 
For explanation of the complexity of compound identification or cause of death 
determination, two examples are discussed in this section Figure 3.1 and Figure 3.2, page 
57, are displayed. 
Methylphenidate, is a psychostimulant drug used in the treatment of attention-deficit 
hyperactivity disorder (ADHD), postural orthostatic tachycardia syndrome and narcolepsy [21]. 
It was classified as a CP hit in sample TIM3052, relative to a postmortem case where the 
cause of death was a phenobarbital overdose. The result was provided by both parallel 
methods employed in RKA and in the method hereby developed. In the latter the presence of 
a product ion in the HE spectrum was what exclusively elucidated its identification. Hence 
this is an example of a LOF facilitated compound identification. 
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Figure 3.1 illustrates the software´s “Analysis Method” view after selection of the 
methylphenidate´s hit in the “Component Summary”. 
The subfigure (I) is the TIC in which it was possible to account for 4 clearly 
highlighted peaks correspondent to nicotinamide (1.06 min), mirtazapine (4.18 min) and both 
its metabolites: 8-hydroxymirtazapine (3.06 min) and N-desmethyl mirtazapine (3.91 min). As 
the finality of a TIC is to provide a holistic view of all chemical entities present in an injection 
(i.e sample), it is dependent on the highest count recorded. In this case it corresponded to 
mirtazapine which peak had an intensity of about 15x105 counts. As this instrument was 
regarded with a high RP (operated at a resolution higher than 18000 at FWHM) it was 
possible to detect a peak that eluted in the proximities (4.10 min) and had an intensity 
several times lower. Most importantly, the software was able to highlight the intended peak in 
a separate chromatogram. 
The chromatogram (II) provides the XIC for the exact mass of 234.14841 m/z, which 
corresponded to that of methylphenidate. However, this software capability is not compound 
specific but it aims for a specific AM. Hence, in this case, it displayed the methylphenidate 
peak but also an isomer that eluted at around 1.5 minutes or the compound that elutes at 1.5 
min had a fragment with the same exact mass of methylphenidate, which is highly 
improbable. Either way, the peak belonged to a compound not listed in the targeted library so 
it remained incognito throughout the analysis. Despite of not providing relevant information 
for the STA, with this example of isomer identification, it was possible to explain the feature 
of UNIFI1.7TM exact mass appointment tool (introduced in page 27, Figure 1.28) 
Subfigure (III) pertained to an additional XIC, this time specific for the exact mass of 
85.08005 m/z that characterized the sole methylphenidate product ion. This fragment was 
Figure 3.1 UNIFI1.7TM “Analysis Method” window of detection for methylphenidate in sample TIM3052. (I) TIC 
evidencing a discrete methylphenidate elution at 4.10 min; (II) XIC for the mass 234.14841 m/z, which characterizes 
the protonated molecule of methylphenidate and a disclosed isomer; (III) XIC for the mass 85.08005 m/z, not 
exclusively related to the identified product ion; (IV) Low collision energy spectrum for the elution time of 4.10 min; (V) 
High collision energy spectrum for the chromatographic peak at 4.10 min. 
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what made possible the indubitable classification of its precursor ion as an UP. In image 
Figure 3.1 (III) the RT of this fragment didn´t exclusively correspond to the elution time of its 
precursor ion (methylphenidate), but also to at least 7 additional RTs. This means that 7 
other compounds in the sample produced a fragment with an exact mass of 85.08005 m/z. 
As similarity of fragmentation pattern indicates similarity of molecular structure, this 
comparison tool proved useful for the identification of transformation products (TP) or 
metabolites, which presence is an active part of the identification criteria referred in 
section 3.1.1. Notably, in this XIC there is a compound signaled as “M”, with a RT of 2.83 
min, its importance for the STA will be addressed in section 3.2.2. 
Figure 3.1 (IV), depicts the spectrum resulted after fragmentation of the PTRC eluted 
at 4.10 min. The collision energy employed was 4 eV and corresponded to the LE function of 
the DIA. There it is illustrated a single peak with mass of 234.14841 m/z and one of its 
isotope, smaller in intensity, with a mass of 235.15152 m/z. In this case of methylphenidate, 
it wasn´t detected any adduct (Na+ or K+). However, they can be detected both in the LE and 
HE spectra and are an integrant part of the identification criteria listed in section 3.1.1. 
Adducts were produced in the method´s ion source and were formed from the 
analyzed precursor ions. The ions preserved all its constituent atoms but instead of a 
protonation, it was added one of the two referred possible atoms. Their importance resided in 
the fact that, with more ionized species for a single PTRC, more parameters were collected 
for the intended compound identification [115]. 
Figure 3.1 (V) presents the high collision energy spectrum for methylphenidate´s RT, 
the final stage of a DIA cycle. The collision energies involved corresponded to a ramping 
starting at 10 eV and finalizing at 40 eV. It provided the most valuable information for 
compound characterization: its fragment(s) exact mass(es). In this case, from the peaks 
present in the LE spectrum, UNIFI1.7
TM
 exclusively revealed the peak with 235.15152 m/z, 
which had, from the previous spectrogram, decreased from 8x105 to about 15000 counts. 
Additionally, it presented the methylphenidate sole fragment with an exact mass of 85.08005 
m/z, which corresponded to that of the protonated pyridine, which is one of the substituents 
of methylphenidate´s phenethylamine backbone structure (see section 1.3.2.2). 
In Figure 3.1 (IV), it is presented the molecular structure of the analyzed PTRC. At 
this stage UNIF1.7TM does not display any structure in the HE spectrum by itself, as the 
structure was there introduced for reader elucidation reasons. 
The provision of fragmentation for methylphenidate (highlighted in Table 3.1) was 
predicted by the method evaluation study referred in section 3.1.2. 
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Table 3.1 LOI, LOD and LTC information for 6 PTRCs present in Figure 6.I-6.5, Appendix I, with methylphenidate in 
evidence. Green background corresponds to fragmentation provision and red background to absence of product ion(s). 
The number zero symbolizes lack of detection. 
 
 
 
The table indicates that this compound was present in the blood sample TIM3052 at a 
concentration higher than 0.002 mg/Kg. This conclusion was in congruence with the LIMS 
database, which listed the compound´s concentration at 0.006 mg/Kg. Still, it is lower than 
the compound´s LTC (0.01 mg/Kg), which is the threshold at which methylphenidate 
manifests its therapeutic properties in the user. 
The classification of methylphenidate as UP proved to be simple and efficient. 
However, cases such as heroin intake determination, exemplified by sample TIM2955, 
revealed to be troublesome. In this sample, the analysis of a morphine peak, illustrated in 
Figure 3.2, attributed a classification of FP to the hit. However, in the LIMS it was reported 
the presence of the compound in the sample. Additionally, the preliminary report pointed the 
cause of death to be methadone poisoning, and that the deceased had a history of drug of 
abuse consumption. Hence, the probable intake of heroin had to be proved, not only through 
the identification of morphine´s fragments, but by a wider set of parameters. 
 
Morphine is the main psychoactive chemical present in opium and one of the active 
TPs of heroin (see section 1.3.1.2) and as stated, it was regarded as a FN in the targeted 
screening of sample TIM2955. 
Figure 3.2 UNIFI1.7TM “Analysis Method” window of detection for morphine in sample TIM2955. (I) TIC evidencing a 
discrete morphine elution at 1.08 min; (II) XIC of the mass of the protonated molecule of morphine (286.14841 m/z); 
(III) Low collision energy spectrum for the elution time of 1.08 min; (IV) High collision energy spectrum for the 
chromatographic peak at 1.08 min. 
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In the Figure 3.2 (I) it is presented the TIC in which it is plotted a low intensity peak 
relative to morphine, eluting at 1.08 min. Additionally it presents several high intensity peaks. 
Among them two belonged to the direct causers of death: methadone (eluted at the minute 
8.59) and EDDP, its toxicologically active phase I metabolite (eluted at 7.45 min) [21]. 
Of relevance it is the fact that morphine has a chromatographic early elution, which 
was an impediment of convenient detection, as there it is present a high degree of ME [71]. 
The XIC illustrated in the Figure 3.2 (II) clearly displays the problematic peak for the 
exact mass of 286.1434 m/z that belonged to morphine (1.08 min). The remaining peaks on 
the XIC were discarded as isomers, as their shape and intensity were not satisfactory. 
Supplementary, as no fragment was detected in this analysis, no additional XIC was 
presented in this targeted screening “Analysis Method” window. 
Figure 3.2 (III) provides the LE spectrum for the RT of 1.08, where the most intense 
stick peaks corresponded to 218.13895 m/z and 123.05544 m/z, with that of morphine 
(286.1434 m/z) being relatively residual. The amount of spectrographic peaks in the 
spectrum resulted from the LE collision energy revealed a problematic detection by the 
TOF/MS. This supports the assumption of the presence of contaminants at an early stage of 
the chromatography. 
Figure 3.2 (IV), respective to the HE spectrum, didn´t revealed any product ion of 
morphine, but exclusively peaks related to the fragmentation of the interfering compounds 
referred in the previous paragraph. One of them had a peak intensity of approximately 
3.5x105 and a mass of 85.02833 m/z, signaled as “C”. This fragment was accounted as the 
most common unknown fragment throughout this thesis, and its structure elucidation was 
covered by the non-targeted screening (see section 3.3.3). 
Additionally, morphine has a high molecular stability, evidenced by its richness in 
aromatic and non-saturated bonds, as observable in the molecular structure, in Figure 3.2 
(IV), (again, at this stage molecular structure is not provided by UNIFI1.7
TM
 and the 
illustration is exclusively presented for elucidation purposes). This signified that, for fragment 
provision, it would be necessary higher fragmentation energies at the DIA´s HE function (> 
40 eV) or a higher concentration of morphine in the sample TIM2955. 
This comes in alignment with the results enclosed in Appendix I, from which Table 
3.2 provides a comprehensive extract for analysis of the morphine hit. 
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Table 3.2 LOI, LOD and LTC information for 6 PTRCs present in Figure 6.I-6.6, Appendix I, with morphine in evidence. Green 
background corresponds to fragmentation provision and red background to absence of product ion(s). The number zero 
symbolizes the deficiency of detection. 
 
 
The LIMS listed morphine in sample TIM2955 at a concentration of 0.034 mg/Kg, 
which is above of its LTC of 0.01 mg/Kg and Table 3.2 reveals that UNIFI1.7TM didn´t provide 
product ions for the concentration attained by parallel quantitative methods. Nevertheless, 
the same table plots “morphine, 6-monoacetyl” (6-MAM), the other active heroin´s phase I 
metabolite (see section 1.3.1.2), as a fragment provider when at a concentration equal or 
above to its LTC of 0.01 mg/Kg. However, 6-MAM´s presence wasn´t reported by the LIMS, 
so its concentration remained non-determined throughout the analysis. Hence, this additional 
heroin metabolite is exclusively present in UNIFI1.7TM´s targeted list and the “Component 
Summary” of morphine (see Figure 3.3) revealed the presence of 6-MAM in the postmortem 
sample TIM2955. 
As demonstrated in the image, 6-
MAM, with a “Response” of 151 provided 
one “Identified High Energy Fragment” 
which had a mass of 268.13323 m/z. This 
signified that the compound was present in 
the sample at a concentration higher than 
0.01 mg/Kg. Hence, 6-MAM was classified 
as an UP, which was used as evidence 
that the deceased had consumed heroin, 
despite the cause of death wasn’t 
attributed to that fact. 
The fragmentation of 6-MAM can be explained by the weak sigma bound between the 
carbon no. 6 of the backbone structure and the reactive oxygen of the acetate group. There 
oxygen’s electronegativity, fueled by the electron attraction from the rest of the acetyl radical, 
contributed to a facilitated bound cleavage. This way, at a collision energy of 40 eV and even 
hypothesizing that 6-MAM is at a lower concentration than morphine, the first exhibited a 
fragment, which was of interest for compound identification, while the latter, with a more 
stable structure, didn´t produce any product ion. 
Figure 3.3 Extract of the “Component Summary” table for 
sample TIM2955, evidencing the presence 6-MAM, and its 
most common fragmentation pathway. 
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Concluding, the parameters which morphine´s hit missed to satisfy, to be classified as 
an UP, were those that permitted the identification of 6-MAM. This rectified the FN 
classification of morphine. 
Both analyses exemplified in Figure 3.1 and Figure 3.2, provided an explanation of 
the line of thought followed for the analysis of the 55 whole blood samples. The results are 
displayed and discussed in section 3.1.6. 
3.1.4 “Excluded” library 
In order to decrease the FPs from the component plot of the “Analysis Method” it was 
assembled an “excluded” library which consisted in listing compounds with minor 
toxicological relevancy but with great contribution for a high FP frequency. Those compounds 
that are present in a substantial number of samples of a batch are to be considered 
excluded. Compounds like tryptophan which “Summary Plot” is presented in Figure 3.4, 
evidenced that they are considerable expendable for the current STA. In the figure it is 
shown that tryptophan was present in every blood based injection. The two exceptions were 
the injections correspondent to “BAMBS 1” and “BAMBS 2” which did not produced any 
response for tryptophan, as they were aqueous solution. BAMBS consisted in a mixture 
containing 64 pure standards of pertinent 
compounds used by RKA in routine 
analysis. Then the BAMBS reference 
solution was substituted by TOF mix A and 
TOF mix B, tested in section 3.1.2.  
Differently, in Figure 3.4, all the 
other blood based injections of batch 1 
produced a response for tryptophan. The 
most intriguing were the injections in which 
it was used blind blood, which produced a 
response of about 5000. This way, it was 
concluded that tryptophan was an 
endogenous chemical of whole blood [21]. 
However it´s response increased in 
injection pertaining to cases where the amount of UP for drugs (medical and of abuse) was 
high. Such as samples: TIM2943, TIM2946, TIM2952 and TIM2955.  
This procedure was repeated to all compounds of the 1030 that had produced at least 
one hit in one of the 6 analyzed batches with the “Identified” filter. Additionally, based on the 
literature [21], toxicological information about the compounds was listed. All the information 
Figure 3.4 “Summary Plot” of tryptophan detector response in 
batch 1. 
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was conjugated in an “excluded” library, present in the Appendix II, being Table 3.3 
representative of this list. 
 
Table 3.3 Tree excluded compounds from the 35 present in the “excluded” library in Appendix II. 
Chemical excluded Description Toxicological information [21] 
Corticosterone Present in all blood samples, including in blind 
blood. 
Endogenous steroid hormone. Non-
PTRC. 
Cotinine Present almost all blood samples, including in blind 
blood. 
Alkaloid metabolite of Nicotine. Rarely 
toxic. 
Tryptophan Present in all injections, including in blind blood.   Endogenous amino acid. Non-PTRC. 
 
Summarizing, 35 compounds from the targeted library were included in the “excluded” 
list of compound. These results were of importance for the filter development study. 
 
3.1.5 Software filters 
In the method evaluation context, while undergoing targeted screening analysis, two 
additional filters were developed, with the objective of reducing the FP rate verified while 
using the software´s standard filter. Hence, 3 filters were accounted for in the targeted 
screening stage of this STA: “Identified” filter, Filter I and “Adduct” filter. 
 
“Identified” filter  
The parameters are present in the topic “Filters” of the section 3.1.1. As stated, this 
filter´s criteria were very broad and produced a great amount of FPs. 
 
Filter development  
To address the FP rate problem a filtering study was delineated. The filter study was 
a possibility because of the export option of the software, which enabled the export of the 
information exclusively displayed in 
the “Component Summary”, present 
in the “Analysis Method” window. 
An example is displayed in Figure 
3.5 for the injection relative to 
sample TIM2938. There, in the 
“View” denominated “EXPORT 
View” it was stored the information 
that was wanted to be exported. 
The information displayed included: 
component name, molecular formula, identification status, analytically acquired RT, response 
of the hit, and the presence of adducts. 
Figure 3.5 “Component Summary” of the “Analysis Method” of sample 
TIM2938, which displayed exclusively data selected in the “EXPORT view”. 
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The file was exported in ExcelTM format (displayed in Table 3.4), which reflected the 
order of the columns of the “Component Summary” present in Figure 3.5, with three 
additional columns that facilitated the filter study. 
 
Table 3.4 Excel format of the UNIFI1.7TM exported data. Additional column (I) for conjugation of all injections into one 
spreadsheet. (II) Additional column created for classification purposes (III) column to display utilized filter in the analysis. 
 
 
The 55 samples analyzed in this project were distributed through 6 batches. Each 
batch had injections that were classified as forensic case sample (TIM followed by four 
algorisms) and quality control injection (e.g. BAMBS). As depicted in the “Summary Plot” in 
Figure 1.26, an analyte listed in the targeted library will give a detector response (= or ≠ 0) in 
every injection. However, when exporting the UNIFI1.7TM data to ExcelTM format, each 
injection will produce results displayed in separated spreadsheets. To facilitate the analysis, 
a macro was programed in order to put, for each one of the 6 batches, every injections´ 
results into a singular spreadsheet. Hence, column (I) presented in Table 3.4, denominated 
“Injection_Name”, listed every injection which would be otherwise separated. 
Column (II) is supplementary to what was exported by the software. It contained 
classification of the various hits, which was indispensable for the filter development. The 
column was purposely named “Label” so the software could recognize the data when 
imported back from ExcelTM format data to UNIFI1.7TM format. This way, for every batch, it 
was possible to display a “Label” column in the “Summary Component” which provided 
immediate classification of any analyte in the “Component Summary”. 
Column (III), named “Filter” was added to the exported ExcelTM file so it could be 
possible to compare the FP rate reduction capabilities of each filter created. 
  
Filter I  
Following the procedure previously described, theoretical filter development was done 
based on ExcelTM, so the parameters for a software filter could be acquired. The objective 
was to discover a filter that reduced the FP rate to a minimum without influencing the 
sensitivity of the method, i.e. the amount of UPs and FNs. 
The results of the filter development are present in Figure 3.6, which displays the 
parameter adopted in the software Filter I. 
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As in the case of the “Identified” 
filter the “Identification status” was plotted 
as “Identified”, meaning that the screening 
would target only for those chemicals 
present in the targeted library. However, in 
the case of Filter I case, the information 
provided in the “excluded” library 
(Appendix II) was implemented in the 
analysis. This meant that in the 1030 target 
library, 35 compounds were plotted as excluded from the analysis, which dramatically 
contributed for the reduction of the FP rate. Hence, the field relative to “excluded” was set to 
“Yes”. 
All responses in the “Component Summary” were considered from the value 114 
onwards, as terbutaline hit of sample TIM2967, from batch 2, was the UP from all the 
targeted screening (employing the “Identified” filter) with the lowest response (114.108). 
Terbutaline is a β2-adrenergic receptor agonist and it is employed as a “reliever” inhaler in 
the management of asthma symptoms [21]. The hit was further classified as CP following 
comparison with the results listed in the LIMS database. The cause of death was directly 
related to a lung disease. 
To additional parameters such as mass error and RT error it was attributed a 
maximum of 3 mDa and 0.45 min, respectively. These parameters were preserved from the 
“Identified” filter. 
 
“Adducts” filter 
From the results of the targeted screening, parameterized by the “Identified” filter, it 
was possible to attain that any hit that had spectral information of the adducts Na+ and K+ or 
both, but not of the protonated molecule were designated FP. Hence, a virtual theoretical 
filter was developed, excluding all hits with this particularity.  
This “Adducts” filter considered the same parameters as Filter I but it had an 
additional field named “Adduct” that was set as “excluded”. In the theoretical ExcelTM based 
study, this filter was the one that most rectified for the presence of FP in the results without, 
conditioning the sensitivity of the method. 
All results from the filter study are presented and discussed in section 3.1.7. 
 
Figure 3.6 Software filter I set parameters. 
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3.1.6 Target analysis results for the 55 forensic samples 
The overall results of targeted screening for PTRCs in the 55 forensic whole blood 
samples are presented in Appendix III. The example of case TIM2938 (see Table 3.5) is 
representative for all the analyzed samples. The screening was elaborated employing the 
“Identified” filter as the amount of FP was not of interest at this stage and exclusively 
sensitivity aspects of the developed method were of relevance. 
The column titled “Case” lists all the forensic samples involved in the targeted 
screening analysis. “RKA Report” column states the conclusion reached by the department 
concerning the cause of death, in the case of a postmortem analysis. It was stated 
“antemortem” for cases in which the person was alive during toxicological investigation. The 
column “Compounds” lists all the chemicals identified either by UNIFI1.7TM or by parallel 
methods employed in RKA. The column designated “UNIFI1.7TM” lists the independently 
acquired results in the method developed in this project. Due to the amount of data, FP hits 
are absent from Appendix III. Exclusively the UPs and FNs are listed in the column. 
 
Table 3.5 Target screening results of sample TIM2938, present in Appendix III. 
Case RKA report Compound UNIFI1.7TM LIMS (mg/Kg) FN evaluation 
 
 
 
TIM2938 
 
 
 
Kidney disease 
Levomepromazine UP 0.024  
Enalapril FN 0.001 LTC Above 
Hydrocodone UP Negative  
Codeine UP 0.16  
Codeine, 
glucuronide- 
UP Negative  
Morphine FN 0.04 LTC Below  
 
In the column titled “LIMS (mg/Kg)” it is shown the concentration at which the 
chemical was identified. The column presents “negative” results for compounds found by the 
method hereby developed, but missed in every parallel instrument employed in the 
investigation of the same forensic case. 
Lastly, the column “FN evaluation” assesses the relevance of compounds absent in 
the UNIFI1.7TM analysis. The evaluation was done, with regard to the LTC (listed in 
Appendix I) for each FN. If the measured concentration, listed in LIMS database, surpassed 
the LTC, then the FN was considered toxicological relevant for analysis. In the eventuality of 
a measured concentration being below the respective LTC, the FN was considered 
redundant as it had no influence in the toxicological diagnostic. In the case of FNs with LTCs 
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below the measured concentration, additional parameters were accounted for in their 
relevancy evaluation. 
Hence, if in the sample it was detected, by UNIFI1.7TM, the parent drug or a 
metabolite of the compound absent in the screening developed in this thesis, the FN was 
considered redundant. Additionally, if in the same sample it was identified a compound (UP) 
with the same toxicological properties as the FN, the latter was considered redundant (see 
the example, in sample TIM2955, of morphine and 6-MAM, present in Table 3.2, page 59). 
Furthermore, if the FN was considered a non-PTRC it was considered redundant for 
diagnostic. Such was the case of ibuprofen (at 5 mg/Kg) in sample TIM3027, as it is an over-
the-counter non-steroidal anti-inflammatory drug (NSAID) [21]. Additionally, this compound is 
only detectable in negative ionization mode, which wasn´t covered by this project. 
In the postmortem forensic case exemplified in Table 3.5, it was registered 2 FNs. 
Enalapril, which LTC is higher than the concentration provided in LIMS, so it was considered 
irrelevant for cause of death appointment. The other FN was morphine which LTC is 4 times 
lower than the concentration provided by the LIMS database. As the deceased hadn´t a 
history of drug of abuse consumption, the morphine present in the sample was probably an 
active component in a pharmaceutical administered to the patient, diagnosed with a kidney 
disease. 
Morphine is the gold standard in commercialized analgesics 
[23]
, contrarily to 6-MAM. 
As there wasn´t heroin intake, the 6-MAM wasn´t present in the blood sample and so this FN 
was one of the two hits that were evaluated as important misses (see Table 3.6) by the 
method herby developed. 
Table 3.6 Targeted screening statistical results 
Classification No. of hits No. of compounds 
UP 231 103 
CP 119 53 
LIMS negative 112 58 
Total FNs 28 18 
Redundant FNs 26 17 
Important FNs 2 1 
 
The table was assembled based on the data interpretation parameters previously 
discussed and on the results provided in Appendix III. 
From Table 3.6, an analysis of the sensitivity of the method´s targeted screening was 
possible (see Table 3.7) and it was based on the equation (1.10) present in section 1.5.3. 
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Table 3.7 Target screening sensitivity in function of FN evaluation 
FN Sensitivity (%) 
Total 231
(231 + 28)
x 100 = 89 % 
Important 231
(231 + 2)
x 100 = 99 % 
Hence, from a holistic point of view, the sensitivity of the method was of 89 %. After 
the toxicological evaluation of the 28 hits classified as FN, the sensitivity raised to 99 %. 
Despite an increase to an almost flawless sensitivity, 2 FNs didn´t permit the method 
to be in agreement to Roman et. al. [71] condition, which states that a targeted screening, in 
a STA, should provide a sensitivity of 100 % [71]. 
The two FNs corresponded to morphine hits in samples TIM2938 and TIM3012. In 
both cases the compound was present in a concentration several times above its LTC and 6-
MAM or other metabolite of heroin were not targeted identified. 
This compound is the most problematic to be identified and, in the case of TIM3012, 
the compound wasn´t possible to be detected by the instrument. Hence, it can be concluded 
that this method is somewhat ineffective to screen for morphine. Another method has to be 
run in parallel to rectify this instrument/software limitation. 
Additionally, a pertinent FN was phenobarbital in sample TIM3052. As a barbiturate, it 
is a neutral but fairly polar compound, however its analysis is confined to methods employing 
negative ionization in the ion source [69]. This PTRC was the cause of death in this forensic 
case but its absence in UNIFI1.7TM wasn´t classified as an important FN, due to the fact that 
this method did not listed the compound in the library. Additionally, even integrated in the 
suspect library for semi-targeted screening, it wasn´t able to be identified. This is justified 
with the fact that this 3 staged screening method was exclusive for basic chemicals and the 
ionization polarity in the source was set to positive in all stages of the analysis. 
To assess the sensitivity of this method to barbiturates, a run of the sample TIM3052 
should be done, in the same instrument, but in ESI negative mode [69]. 
As it wasn´t possible to perform this procedure, this FN hit was classified as 
inconclusive. 
Despite some drawbacks, this method was able to obtain a generous amount of hits 
classified as UP but absent in the LIMS database. Indeed, for the 55 samples analyzed, 112 
hits were exclusively identified by the method developed in this project, but not by any of the 
methods ran in parallel. 
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3.1.7 False positive frequency 
It is stipulated that an STA has to be time efficient and sensitive [71]. As a sensitivity of 
100 % wasn´t possible, for the reasons stated in the previous section, a specificity study was 
implemented in order to provide the lowest number of FP hits without influencing the UP hits 
obtained in the analysis parameterized by the “Identified” filter. 
A comparison between the three 
filters considered in section 3.1.5 
regarding the number of FP and UP hits 
was performed and the results are 
presented in Figure 3.7. 
From the graphical information, it 
is possible to attain all that the filters 
provided the same amount of UP, hence 
there wasn´t variability between the 
sensitivity of the method during the filter 
study. The only aspect that varied from 
the filter with the broadest parameters (“Identified” filter), to the one with the narrower filter 
criteria (“Adducts” filter), was the amount of hits classified as FPs. In Table 3.8 specific 
quantities and the FP frequency (see equation 1.9 in section 1.5.3) for each filter are listed. 
Table 3.8 FP and UP count, and FP rate. 
Filter No. de FP No. de UP Frequência de FP (%) 
“Identif ied” f ilter 1859 231 1859
(1859 + 231)
X 100 = 89 
Filter I 479 231 479
(479 + 231)
X 100 = 68 
“Adducts” f ilter 256 231 256
(256 + 231)
X 100 = 53 
 
In Roman et al [71] it was developed a targeted screening method with a targeted 
library containing 240 PTRCs. Based on that amount, the author defined that the number of 
FP should be 5 % of the total hits in each analysis. Therefore, as the developed method 
employed a targeted library containing 1030 compounds, a FP frequency of 22 % was 
considered optimal to allow a time efficient but sensible analysis. 
Information about the filters´ parameters is present in section 3.1.5, and from Table 
3.8, the filter that better reduced the overall number of FP without compromising the UP hits 
was the “Adducts” filter. However, due to a UNIFI1.7TM deficiency, it was not possible to 
apply this theoretical filter as a software filter. For example, if in the “Enter the Filters Criteria” 
window (see, eg. Figure 3.6) it was selected the exclusion of hits that were exclusively 
Figure 3.7 Filter comparison regarding FP and UP hit count. 
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detected as a Na+ adduct (not providing the protonated molecule in the spectrogram), the 
filter would exclude all hits that provided the Na+ adduct, including those associated with the 
protonated ion (which presence is compulsory to classify the hit as a UP). In this way the 
“Adducts” filter was excluded from analysis and the problem was reported to the 
manufacture´s software developers. 
Thereof, Filter I (criteria present in Figure 3.6 and explained in section 3.1.5) was 
the most suited to be employed in the method targeted screening. Comparatively to the 
“Identified” filter, it provided a reduction of 74% in the number of FP hits without influencing 
the sensitivity of the method. Despite its FP frequency was 3 times greater than that 
proposed by Roman et al [71], the time required to analyze each injection varied from 2 to 20 
minutes, which was considered acceptable for RKA standards. 
 
3.2 Semi-targeted screening 
3.2.1 Semi-targeted library 
As referred in section 1.4.9, the main distinctions between targeted and the semi-
targeted screenings are the fact that the latter neglects the RT of all compounds and, in most 
cases, it only accounts for the suspect molecular formula, which is then translated to exact 
mass by the UNIFI1.7TM. 
The semi-targeted database was assembled in ExcelTM format and lists 1392 
compounds of toxicological relevance obtained from 14 different sources (see Table 3.9). 
The compounds were absent in the targeted library and for each, compound name and 
molecular formula were compulsorily plotted in the semi-targeted library. Additional 
compound information present in the database was: molecular structure encrypted in a .mol. 
file; exact mass of fragments obtained from literature; IUPAC name; drug classification based 
on compound structure; and CAS Number. 
Table 3.9 Extract of the in-house built semi-library. 
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The different sources used for database assembling can be divided into websites, 
scientific literature, RKA research, international organizations and drug forums. 
Websites 
 Southern Association of Forensic Scientists. This site displays a database 
providing molecular formula and structure of common and uncommon drugs of 
abuse. Its elaboration is the result of the crossing of analytical results from seized 
drugs in an inter-laboratory strategy. Its main purpose is to serve as an analytical 
tool in order to facilitate the identification of unknowns [116]. It contributed with 357 
compounds for the semi-targeted library. 
 Wikipedia. A free-access/collaboratively edited Internet encyclopedia in which the 
listing of “designer drug” is actively actualized [117]. It contributed with 38 suspect 
compounds. 
 Chemograph Plus. This website corresponds to a German language program for 
formulation of chemical structures based on adulterations of previously known 
molecular structures. It´s main purpose is the provision of predictions of the black 
market manufacturers´ future productions [118]. It provided 325 suspect compounds 
to the library. 
 Chemicalsoft. This software provided a mass spectra library of reference 
compounds fragmented at an energy ranging from 20, 35 and 50 eV. It has a 
specific section for “designer drugs”. It provides nominal mass of parent and 
product ions [119]. It contribuited with 88 compounds to the library. 
Scientific literature 
 de Castro, et al. [120].This research covered a validation of a targeted-screening 
method based on AM acquisition. It provided the backbone for the semi-targeted 
library developed in this project. This paper supplied the suspect database with 
exact mass of product ions, predicted with resource to ACD/MS Fragmenter™. 
145 suspect compounds with the respective fragment(s) exact mass at a collision 
energy of 40 eV, were added to the developed database [120]. 
 Roman et.al. [71]. This paper revealed a similar procedure to that developed in de 
Castro, et. al [120]. 27 additional common drugs of abuse and pharmaceuticals, 
absent in the hereby utilized targeted library, were added to the suspect library. 
On-going research 
 PhD research taking place in RKA provided additional 154 compounds relative to 
synthetic cannabinoids. It provided the parent drug and metabolites exact masses, 
including those of the respective product ions. 
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International organizations 
 EMCDDA. The data presented in this organization’s website provided a table 
outlining the similarities and differences of the national system in the EU and 
Norway, regarding the classification of drugs and precursors according the three 
UN Conventions of 1961, 1971 and 1998 [121]. The report provided additional 10 
suspect compounds. 
 UNODC: The website of the United Nations Office on Drugs and Crime provided a 
report highlighting the importance and the challenges behind the identification of 
new psychoactive substances [122]. Additional 173 compounds with the respective 
structures were added to the semi-targeted library. 
Drug forums 
 Erowid Experience Vaults. Website where it is attempted to catalog a wide variety 
of experiences people have with psychoactive plants and chemicals [123]. 60 
compounds absent in the targeted library where found in the testimonial reports 
and added to the semi-targeted library. 
 Drug-Forum. This website is similar to Erowid [124]. The database there presented 
contributed with 15 compounds for the suspect library assembling. 
 
3.2.2 Sample analysis based on import of fragment´s AM 
From the total amount of compounds present in the semi-targeted library, 352 had at 
least one fragment with exact mass. All product ions’ AMs were provided by literature [71, 120]. 
Compound fragmentation pattern information can be imported by plotting the exact 
mass of the fragments in the convenient slot. 
Table 3.10 exemplifies an importation template for 5 analytes to which it was possible 
to obtain exact mass values for the fragments. 
 
Table 3.10 Importation table for 5 analytes containing fragments with exact mass. 
 
 
The ExcelTM table has to be always in this format, even if there were empty columns, 
such as “Structure” and “Adduct” in this case. 
Additionally, it is important to state that the table contains a value for RT, even though 
this criterion isn’t of relevancy for the semi-targeted screening. This happens because, in 
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every occasion, UNIFI1.7TM has to detect a RT value in order to import a library. This value 
(0.5 min in this case) can be deleted afterwards, in the software settings. 
The same 6 batches used in the targeted screening were then updated in order to 
delete the targeted-library and import the semi-library with 1392 compounds. 
As with the targeted library, all the compounds in the in-house database were now 
regarded as “identified”, which is important for filtering purposes. 
A new Filter II was developed to meet the required criteria for a time efficient semi-
targeted screening and is displayed in Figure 3.8. The parameters there present were the 
ones that were considered for every stage of the semi-targeted screening, of the same 55 
whole blood samples treated in the targeted analysis. 
Only compounds with responses 
above 1000 were to be taken into account. 
Given the amount of FPs in the targeted 
screening with a response threshold of 
114, it was concluded that for semi-target 
analysis a higher threshold had to be used, 
as the screening considered a larger library 
and produced more hits due to isomerism. 
The m/z was selected to be below 1000 as 
it is screened for small molecules. The 
identification status was “Identified”, like in Filter I (Figure 3.6), but now with a different 
compound library. 
The considered RT was less than 10 min, so all the compounds that eluted after this 
time were filtered out, as it was previously observed that they corresponded to interferences. 
Mass error (mDa) and RT error were preserved from the filter used in targeted 
screening. 
The first stage of the semi-targeted analysis of the 55 whole blood samples, 
comprehended the import of the 1392 compound semi-library, with 352 compounds with 
predicted fragments with exact mass, provided by literature. All fragmentation information 
from these suspects was exclusively imported as exemplified in the Table 3.10. 
At this stage of semi-targeted screening, based on prediction of exact mass of 
fragments by softwares other than UNIFI1.7TM, 7 hits ware considered UP and 6 compounds 
were identified. Results are presented in section 3.2.5. 
Figure 3.8 Software Filter II parameters. 
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Among the semi-targeted identifications, there is ritalinic acid in sample TIM3052, 
illustrated in Figure 3.9. This example of semi-targeted screening provided complimentary 
information to that obtained in the targeted analysis of the same sample (see Figure 3.1). 
In Figure 3.9 (I), it is presented the TIC where 2 major hits, labeled as pirbuterol 
(1.05 min) and lysergic acid amide (2.73 min) where later classified as FP. Ritalinic acid, the 
inactive major metabolite of methylphenidate [125], was not visible as it had a peak with a 
comparative lower intensity. 
Subfigure (II) is relative to the XIC for the exact mass of 220.13325 m/z, which is 
exclusively characteristic to ritalinic acid (2.83 min). In this case there is only one hit for the 
suspect in analysis. This is a plausible occurrence when not providing RT in the library, but 
generally, it is common to exist, for a single suspect analyte, multiple hits in the XIC. This is 
dependent in the number of isomers in the injection (which is zero in this example). This 
matter will be further discussed in section 3.2.4. 
In the second XIC (subfigure (III), relative to the mass 174.12694 m/z, a fragment 
was identified but can be classified as irrelevant as the intensity (just above 200 counts) is 
too low for a clear correlation with other PTRCs in the sample. 
The XIC (IV), of the mass 85.08005 m/z, is of relevance in terms of fragmentation 
pattern information, as it correlates ritalinic acid with other compounds present in the same 
sample, such as those that eluted at 1.05, 1.51, 1.72, 2.44 and 4.20 minutes. The latter is the 
RT of compound “P”, correspondent to methylphenidate which was identified in the targeted 
analysis, (illustrated in Figure 3.1), and ritalinic acid was the compound “M” of the same 
figure, but was now possible to be identified as it was present in the suspect library. 
Figure 3.9 UNIFI1.7TM “Analysis Method” window of detection for ritalinic acid in sample TIM3052. (I) TIC 
evidencing two suspect hits with high intensities and a discreet non-identified peak at 4.10 min corresponding to 
compound P; (II) XIC for the mass 220.13325 m/z, which characterizes the protonated molecule of ritalinic acid;. 
(III) XIC for the mass 174.12694 m/z, exclusively related to the identified product ion; (IV) XIC for the mass 
85.08005 m/z, characteristic of the fragment produced both by suspect M (2.83 min) and compound P (4.10 min); 
(V) Low collision energy spectrum for the elution time of 2.83 min; (VI) High collision energy spectrum for the 
chromatographic peak at 2.83 min. 
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The provision of the fragment with mass of 85.08005 m/z made possible a correlation 
between a parent compound (methylphenidate) and its TP (ritalinic acid). This satisfied the 
identification criterion which states that the presence of a metabolite (even if not a non-
PTRC) enhances the credibility of the precursor ion´s hit. 
The spectra provided in the right quadrant of the Figure 3.9 reveal the suspect´s 
protonated ion (220.13325 m/z) and its sodium adduct (252.11500 m/z) in the LE spectrum 
(Figure 3.1 (V)). Additionally, the already referred fragments (174.12694 m/z and 85.08005 
m/z) are presented in the HE spectrum (Figure 3.1 (VI)). The ritalinic acid molecular 
structure illustrated was not directly provided by the software, as this is not the case of a 
semi-targeted screening based on fragmentation prediction acquired from molecular 
structure importation. The structure is exclusively presented for elucidation reasons. 
 
3.2.3 Validation of fragment prediction based on molecular 
structure import 
The previously discussed hit was possible after importation of fragmentation exact 
mass predicted by literature. However, it was found that UNIFI1.7TM enclosed the capability 
of predicting, by itself, fragmentation. Literature revealed that ACD/MS Fragmenter™ is the 
tool of choice for product ion prediction [71, 120]. 
As there isn´t any literature disclosing UNIFI1.7TM capabilities in this ambit, this 
project firstly provided an evaluation study before implementing this software´s feature in the 
method hereby developed. 
The experiment comprehended 4 designer drugs: 
 Pyrovalerone: a pyrrolidinophenone based designer-drug; 
 5-FUR-144 (or XLR11): a tryptamine based designer-drug; 
 5-F-AKB48: a tryptamine based designer-drug; 
 α-PVP: a pyrrolidinophenone based designer-drug. 
All 4 compounds were not present in the targeted library, but they were listed in the 
suspect-library. Pure standards were available a priori. 
This experiment had the objective of, with a narrow suspect-library, evaluate if it was 
possible to detect and identify the 4 compounds diluted in whole blood and under controlled 
conditions with both methods of fragmentation prediction: AC/D MS FragmenterTM and 
UNIFI1.7TM. 
The procedure was divided in 3 parts: spiking, fragmentation prediction by UNIFI1.7TM 
and correlation with AC/D MS FragmenterTM fragment prediction. 
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3.2.3.1 Blood spiking with 4 pure standards 
 The respective pure standard solutions of all 4 compounds, at a concentration of 
1.0 mg/mL were diluted in a aqueous solution of MeOH (50:50 v/v) to make the 
respective 4 solution at a concentration of 1 µg/mL; 
 A volume of 2 µL of each resulting solutions was spiked into three blind blood 
samples with volumes of 100 µL, in order to produce three homologous biological 
matrixes with a representative concentration of 20 ng/mg each; 
 Each tube was shacked and undergone further automatic sample preparation ( see 
procedure in section 2.3.1); 
 The three samples were then injected into the instrument; 
 The resulted raw data was analyzed through UNIFI1.7TM; 
 The software filter employed in the study was the “Identified” filter (parameters 
presented in section 3.1.1). 
 
3.2.3.2  Import of molecular structure to UNIFI1.7TM  
To exemplify the import procedure of molecular structure for prediction of 
fragmentation of intended analytes, Table 3.11, provides the importation of the 4 designer 
drugs used for validation of the UNIFI1.7TM capability of predicting the fragmentation pattern 
of suspects. 
Table 3.11 Import table for 4 designer drugs containing molecular structure for further fragmentation prediction. 
 
 
To obtain the structures it was drawn in the ChemBioDraw Ultra 12.0TM the respective 
molecular structures in .mol format. 
The RT corresponds to 0.5 min for the same reason explained in section 3.2.2. 
It is possible to attain that, in this 
case the columns relative to fragmentation 
exact mass are empty and the column 
“Structure” has the same identification 
name of the .mol file. Both names have to 
be equal for correct structure importation 
(see Figure 3.10). Figure 3.10 File containing ExcelTM file and .mol files 
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Additionally, the ExcelTM file that holds the import table has to be in the same folter as 
the respective .mol files when the spreadsheet is imported to the software. 
The three homologous blood samples were analyzed by UNIFI1.7TM. It is given the 
case of α-PVP in Figure 3.11, as a representative example of the analysis of the 
fragmentation prediction by molecular structure import. 
Subfigure (I) is referent to the TIC of one of the homologous blood samples and it 
presents four peaks of high intensity: pyrovalerone (5.84 min), XLR11 (11.92 min), 5F-
AKB48 (12.22 min) and α-PVP (4.42 min), the reference standard in analysis. 
XIC (II) for the exact mass 232.107018 m/z, which is exclusive to α-PVP, presents 
only one peak, meaning that there is not any endogenous compound in blood that is an 
isomer of α-PVP, otherwise the XIC would have more than one hit for this reference 
standard. This could be possible as there isn´t any RT stored in the 4 compound library used 
in this analysis. 
Figure 3.11 (III) plots the low collision energy spectrum for the elution at 4.42 min. It 
highlights the protonated α-PVP peak, corresponding to the mass of 232.107018 m/z. 
Figure 3.11 (IV) presents the high energy spectrum of the compound eluting at min 
4.42, signaled as (a) and its product ions: (b) with mass of 198.11384 m/z, (c) with mass of 
161.09677 (m/z), (d) with mass of 126.12807 m/z, and (e) with mass of 105.03386 m/z. A 
molecular structure is illustrated exclusively for fragment (c), for illustrative convenience, as 
the software can illustrate the molecular structure for every fragment it predicts. 
Figure 3.11 UNIFI1.7TM “Analysis Method” window of detection for α-PVP in a whole blood at 20 ng/mg. (I) TIC evidencing 
the four spiked reference standards; (II) XIC for the mass 232.107018 m/z, correspondent to the protonated α-PVP; (III) 
Low collision energy spectrum for the elution time of 4.42 min; (IV) High collision energy spectrum for the chromatographic 
peak at 4.42 min, displaying the molecular ion (a), and its characteristic  fragments (b -e). 
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Using this method of fragmentation 
pattern prediction, UNIFI1.7TM erroneously 
considers the molecular ions (parent ion (a)) 
as an “Identified High Energy Fragment” as it 
is possible to attain from the “Component 
Summary” of α-PVP´s “Analysis Method” (see 
Figure 3.12). This pyrrolidinophenone 
provides 4 fragments (b to e) and not 5, as it 
was previously stated in the Figure 3.11. 
Additionally, this method of fragmentation prediction did not display any additional 
XIC besides the one relative to the exact mass of the protonated molecule, as it is 
observable in Figure 3.11. This is a disadvantage of the product ion prediction by part of 
UNIFI1.7TM. Despite predicting 4 fragments in the case of α-PVP, the software doesn´t 
displays the respective XICs, as it occurs in the case of fragment prediction based on AM 
import. 
The proof of concept of this method of product ion prediction can only be achieved 
with the comparison of its results with those of a homologous product ion prediction by part 
of AC/D Mass FragmenterTM. 
 
3.2.3.3  Prediction of fragmentation by AC/D Mass FragmenterTM  
Fragment prediction UNIFI1.7TM results for α-PVP were compared with those 
obtained employing AC/D Mass FragmenterTM. The used parameters were the same as 
those stipulated in section 2.4.2. 
The results of this software are presented in Figure 3.13, being α-PVP representative 
for the three remaining designer drugs involved in this study. 
Figure 3.12 “Component Summary” of the 4 reference 
standard compounds.  
Figure 3.13 AC/D Mass FragmenterTM results of fragment prediction of α-PVP. 
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The software displayed a tree diagram for each analyte, and each box listed 
information such as nominal mass (Mn), monoisotopic mass (Mmi), isotopes average mass 
(Mav), the chemical formula of the molecule/ion and the atoms that were subtracted from the 
parent compound´s molecule (α-PVP in this case). The mass of interest (Mmi) is highlighted 
for comparison purposes. 
Figure 3.13 provides additional letters (a-e) as they are directly correlated with the 
“Identified High Energy Fragments” predicted by UNIFI1.7TM (see Figure 3.11 (IV)). Indeed, 
it was possible to attain that, within the allowed 3 mDa deviation, all 4 fragments and the 
protonated molecule of α-PVP predicted in the previous method are also predicted by AC/D 
Mass FragmenterTM. The fragments possess similar monoisotopic mass. For example, in 
Figure 3.11, the product ion (c) has an exact mass of 161.09667 m/z, which has a 
divergence of just 0.000679 Da from that registered by AC/D Mass FragmenterTM. 
From this it is possible to say that UNIFI1.7TM has a similar capability of predicting the 
fragmentation pattern of protonated molecular ions. 
However, some differences are presented in the AC/D Mass FragmenterTM process. 
As it is possible to observe, there is a  symbol in each of the 5 results in the 3rd row of the 
tree diagram. They inform that the software predicted additional 2nd cycle fragments from the 
fragments there displayed. This signifies that increasing the number of fragmentation cycles 
in an analysis, the higher will be the amount of fragments proposed by the software. 
In the case of α-PVP, which has a structure rich in σ bounds, the fragmentation is 
predictable. However, in compounds such as morphine (see Figure 3.2) it would be very 
problematic to choose which fragment monoisotopic mass were to be selected for 
characterization studies. Additionally ambiguity can increase as more fragmentation cycles 
are needed to predict product ions from molecules rich in π bounds, such as steroids and 
opiates. 
Summarizing, the three staged validation study results indicated that fragmentation 
prediction by UNIFI1.7TM is a simple and time efficient process that can provide the same 
results as AC/D Mass FragmenterTM.  
Despite no provision of XICs for the exact mass of the fragments proposed (which are 
very elucidative), it was concluded that UNIFI1.7TM could substitute AC/D Mass FragmenterTM 
in fragmentation pattern studies. 
 
3.2.4 Sample analysis based on fragment prediction by UNIFI1.7
TM
 
In section 3.2.2, a screening employing the fragmentation pattern prediction from 
AC/D Mass Fragmenter
TM was implemented to 352 compounds of the 1392 semi-targeted 
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library. With the UNIFI1.7TM product ion prediction assessed, a screening including the 
remaining 1040 compounds was elaborated. 
However, at this stage the semi-targeted library only provided ID name and the 
molecular formula (exact mass). Despite this limitation of criteria, it was possible to narrow 
down the hits acquired. Hence it was selected, for further analysis, exclusively the peaks that 
provided an acceptable shape and particularly low mass deviation ( < 1 mDa). The number of 
hits that were considered acceptable was 97 and the number of compounds that were 
plausible to be identified by the semi-targeted screening was 61. The filter used for analysis 
was Filter II (see criteria in Figure 3.8). 
To each compound of this subgroup, using ChemBioDraw Ultra 12.0TM, the respective 
molecular structure was drawn. The procedure of software data importation was the same as 
the one described in section 3.2.3.2. 
In the final stage of the procedure, 12 hits were classified as UP based on 
fragmentation pattern and 9 suspects were considered as presumptively present in the 
samples. Results are listed in section 3.2.5 
Among them was 7-OH-quetiapine in samples TIM2978 and TIM2982. The analysis 
of the latter is presented in Figure 3.14. This further elucidated the advantages and 
disadvantages of fragmentation prediction by importation of a molecular structure. As it is 
possible to attain in Figure 1.4, quetiapine (7-OH-quetiapine parent drug) has a molecular 
structure susceptible to fragmentation, particularly in the non-aromatic section of the 
structure. Hence, abundant fragmentation was expected in its metabolite. 
Figure 3.14 UNIFI1.7TM “Analysis Method” window of detection for 7-OH-quetiapine in sample TIM2982. (I) TIC 
evidencing three suspect hits with high intensities; (II) XIC for the mass 400.16964 m/z, which characterizes the 
protonated molecule of 7-OH-quetiaine; (III) Low collision energy spectrum for the elution time of 3.17 min; (IV) 
High collision energy spectrum for the chromatographic peak at 3.17 min, evidencing 3 UNIFI1.7TM proposed 
fragments. 
Targeted, semi-targeted and non-targeted screening for drugs in whole blood by UPLC-TOF-MS 
with data-independent acquisition (DIA) 
79 
Figure 3.14 (I) is referent to the TIC of sample TIM2982 and it presents four peaks of 
high intensity. Three were labeled as 4-OH-DET (2.56 min), JWH-018 (5-chloropentil) (4.11 
min) and 2C-N (6.34 min). All were classified as FP. 
XIC (II) for the exact mass 400.16964 m/z, which is relative to 7-OH-quetiapine, 
evidences 3 chromatographic peaks, indicating that the compound´s RT is not restrained to 
3.17 min but also to 4.42 min and 4.69 min. As introduced before, suspect screening do not 
provide RT to the compounds listed in the library. Hence, the correlation between measured 
results and the data stored in the suspect library is exclusively based on the exact mass to 
which the measured peak corresponds and the fragment(s) that are produced in the HE 
spectrum. In summary, all three peaks (the hit in analysis and both peaks (a) and (b)) shared 
equal probability of corresponding to the correct elution time, as they provided convenient 
product ions in their respective HE spectra (data not provided). For this reason an additional 
instrumental run of the respective reference standard was compulsory to unambiguously 
identify 7-OH-quetiapine in the sample. Results are provided in section 3.2.6. 
The spectra provided in the right quadrant of the figure reveal the suspect´s 
protonated ion (400.16964 m/z) in the LE spectrum (Figure 3.14 (III)). Additionally, the 
predicted fragments with masses 208.10001, 269.07454 and 226.03256 m/z are presented 
in the HE spectrum (Figure 3.14 (VI)). For the latter, the respective molecular structure is 
presented, but the same was a possibility for the remaining UNIFI1.7TM predicted product 
ions. 
 
3.2.5 Semi-targeted analysis results for 55 forensic samples 
Table 3.12, provides the final semi-targeted results by conciliating both suspects 
semi-targeted identified, mediated by importation of fragments´ AM from literature (see 
section 3.2.2) and PTRCs identified through product ion prediction by UNIFI1.7TM (see 
section 3.2.4). 
Both product ion prediction methods could not be imported in the semi-targeted 
library simultaneously, as UNIFI1.7TM prioritizes results obtained from product ion exact mass 
over compound structure in library, not providing the results of the latter. Hence the two 
analyses were effectuated separately but complementarily. 
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Table 3.12 Semi-targeted screening overall results. 
 
 
From the table it is possible to state that 7 suspect hits were classified as UP. Their 
identification was based on fragment AM prediction by ACD/MS Fragmenter™, provided by  
literature [71, 120]. Among them, there are 2 E-Z isomers: E-10-OH-Nortriptyline and Z-10-OH-
Nortriptyline. To each the pure standard was available. They were spiked in whole blood to 
prepare a biological mixture with a concentration of 20 ng/mg for each nortriptyline TP. The 
procedure was homologous to that described in section 3.2.3. The RTs for each diasteromer 
were 4.86 min for the E and 5.78 min for the Z. The retention time was coincident to those 
obtained in the semi-targeted screening of samples TIM3018 and TIM3033. This signified 
that both metabolites of the tricyclic antidepressant (TCA) [21]. were present in sample 
TIM3033 and the Z diasteromer was present in sample TIM3018. This example, besides 
proving the concept of semi-targeted screening based on import of fragment exact mass, it 
Case Semi-targeted (352+61) Fragment prediction method Reference standard 
elucidation 
TIM2938 Metopon Molecular structure import No 
 Yangonin Molecular structure import No 
 2C-O-4 Molecular structure import No 
TIM2949 Zotepin Molecular structure import No 
 2C-PYN BU Molecular structure import No 
TIM2955 Zotepin Molecular structure import No 
 Metopon Molecular structure import No 
TIM2978 7-OH-Quetiapine Molecular structure import RT = 3.20 min 
TIM2982 7-OH-Quetiapine Molecular structure import RT = 3.20 min 
TIM3001 Mecloqualone Molecular structure import No 
TIM3018 Z-10-OH-Nortriptiline Fragment exact mass RT = 5.78 min 
 4-Ethylethcathinone Molecular structure import No 
 E-10-OH-Amitriptiline Fragment exact mass No 
TIM3019 Acetil-alpha-metilfentanil Molecular structure import No 
TIM3033 E-10-OH-Nortriptiline Fragment exact mass RT = 4.86 min 
 E-10-OH-Amitriptiline Fragment exact mass No 
 Z-10-OH-Nortriptiline Fragment exact mass RT = 5.78 min 
TIM3034 4-AcO-DMT Molecular structure import No 
TIM3038 Yangonin Molecular structure import No 
TIM3052 Ritalinic acid Fragment exact mass No 
 Norpromazide Fragment exact mass No 
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functioned as an additional evidence to prove the presence of nortriptyline, a targeted 
identified PTRC in both sample TIM3033 and TIM3018. 
Another identified hit based on import of AM of product ions from literature was 
ritalinic acid. Despite the non-availability of the respective pure standard, the information 
provided in both Figure 3.1, and Figure 3.9, provide important information that proves, to an 
acceptable extent, the presence of methylphenidate and its TP in sample TIM3052. 
Additionally, 14 suspect hits were regarded as UP and the fragmentation prediction 
was performed by UNIFI1.7TM after molecular structure import. Among the hits, 2 were 
relative to 7-OH-quetiapine (present in samples TIM2978 and TIM2982). In section 3.2.4 the 
analysis of this quetiapine metabolite in sample TIM2982 was illustrated in Figure 3.14 to 
demonstrate the ambiguity of RT allocation in semi-targeted screening. 
In the next section it is demonstrated the elucidative capability that RT has, obtained 
from the pure standard, in order to prove the presence of the intended compound. 
 
3.2.6 UNIFI1.7
TM
 fragment prediction proof of concept 
In section 3.2.4, the XIC of Figure 3.14 (II), page 78, provided three possibilities of 
elution time: 3.17 min (the analyzed peak), 4.42 min (a) and 4.69 min (b). As the reference 
standard of quetiapine was available, a procedure similar to that described in section 3.2.3 
was implemented. The analysis of the injection containing the spiked whole blood is 
displayed in Figure 3.15, which served as proof that 7-OH-quetiapine was present in sample 
TIM2982 (such as in TIM2978). Additionally it substantiates the credibility of the targeted 
identification of quetiapine. 
Most importantly, the measurement of the RT time of 7-OH-quetiapine by injection of 
its pure standard and the similarity to one of the three obtained in Figure 3.14 (II), proved 
the concept that UNIFI1.7TM was able to perform an independent semi-targeted screening. 
Figure 3.15 (I) displays the TIC in which only 7-OH-quetiapine was displayed, as at 
an intensity count of 600000
 
no other peak corresponding to an endogenous compound was 
displayable. 
Figure 3.15 (II) displays the XIC for the mass of 400.16940 m/z, which characterizes 
7-OH-quetiapine. Form the information there provided, the RT of this quetiapine TP was 
disambiguated and considered to be 3.17 min in the semi-targeted analysis of sample 
TIM2982 (Figure 3.14). The RT error in Filter II was ± 0.45 min, which validated the 
correlation between the results of the forensic sample analysis and those of the pure 
standard injection. 
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Figure 3.15 (III) reveals the protonated molecule, the Na+ and the K+ of 7-OH-
quetiapine, which further enhanced the credibility of 7-OH-quetiapine identification. 
Figure 3.15 (IV) presents the high collision energy spectrum revealing 7 product ion. 
Among them there are 269.07379 m/z and 208.10001 m/z, which were also present in 
Figure 3.14 (IV), within the permited mass error of 3 mDa. Additionally, the fragment with 
the mass of 226.03300 m/z, with the attached molecular structure, was also present in 
sample TIM2982, with an AM of 226.03256 m/z. 
With this example it was proved that the methods´ semi-targeted screening is a viable 
option for identification of compounds not present in commercial libraries or to which pure 
standards are of complicated acquisition, such as metabolites. 
Notwithstanding, the pure standard and the information that RT provides are 
indispensable for the unambiguous identification of the compound semi-targeted identified. 
Another group of small molecules to which reference standards are of difficult access 
are designer drugs. Next section provides the example of the designer drug that was semi-
targeted identified by the screening method herby developed. 
  
Figure 3.15 UNIFI1.7TM “Analysis Method” window of detection for 7-OH-quetiapine in a whole blood at 20 ng/mg. 
(I) TIC evidencing the spiked reference standard with a high intensity peak; (II) XIC for the mass 400.16940 m/z, 
correspondent to the protonated 7-OH-quetiapine; (III) Low collision energy spectrum for the elution time of 3.20 
min; (IV) High collision energy spectrum for the chromatographic peak at 3.20 min, displaying 7 product ions. The 
molecular structure of fragment with mass of 226.03300 m/z is highlighted and illustrated by the software.  
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3.2.7 Designer drug identification 
In Figure 3.16, it is presented the “Analysis Method” of O-acetylpsilocin (4-AcO-DMT) 
which was semi-targeted identified in sample TIM3034. 
As in the case of 5-MeO-DIPT (see Figure 1.12) 4-AcO-DMT is a tryptamine derivate, 
synthetically produced, designer drugs. It was listed in the UNDOC database of “new 
psychoactive substances”. It is the acetylated form of psilocin (structure also present in 
Figure 1.12), which is a natural occurring alkaloid present in the psilocybe semilanceata, 
colloquially known as “magic mushroom” [126]. 
Figure 3.16 (I) provides the TIC of sample TIM3034, displaying the peak relative to 4-
AcO-DMT with an intensity of 200000 counts and eluting at the minute 1.98. The other semi-
targeted identified compound (2C-O-2PR) with a RT of 6.67 min was classified as FP. 
Figure 3.16 (II) illustrates the XIC for the mass of 247.14395 m/z, characteristic of O-
acetylpsilocin. It didn´t display the common RT ambiguity that characterizes the semi-
targeted screening, as an individual peak was exclusively illustrated. This enhanced the 
credibility of the hit. 
Figure 3.16 (III) displays the low collision energy spectrum, evidencing the designer 
drug´s molecular structure attached to the spectrographic peak relative to the protonated 
molecule. Additionally it is displayed the Na+ adduct, which meet the identification criteria 
listed in section 3.1.1. Also, it presents the fragment with mass of 188.07034 m/z. Given that 
the analytes´ molecule is prone to fragmentation, it is acceptable to admit that the molecule 
could have produced product ions at a collision energy of 4 eV. 
Figure 3.16 UNIFI1.7TM “Analysis Method” window of detection for 4-AcO-DMT in sample TIM3034. (I) TIC evidencing the 
suspect under analysis with a high intensity peak, and 2C-O-2-PR (6.67 min); (II) XIC for the mass 247.14395 m/z, 
correspondent to the protonated 4-AcO-DMT; (III) Low collision energy spectrum for the elution time of 1.98 min; (IV) High 
collision energy spectrum for the chromatographic peak at 1.98 min, displaying 6 from the 11 product ions identified. The 
molecular structure of the fragments with mass o of: 60.08008 m/z, 145.05969 m/z and 188.07045 m/z are highlighted by the 
software. 
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The high collision energy spectrum 
Figure 3.16 (IV) provides the most 
substantial evidence to classify the hit as a 
UP due to the amount of fragments 
produced (see Figure 3.17). In the Figure 
3.16 (IV), there are present 6 of the 11 
product ions proposed by UNIFI1.7TM. To 
three of them, 60.08008 m/z, 146.05969 
m/z and 188.0745 m/z, the respective ionic 
structures are illustrated, evidencing cleavage in the most electrically unstable bonds of the 
parent compound´s molecular structure. 
In sum, all chromatographic and spectral information provided information to classify 
the hit as a UP. However, for non-doubtful classification, the respective pure standard need 
to be run to gather the RT and compare it with that obtained in this case: 1.98 min. 
Unfortunately, the reference standard wasn’t available at the time of the analytical procedure. 
Notwithstanding, the objective of semi-targeted identification of a designer drug was 
accomplished. 
 
3.3 Non-targeted screening 
For this screening method, accounting the results obtained from targeted and semi-
targeted screenings, it was made a selection of samples in which the hypothetical presence 
of a designer drug was more probable. 
12 cases were selected for further non-targeted toxicological screening: TIM2938, 
TIM2946, TIM2952, TIM2955, TIM2978, TIM2998, TIM3012, TIM3017, TIM3038, TIM3044, 
TIM3045 and TIM3068. 
The procedure was divided in 3 stages: 
• Search for unique peaks; 
• Search for molecular formula; 
• Molecular structure elucidation. 
Along with the “identified” filter, both software filters developed in section 3.1.5 
contained parameters too wide to provide an analyzable amount of candidate peaks. Hence, 
a new Filter III was employed and its parameters are present in Figure 3.18. 
Figure 3.17 “Component Summary” of the 4-AcO-DMT and 3 
other suspect hits. 
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By convention, small molecules are 
those that correspond to a molecular mass of 
less than 1000 Da. However, the considered 
mass interval, for non-targeted screening, was 
between 100 and 700 m/z. This was justified 
because of the large amount of unknown 
peaks detected in a single injection and by the 
fact that, in congruence with de Castro et al. 
[120], all the peaks eluted outside that mass interval corresponded to interferences derived 
from ME. 
The retention time was from 1 to 10 minutes because after 10 minutes it was common 
the elution of a considerable amount of non-PTRC interferences. By trial and error, it was 
concluded that a threshold in the response should be implemented. Hence, exclusively hits 
with more than 30000 detector counts were considered. The “Identification status” field was 
set to “None” as no reference software library was used at this stage of the overall screening 
method. 
Additionally, specific software features such as “mass difference elucidation tool” and 
“elemental composition elucidation tool”, used for candidate peak interpretation, will be 
presented. 
 
3.3.1 Search for unique peaks 
The application of Filter III provided an exponential reduction of the putative 
candidate list, from several hundreds to exactly 40 hits, shared by the highlighted 12 cases. 
The results are provided in Table 3.13 where a color filter was applied to correlate 
candidates with the same exact mass (limited to a mass error of 3 mDa) and retention time 
(RT error up to 0.02 min). 
Table 3.13 List of 40 software filtered candidates, with colorimetric results of peak uniqueness assessment based on accurate 
mass and RT. 
 
Figure 3.18 Software Filter III set parameters 
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As results, 8 compounds were regarded with the classification of “UNIQUE 1”. This 
signified that they passed the criteria of AM and RT uniqueness (results displayed in columns 
“Analyte” and “RT (min)”, respectively). At this stage, from the initial 12 samples, only 5 
(TIM2938, TIM2978, TIM2998, TIM3038 and TIM3044) were selected for further 
interpretation. 
Extended investigation involved the attribution of fragment exact mass for each 
UNIQUE 1 candidate. The fragments were acquired from the HE spectrum of each unknown 
and only the 4 (if provided) with the highest detector count were considered in this analysis. 
Figure 3.19 is an example of the procedure of allocation of product ions to the correct 
parent ion. It provides the spectral information of the candidate 325.0713 m/z from injection 
TIM3044. 
Chromatograms (TIC and XIC) were not provided by the software, in non-targeted 
screening, due to the amount of hits that are detected. It´s presentation would require a great 
amount of computer power which would turn the analysis time ineffective. However, despite 
no graphical display of chromatographic results, UNIFI1.7TM attributes the empirically 
acquired RT for each candidate. For the case of candidate in Figure 3.19 the observed RT 
corresponded to 5.91 min (see Table 3.13). 
In the low collision energy spectrum it is possible to observe that the candidate in 
analysis, inside the grey box, was relative to the parent ion (M) associated with the Na+ 
adduct. For this assumption it was of great contribution the software´s “mass difference 
elucidation tool”, which information are displayed in red in Figure 3.19. 
The proton, sodium ion and potassium ion have exact masses of 1.007276 m/z, 
22.989219 m/z and 38.963158 m/z, respectively [127]. From that, the software was able to 
Figure 3.19 Adduct identification and fragmentation allocation for candidate with mass of 325.07128 m/z, and. 
protonated molecule isomer identification. 
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calculate de differences between all the peaks (including the isotopes for each specie, 
exemplified by (a), (b) and the isotope with mass of 306.08946 m/z), which assisted in the 
identification of the spectral peaks. This was of extreme importance for the molecular formula 
and structure elucidations procedures. 
Therefore, fragments 1, 2 and 3 were unambiguously regarded as product ions, as 
they increased considerably in quantity (Intensity [count]) from the LE to the HE spectrum. 
However, the peak at 303.08914 m/z, which could be confused with a fourth fragment of the 
candidate with 325.0713 m/z suffered a reduction in Intensity [count]. Hence it could not be 
appointed as a product ion, but instead as the protonated parent ion, as the “mass difference 
elucidation tool” revealed. 
Furthermore, it was possible to identify the peaks 303.08914m/z and 341.04498m/z 
as the protonated molecule and the potassium adduct respectively, and the candidate 
325.0713m/z corresponded to the sodium adduct. 
This directs to the conclusion that all three peaks highlighted in the previous 
paragraph corresponded to the parent ion and the respective adducts of an unknown 
compound having an exact molecular mass of 302.081864 Da. However, this example 
describes a rare case where the highest MS peak corresponded to one of the adducts. 
Additionally it is presented the isotopes for the protonated molecule. The isotopes (a) 
and (b) were of high importance in the molecular formula prediction effectuated in section 
3.3.2. 
This example also demonstrates the degree of complexity when performing reverse 
search through a non-targeted screening method. 
The procedure was reproduced for the remaining UNIQUE 1 candidates and the 
results are presented in Table 3.14. 
 
Table 3.14 List of 8 UNIQUE 1 candidates with colorimetric results of candidate uniqueness assessment based on exact 
mass of fragments. 
 
 
At this stage, fragmentation pattern was introduced as an additional criterion that was 
applied to narrow down the list of candidates. As it is possible to attain in the color tags of 
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Table 3.14, three compounds, with the exact masses of 332.1405 m/z, 332.2795 m/z and 
346.1198 m/z shared at least one fragment. As for that they were excluded from further 
molecular formula elucidation (discussed in section 3.3.3). 
Despite the fact of two candidates, from sample TIM2938 with masses of 380.2075 
m/z and 232.1546 m/z, shared a common fragment, they were considered for further 
analysis. This resided in the fact that the common fragment, 85.02851 m/z (red), was 
accounted as the most commonly detected mass in the HE spectra (see Figure 3.2). Hence, 
an attempt to identify its ionic structure was considered of interest. 
 
3.3.1.1 Co-eluting peaks 
In section 3.3.1 it was referred that identical RT between two candidates was enough 
to exclude them from further analysis. This criterion was adopted, because co-eluting peaks, 
within 0.02 minutes, provided complicated HE spectra, as illustrated in Figure 3.20. There, it 
is exemplified the candidates with exact masses of 517.1814 m/z and 533.1539 m/z, from 
the case TIM2938 and eluting at min 6.37. 
 
In this case, the co-eluting peaks are indicated in the same LE spectrum, which is 
abnormal and was not verified in any targeted and semi-targeted hit classified as UP. Hence, 
in the high collision energy spectrum of Figure 3.20, the peaks signaled with an interrogation 
mark weren´t possible to be individually correlated to either the candidate with mass of 
517.18143 m/z or to the candidate with mass of 533.1592 m/z. So, they were excluded from 
analysis. From the 40 initial candidates, 13 candidates were discarded from analysis solely in 
the basis of spectra that resulted from co-elution. 
Each DIA complete cycle time was of 0.424 seconds, which corresponded to 0.007 
min. This signified that, at every moment of the considered detection interval (from minute 
0.9 until minute 13) data was independently acquire, not covering small intervals of 0.024 s, 
between each DIA scan. 
Figure 3.20 HE and LE spectra of co-eluting candidates: 517.18143 m/z and 533.1592 m/z. 
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Hence, the problematic did not reside in the software nor in the computational power, 
but in the resolving power of the instrument. As chromatographs with more resolution are 
needed in order to provide a more effective peak separation, so these co-eluting peaks may 
be considered for molecular formula allocation. 
However, the development of micro-channeling technology that serves as background 
of LC instruments as reached a plateau. This stagnation may be explained by the 
uncontrollable nano-effects that characterize columns with particles under 1.7µm [128]. 
As a mean to circumvent this problematic, the adoption and development of a new 
dimension, in terms of analyte separation, should be employed. 
Ion mobility spectrometry (IMS) combined with MS, a relatively new separation 
technology with applicability in trace chemical detection and analysis, fits the criteria to be a 
feasible option to overcome the resolution limitations of LC [129]. 
In its simplest scenario, IMS consists in the acceleration of an ion by an electrostatic 
field in one direction. Collisions with background gas molecules or other species hinder the 
ion´s path in the electric field. So, an ion is accelerated by the electric field and collides with 
neutral molecules (devoided of fragmentation) losing all of its momentum, and is 
subsequently accelerated again. Hence, the preponderant criteria in this analyte separation 
is the ionic structure´s size and conformation [129]. 
Despite promising, this technology is still futuristic and further development and 
validation are necessary [129] to confirm its ability to provide a separation platform, with 
enough resolution to match the computation power of the detector employed in this thesis. 
 
3.3.2 Search for molecular formula 
At this stage, the molecular formulas of the 5 candidates classified as UNIQUE 2 
were probabilistically obtained using the software’s “elemental composition elucidation tool”. 
The candidate with mass to charge ratio of 325.07128 m/z continues to serve as example of 
the procedure. Hence, Figure 3.21 illustrates the operating settings of the tool, with 
comprehensive legends. 
After identification of the fragments that characterized the candidate, the intended 
mass of the protonated ion was plotted in the “m/z” field (Figure 3.21 (I)). It is relevant to 
state that UNIFI1.7TM considers the mass of the sodium adduct when predicting the 
molecular formula of the candidate. For this purpose it was used the exact mass of 303.0891 
m/z instead of 325.07128 m/z, since the candidate have been detected as a sodium adduct 
in the first place. This is of importance as the molecular structure elucidation procedure 
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(section 3.3.3) was based on data correlation with reference libraries present in websites. 
These libraries do not store molecular formulas/AM of adducts but exclusively of the 
protonated molecule. 
The AMs of the 3 identified fragments (see Figure 3.19) were introduced in the 
“Fragment peaks” field (II). The mass deviation accounted for in the elemental composition 
elucidation had the maximum mass deviation of 3 mDa, as observed in “m/z tolerance” field 
(III). 
With the three parameters selected, the calculation of a probabilistic molecular 
formula was initiated. 
The most relevant criterion of this non-targeted analysis stage was the “i-FIT 
Confidence (%)”, relative to column (IV), which algorithmically provided molecular formulas 
(C16H15ClN2O2 and C14H14ClF3N2, in this case) by correlating the predicted isotope pattern, 
present in graph (V), with the experimentally measured in the LE spectrum of Figure 3.19. 
The “i-FIT” calculates the degree of similarity of the isotopes (a) and (b) acquired in both 
sources. In the case of the protonated ion of the candidate 325.07128 m/z (303.0891 m/z) 
the most probable molecular formula was C16H15ClN2O2 with an “i-FIT” of 99.9 %, and from 
the two displayed in the results (Figure 3.21 (IV), it was the one used for further structure 
elucidation of the intended candidate. 
This procedure was repeated for the 4 remaining UNIQUE 2 candidates and the 
results are presented in Table 3.15. 
  
Figure 3.21 Description of software´s “Elemental composition elucidation tool” for molecular formula prediction of 
the protonated molecule of sample TIM3044´s candidate. 
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Table 3.15 Proposed molecular formulas for UNIQUE 2 candidates. 
 
 
Only the compounds with an “i-FIT” Confidence above 50% were submitted to 
structure elucidation. As for that only the compounds I, II and III were considered for further 
structure elucidation. 
 
3.3.3 Molecular structure elucidation 
At this stage, two databases available online were employed for structure elucidation: 
mzCloudTM and ChemSpiderTM. The former was the first choice for molecular structure 
identification and the latter was used if not sufficient data was achieved in mzCloudTM. 
Additionally, if for a molecular formula, more than one chemical structure were 
displayed in the ChemSpiderTM, ChemBioDraw Ultra 12.0TM was utilized for fragmentation 
prediction. Hence, the latter contributed for the identification of the correct hit from the 
options provided in ChemSpiderTM. Both mzCloudTM and ChemBioDraw Ultra 12.0TM 
approaches had as reference the measured product ions, presented in Table 3.14, page 87. 
In this section it is presented the final results from structure elucidation of compounds 
I, II and III, listed in Table 3.15. 
Compound I 
The candidate from sample TIM2938 with mass of 380.2075 m/z was not listed in 
neither the considered on-line databases and for such it was excluded from the analysis. 
This result suggests that candidates with an “i-FIT” value under 70 %, should not be 
considered for further analysis. 
 
Compound II 
The structure of candidate from sample TIM3038, with mass of 232.1546 m/z, was 
elucidated via mzCloudTM. The website search criteria were those listed in section 2.5.3, with 
232.1545 m/z plotted in the “Precursor m/z” field and the masses 85.0211 m /z, 144.10179 
m/z and 173.08074 m/z plotted in the “Peak list” field. 
The results are illustrated in Figure 3.22, were it is possible to observe that, 
respecting the employed margin of 0.009 Da, the structures for the precursor and product 
ions were elucidated. 
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With the reverse search completed (from the candidate´s exact mass to the 
acquirement of the molecular structure) the molecular formula was introduced in the search 
engine of ChemSpiderTM, displaying 369 isomers for C11H21NO4. However, with the 
mzCloud
TM results, it was straight forward to find the ChemSpiderTM file containing the correct 
compound and relevant information. In this case it corresponded to that with ID number of 
388877. 
Compound II was identified as O-butyryl-(L)-carnitine, which is an acyl ester of 
carnitine or acylcarnitine [130]. 
Carnitine and its acyl esters are essential compounds for the metabolism of fatty 
acids. These compounds are present in tissue at relatively high concentration, typically 
between 0.2 and 6 mmol/kg, with most being present in the heart and skeletal muscle [130]. 
Acylcarnitines are a large group of endogenous compounds and, in addition to compound II 
there are, for example, O-hexanoyl-(L)-carnitine, O-octanoyl-(L)-carnitine and O-decanoy-(L)-
carnitine [130]. As the name suggests, they vary only in the number of carbons present in the 
aliphatic chain. Hence, fragment (a) and fragment (b) in Figure 3.22, are unchangeable in all 
varieties of acylcarnitines. This justified the fact that fragment (a) was the most commonly 
detected fragment in the herby developed screening method (see Figure 3.2, and Table 
3.14). 
Despite belonging to a non-PTRC, this hit proved the concept of non-targeted 
screening. A peak was identified from a chromatogram without any library support or 
previous knowledge about what was being analyzed. 
Additionally, and most importantly, as fragments (a) and (b) from Figure 3.22 are 
non-variable in this abundant group of endogenous compounds, they can be used to reduce 
the number of non-targeted hits, by excluding from analysis all the unknown peaks that 
include the exact masses of 85.0211 m/z and 144.10179 m/z in their HE spectra. The 
process is similar to that adopted in the targeted screening in order to exclude compounds 
present in the “excluded” library (see section 3.1.4). This procedure may be applied to other 
Figure 3.22 mzCloudTM structure elucidation of candidate with mass 232.1546 m/z. 
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endogenous compounds in whole blood, so the sensitivity of the method may increase, 
because with less non-targeted hits to account for, a lower response threshold (lower than 
30000) can be plotted in Filte III. 
 
Compound III 
C16H15ClN2O2 was the molecular formula elucidated by UNIFI1.7
TM from the 
candidate´s protonated molecule AM of 303.0891 m/z. When introduced in the search engine 
of mzCloud
TM
, the formula failed to provide any hit. However, it produced 1232 hits in the 
ChemSpiderTM database. 
In order to elucidate the molecular structure it was used ChemBioDraw Ultra 12.0TM 
for the simulative study of the candidate´s fragmentation pattern, in the light of the 
fragmentation rules referred by Niessen [131]. The molecular ion prediction was based upon 
the structures proposed in the referred website database and in comprehensive targeted 
screening results for the antmortem traffic case TIM3044. 
Ionic structures were proposed, which satisfied candidate III and the respective 
fragments´ measured exact masses. The results are illustrated in Figure 3.23. 
The three fragments provided by the UNIFI1.7TM´s HE spectrum had 246.06756 m/z, 
228.05691 m/z and 193.08816 m/z. as exact masses. The illustration depicts the exact 
masses provided accordingly to ChemBioDraw Ultra 12.0
TM
. Hence, for rigorousness, the 
permitted deviation from this platform relatively to UNIFI1.7TM measurements was 9 mDa. 
 
Through a lengthy attempt and error procedure, it was concluded that compound III 
was probably related to the targeted screening hit correspondent to temazepam, a 
psychoactive benzodiazepine prescribed drug [132]. 
Figure 3.23 Metabolic pathway of temazepam and fragmentation pattern of candidate III. 
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The metabolic pathway of temazepam is known to be incomplete and only two 
metabolites had been identified so far. One corresponds to a major metabolite resulting from 
the conjugation of glucuronate or sulfate with the oxygen from the ketone. The second 
results from the demethylation of nitrogen of the precursor or from the nitrogen of already 
formed O-conjugated TPs 
[132]
. 
Compound III probably corresponds to an additional non-toxic temazepam metabolite 
(not identified in literature) originated from the saturation of its parent compound. Its non-
targeted identification enhance the credibility of the CP hit attained by both the developed 
screening method and parallel confirmatory MS/MS methodologies, in which results are 
listed in the LIMS database. According to the latter, the precursor molecule (temazepam) 
was quantified at 0.2 mg/Kg, a concentration 10 times higher than its LTC. Hence, high 
degree of metabolization was expected. 
The previously highlighted assumption is supported by the fragments´ structures 
elucidation, which was guided by the rules of fragmentation of even-electron ions [131]. 
According to the nitrogen rule, an odd-electron ion with and odd number of nitrogen 
atoms should have an odd m/z, whereas an even-electron ion with an odd number of 
nitrogen atoms should have an even m/z. By exclusion of parts, as the elucidated 
candidate´s structure has an odd m/z (303.0895) and an even number of nitrogen atoms, it 
can be stated that it corresponded to an even electron ion. This meant that it satisfied the 
criteria of a protonated ion generated by an ESI, enhancing the credibility of the compound 
III´s hit [131]. 
Parity rule or even-electron rule states that upon fragmentation the electron pairs 
remain intact [131]. So the counterparts of fragments 1, 2 and 3 of Figure 3.23, corresponded 
to a neutral loss molecule. This was fundamental for the understanding of the saturated 
bounds resulted from the conjugation of the unpaired electrons at each cleavage site. This 
was observable in all three fragments. 
As a consequence, the loss of a neutral molecule from an even-electron ion (that 
conserves the intended product ion as even in terms of m/z) is far more likely than the loss of 
a radical, which would originate and odd-electron fragment ion. Both fragments 1 and 2 
respected this assumption. However, fragment 3 had an odd m/z. This was due to the fact 
that the most important deviations of the even-electron rule involves the loss of relatively 
stable radicals from aromatic ring systems, such as NO2
•, NO•, Br• and the one of interest, Cl• 
[131]. Therefore, fragment 3 continued to be congruent with what was expected from the rules 
stipulated in the fragmentation of even-electron ions. 
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Another important criterion that validated the proposed fragments as a plausible hit 
was the fact that even-fragmentation in protonated molecules involves carbon-heteroatom 
cleavage [131], which was observable in all 3 fragments. 
Additionally, all the fragments provided by the ChemBioDraw Ultra 12.0TM where 
within the mass error of 9 mDa, stipulated previously. 
With this it can be stated that compound III has a high probability of having the 
structure proposed in Figure 3.23. However such in the previous semi-targeted screening of 
this 3 staged screening methodology, the pure standard is a necessity for unambiguous 
identification of the analyte, which was not available due to non-acknowledgement of the 
non-targeted identified temazepam metabolite. 
 
3.4 Comparison with literature 
This section provides the comparison between the results achieved by the STA 
developed in this project, with those published by nine research teams covering the two 
dualities stressed in the thesis´ literature review (see section 1.6): STA based on product ion 
spectra vs GUS based in HR/AM acquisition; and DDA vs DIA. 
The screening capabilities of the screening methodology hereby developed will be 
comparatively assessed. 
When comparing the chromatograms and spectra of results in Lafaye, et al. [7] (see 
Figure 1.31) with the “Analysis Method” window from the software employed in this thesis 
(e.g. see Figure 3.1, Section 3.1.3), it is possible to highlight some distinctions that reveal 
the technological gap of 10 years between the two screening methodologies. Therefore, 
using the data acquisition as the comparison argument, the red double edged arrow in the 
Figure 1.31, page 36, evidences the absence of an algorithm to correctly align spectrums 
(II) and (III). Additionally, it is possible to attain that the peak correspondent to ≈385 m/z has 
a distinct nominal mass between (II) and (III), not to mention the difference of exact 
masses. 
In the same context, the DIA screening based on HR/AM acquisition, developed in 
this project, employed algorithms that correctly align spectra peaks of parent, metabolite and 
fragment ions generated from 2 distinct collision induced dissociation (CID) energies (see 
Figure 1.30, page 34). Additionally to this virtual spectra alignment, which ultimately gave 
the upper hand for unambiguous analyte/candidate identification, UNIFI1.7TM was able to 
correlate the accurate mass (up to 4 decimal houses) of spectral peaks between both 
acquisition functions. This way, the resolution was much superior to that of nominal mass 
based screening methods, such as the one employed by Lafaye, et al. [7]. 
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Dularent, et al. [4] STA based on product ion spectra provided a successful 
application of a screening involving an artificially intelligent data acquisition (DDA in this 
case). However, the methodology was prone to a certain degree of impairments in terms of 
sensitivity, as the standard LOD was of about 10 ng/mL. Whereas, in this project´s 
developed screening method, it was proved that the LOD spammed from 1 ng/mL to 100 
ng/mL for 198 representatives PTRCs (see section 3.1.2 and Appendix I). Additionally, in 
order to increase the sensitivity for some compounds, the author ran intended samples, in a 
single polarity, exclusively in MS
2
. However, the resulting specificity was so conditioned that 
the confirmatory data wasn’t possible to be recorded in the MS3 scan. So, for cases where 
very high sensitivity was needed, a parallel method was required [4]. 
In contrast, despite the targeted screening results of this thesis had been compared 
with those of other instruments, ran in parallel at RKA, the aim of this project was to develop 
an all-purpose screening method. Therefore, analyses made in a way that solely 
contemplated a particular analyte, due to sensitivity threshold, were categorically discarded. 
However the all-purpose screening capability was impaired due to sensitivity deficiency 
regarding the detection/identification of morphine and compounds exclusively detectable 
when negatively ionized. 
With an example of an STA based on product ion spectra ,but without resource to any 
artificially intelligent data acquisition, Liu, et al. [98] were able to implement a novel 
fragmentation approach which consisted in providing voltage ramping and broadened mass 
window for activation (or fragmentation width) [98]. 
However, this paper failed to provide a representative amount of real postmortem 
cases, as only 12 were reported. Additionally, despite being considered toxicologically 
representative by the author, in all of the cases opiates were identified, which may indicate 
that the sample selection wasn’t representative for the whole spectrum of cases generally 
screened in postmortem toxicology [98]. 
For comparative purposes, it is relevant to restate that the method relative to this 
thesis covered 55 real antemortem and postmortem cases in which the whole blood samples 
were the representative biological matrix. Additionally, the DIA mode providing the parent 
(precursor) ion spectra at 4 eV and the ramping voltage at the CID cell was also a feature of 
the software/instrument used in this thesis. However this was exclusively applied in the high 
energy fragmentation function, which maximum voltage reached 40 eV. 
Polettini´s research group employed a GUS based on HR/AM detection, which 
allowed them to explore the reproducibility of compound accurate molecular mass to the 
extent of assembling a targeted database containing 50500 toxicological relevant 
compounds and their metabolites. The massive database was based on ChemSpiderTM 
which contains more than 30 million compounds [3, 106]. 
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On its image, in the present thesis it was defined a strategy similar to that of Polettini 
and associates, as the RT was also not considered for the semi-targeted screening, due to 
the fact that it is too irreproducible between instruments and even between trials in the same 
instrument [3, 106]. Molecular formula was the criterion of choice for semi-targeted and non-
targeted screenings in this thesis context.  
Comparatively, the main advantage of this work resided in the ability of UNIFI1.7TM´s 
“i-FIT” tool to correlate AM of precursor and respective fragments with molecular formulas. 
This provided an additional dimension for the identification of unknowns, such as O-butyryl-
(L)-carnitine and the saturated transformation product of temazepam (see section 3.3.3) 
As in the case of this thesis, Lee et al. [2] reported a “real-time” HR/AM acquisition of 
low and high fragmentation spectra in the same analysis. The author considered exact mass 
determination to four decimal places, per se, the main criterion for achievement of adequate 
specificity. However this thesis´ filter development results suggested that AM is not enough 
and further criteria, such as mass error and RT error thresholds, had to be adopted in order 
to narrow down the FP frequency from a maximum of 89 % (“Identified” filter) to a minimum 
of 68 % (Filter I). 
Pedersen, et al. [6] reports a methodology that functioned as the precursor of the 
STA of this thesis. The usage of automated SPE in sample preparation instead of automated 
PPT, the sample volume of 200 μL (in place of 100 μL of whole blood) needed for sample 
preparation and the software used for data treatment (ChromaLynx XSTM alternatively to 
UNIFI1.7TM) were the main differences between both methods [6]. 
The author carried out STAs of 1335 authentic forensic traffic cases by screening for 
the intended 256 drugs. A number greater and more representative than the 55 (antmortem 
and postmortem) forensic cases covered in this thesis [6]. 
This thesis gave particular importance to LOI (extensively dependent on provision of 
fragmentation information) having Pedersen´s compound selection as a reference for the 
evaluation studies performed in this project [6]. 
Therefore, in terms of sensitivity studies, this thesis implied exclusively the LOI 
(almost fully reduced to LOF) determination for 198 compounds (an extract of Pedersen et al. 
database of 256) from those 1030 present in the commercial targeted library. 
Despite being comparatively more accomplished in what regards the screening for 
targeted analytes, this literature example failed to explore the RP of the instrument to the 
extent of performing semi-targeted and non-targeted screenings, which are provided in this 
project (see section 3.2 and section 3.3, respectively). 
Humbert et al. [62] provided an example of a rare case in which a STA based on 
product ion spectra, associated with an artificial intelligent data acquisition (DIA in this case). 
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In comparison with this project, Humbert´s nominal mass DIA approach provided a 
broader study platform for further characterization of intended compounds. This was due to 
the fact that this literature was based on fragmentation pattern displayed in up to 10 times 
more spectra (with different CID energies) than those provided in this thesis [62]. 
Paul et al. [109] is a very recent publication concerning the employment of a STA 
based on HR/AM detection with application of a non-targeted DDA. 
Similarly to the method developed in this project, Paul, et al. [109] procedure had the 
limitation of not providing quantitative nor semi-quantitative results. Hence it was missed an 
important criterion for the non-dubious identification of both targeted compounds and drug 
candidates [109]. 
On the other hand, this thesis’ method encompassed a “true” non-targeted screening, 
in which no initial information on the candidates was available. Hence, instead of giving 
prominence to information provided by literature or operators’ knowledge about 
metabolism/fragmentation, in the project herby presented the identification was mainly 
dependent on spectra deconvolution algorithms. These typically revealed chromatograms 
with several thousands of peaks in just an individual blood sample. Subsequently, AM, 
isotope patterns and fragment ions of candidates were accounted for by the “i-FIT” tool, 
provided by the software (UNIFI1.7TM), in order to obtain molecular formulas from measured 
exact masses. From the correct molecular formula, tentatively identification of molecular 
structure followed. 
The Finnish research group headed by Ojamperä was, in the last decade, the most 
committed in the contextualization of HR/AM acquisition methodologies into the ambit of 
STA. 
The semi-targeted database assembled in this project (section 3.2.1) was assembled 
in the lighting of this author’s work, although with some additional features, made available 
today through computational technology advances, and with the knowledge that AM and 
isotope pattern alone are not sufficient for unambiguous compound identification [111]. 
The screening technique developed in this thesis was extensively based on their 
findings, but with a more capable parent ion fragmentation approach. 
Following up Ojampera’s group findings, this study attempted to elucidate the 
importance of fragmentation pattern for targeted analytes identification and, most 
innovatively, for the elucidation of the molecular structure of PTRCs candidates in actual 
blood samples of forensic cases. 
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4 CONCLUSION AND FUTURE 
PERSPECTIVES 
4.1 Conclusion 
The method´s targeted screening provided an overall sensitivity lower than other LC-
MS/MS methods employed in RKA, highlighting morphine as the most problematic PTRC to 
be screened for. On the other hand, it made available a wider analytical range, screening for 
1030 basic small molecules in a single run, which revealed the method´s importance in the 
guidance of further quantitative STAs. 103 PTRCs, distributed throughout 231 detector hits, 
were identified. 50 compounds more than in all the methods ran in parallel in the RKA, being 
112 identified hits exclusive to the developed targeted screening method. 
The software Filter I provided an option to dramatically reduce the analysis time to a 
maximum of 20 min, for PTRC rich forensic samples, revealing the importance of the filtering 
parameters for a time efficient GUS. 
The concept of semi-targeted was proved through the identification of 3 suspect 
PTRCs (active metabolites) to which convenient pure standards were available. 
UNIFI1.7TM fragmentation prediction feature was evaluated by comparison with 
product ion prediction from ACD/MS FragmenterTM, and results were satisfactory. 
Globally, 15 suspect compounds were identified by semi-targeted analyzing all 55 
forensic samples. The compounds were distributed through 21 suspect hits. One hit with a 
particularly high probability of being a true positive corresponded to a designer drug, but the 
pure standard wasn’t available for unambiguous identification. 
A non-targeted screening methodology was developed revealing lack of sensitivity in 
the analyzed 12 samples. It also suggested that at this stage, non-targeted screening is too 
 Conclusion and future perspectives 
  
100 
laborious for a time effective STA. Two compounds were structurally elucidated by the non-
targeted method, contributing for the methods proof of concept. 
In what concerns the total amount of positively identified hits by the developed 
method, 90.9% corresponded to targeted screening, 8.3% to semi-targeted screening and 
0.8% to non-targeted screening. 
 
4.2 Future perspectives 
In the 55 samples analyzed, a cause of death corresponded to phenobarbital 
poisoning. In order to obtain results for barbiturates, a run in negative mode ESI should be 
performed to verify the method´s sensitivity for this group of PTRCs. 
As for semi-targeted screening, UNIFI1.7TM capability of fragmentation pattern 
prediction was validated. Hence, in addition to the 61 imported molecular structures, the 
remaining 1331 should be drawn and implemented in the semi-targeted screening method. 
Additionally, the reference standard of 4-AcO-DMT has to be run for provision of the 
analyte´s RT, so the designer drug hit in sample TIM3034 may be undoubtedly classified as 
a true positive. This would provide the ultimate proof of the methods´ feasibility in STA 
context. 
The non-targeted screening is in its primordial stages of development. In order to 
increase the sensitivity of the method, the response threshold has to be dramatically reduced 
in the filtering parameters; or the sample volume (before preparation) has to be increased 
(e.g. from 1 µL to 5 µL). To avoid the latter resolution, a non-targeted “excluded” library 
should be assembled. This process would require the identification of the peaks (parent and 
product ions) respective to endogenous compounds of whole blood, such as the 
acylcarnitines. The respective exact masses should be deselected from the reverse analysis. 
Additionally, the on-line MS/MS spectra databases with exact mass provision have to 
be further developed. At this stage there isn´t any feasible option that allows a time efficient 
molecular structure elucidation. 
With an appropriate refining of the instrumental and software tools herby presented, 
non-targeted screening may be a reality in a STA context, in the near future. Moreover, the 
advantages that reverse search encloses will most probably serve other fields where 
analytical chemistry is of utility. 
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6 APPENDIXES 
Appendix I 
Limit of detection, limit of fragmentation and lower therapeutic concentration for 198 
representative pharmaco-toxicologically relevant compounds. 
The 198 pure standards were present in the mixtures TOF mix 1 and TOF mix 2, 
having purities ≥ 98 %. 
The concentrations considered in this sensitivity evaluation procedure ranged from 
0.001 mg/Kg to 0.1 mg/Kg. 
21 % did not fragment at concentrations below the LTC, 2 % were not detected within 
the considered concentrations and 4 didn´t provide fragments at the concentration of 0.1 
mg/Kg. 
Morphine was the most important miss on the provision of product ions. 
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Appendix II 
“Excluded” library listing the 34 compounds not considered in Filter I. 
Chemical excluded “Summary plot” report Toxicological information [21] 
Adrenalone 
 
Present in all blood samples, 
including in blind blood.  
 
Adrenergic agonist used as a topical 
vasoconstrictor and hemostatic. 
Non-PTRC. 
Allopurinol 
 
Present in almost all blood 
samples, including in blind blood. 
 
Xanthine oxidase inhibitor for 
treatment of hyperuricemia. Non-
PTRC. 
Benalaxyl 
 
Present in almost all blood 
samples, including in blind blood. 
Fungicide. Rarely toxic. Not 
appropriate for analysis. 
Caffeine 
 
Present in almost all blood 
samples, including in blind blood. 
Mild central nervous system 
stimulant. Non-PTRC. 
Carbidopa 
 
Present in almost all blood 
samples, including in blind blood. 
Employed in the treatment of 
Parkinson´s disease by inhibiting the 
peripheral metabolism of levodopa. 
Non-PTRC. 
Cefalexin 
 
Present in 10% of samples, 
including in blind blood.   
Only as an Na+ Adduct. 
Cephalosporin antibiotic. Good 
alternative to penicillins to treat 
patients with penicillin 
hypersensitivity. Non-PTRC. 
Clindamycin 
 
Present in 10% of samples, 
including in blind blood.  Only as 
an Na+ adduct. 
 
Lincosamide antibiotic used to treat 
infections with anaerobic bacteria 
and some protozoal diseases, such 
as malaria. Not appropriate for 
analysis. 
Corticosterone 
 
Present in all blood samples, 
including in blind blood. 
Endogenous steroid hormone. Non-
PTRC. 
Cortisol 
 
Present in all blood samples, 
including in blind blood. 
Endogenous steroid hormone. Non-
PTRC. 
Cortisone 
 
Present in all blood samples, 
including in blind blood. 
Endogenous corticosteroid released 
by adrenal gland in response to 
stress. Non-PTRC. 
Cotinine 
 
Present almost all blood samples, 
including in blind blood. 
Alkaloid metabolite of Nicotine. 
Rarely toxic. 
Demeton-S-Methyl 
Sulphone 
Present in 30% of samples, 
including in blind blood. 
Acaricide and Insecticide.  
Toxicological relevant. 
Diprophylline 
 
Present in 20% of samples, 
including in blind blood. 
 
Xanthine derivate with 
bronchodilator and vasodilator 
effects. Used for treatment of 
asthma, bronchitis. Non-PTRC. 
Drospironone 
 
Identified in 10% of samples, 
including in blind blood. 
Synthetic hormone used in birth 
control pills. Non-PTRC. 
Ecgonine methyl  
ester 
 
Present in almost all blood 
samples, including in blind blood. 
 
Compound that result from the 
consumption of cocaine and alcohol 
within a short time spam. Not suited 
for analysis. 
Etamiphyline 
 
Present in 50% of samples, 
including in blind blood. 
Xanthine intended for use as anti-
asthma agent. Non-PTRC. 
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Appendix II (continue)   
Chemical excluded “Summary plot” report Toxicological information [21] 
Etamivan 
 
Present in all samples, including in 
blind blood. 
 
Respiratory stimulant drug used for 
treatment of barbiturate overdose 
and chronic obstructive pulmonary 
disease. Rarely toxic. Not suited for 
analysis. 
Hydroxyprogesterone  
 
Present in 10% of samples, 
including in blind blood.  
 
Endogenous steroid hormone 
produced during the synthesis of 
glucocorticoids and sex steroids.  
Non-PTRC. 
Lovastatin 
 
Present in all blood samples, 
including in blind blood. 
Antihyperlipidermic agent. Non-
PTRC. 
Meropenem 
 
Present in 30% of samples, 
including in blind blood. 
 
Ultra-broad spectrum injectable 
antibiotic used to treat a wide 
variety of infections. Very effective 
against enterobacteriaceae but not 
so much against gram +ve species. 
Not appropriate for analysis. 
Methylprednisolone Present in 20% of samples, 
including in blind blood. 
 
Synthetic glucocorticoid or 
corticosteroid with anti-
inflammatory effects. Over usage 
may lead to hyperglycemia and 
hypertension.  Not appropriate for 
analysis. 
Metipranolol 
 
Present in all blood samples, 
including in blind blood. 
Beta blocker used in eye drops to 
treat glaucoma. Non-PTRC. 
Naftifine Present in 20% of samples, 
including in blind blood.  
Only as a Na+ adduct. 
Antifungal drug. Precise mechanism 
of action unknown. Not appropriate 
for analysis. 
Nateglinide Present in all samples, including in 
blind blood. 
Drug for treatment of Type 2 
Diabetes. Non-PTRC. 
Nicotinamide Present in all blood samples, 
including in blind blood. 
Amine of nicotinic acid (Vit. 
B3/niacin). Non-PTRC. 
Norelgestromin Present  in 10% of samples, 
including in blind blood. 
Only as a Na+ adduct  
Progestin used in the contraceptive 
patch called Evra. Non-PTRC. 
Phenylephrine 
 
Present in more than 30% of 
samples, including in blind blood.  
 
Selective Alpha-drenergic receptor 
agonist used primarily as a 
decongestant, then as a pupil dilator 
and lastly, to increase blood 
pressure. Non-PTRC. 
Simvastatin Present in almost in all blood 
samples, including in blind blood. 
Reductase inibitor related to 
lovastatin. antihyperlipidermic 
agent. Non-PTRC. 
Spiromesifen Present in 40% of samples, 
including in blind blood.  
 
New generation insecticide against 
the whitefly (specie that attack 
crops). Not appropriate for analysis. 
Theobromine 
 
Present in all blood samples, 
including in blind blood.  
Bitter alkaloid of the cacao plant. 
Non-PTRC. 
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Appendix II (continue)   
Chemical excluded “Summary plot” report Toxicological information [21] 
Theophyline Present in all blood samples, 
including in blind blood.  
Related to caffeine. It is a 
bronchodilator in asthma 
treatment. Non-PTRC. 
Tryptophan Present in all blood samples, 
including in blind blood.  
Endogenous aminoacid. Non-PTRC. 
 
Urapidil Present in 10% of samples, 
including in blind blood.  
 
Sympatholytic antihypertensive 
drug that acts as an α1-
adrenoceptor antagonist and as an 
5-HT1A receptor agonist. Non-PTRC. 
Valaciclovir Present in 10% of samples, 
including in blind blood. 
Only as a Na+ adduct. 
 
Antiviral drug used in the 
management of herpes simplex, 
herpes zoster (Shingles) and herpes 
B. Non-PTRC. 
Veralipride Present in 20% of samples, 
including in blind blood.  
Benzamide neuroleptic drug 
employed in the treatment of 
vasomotor symptoms associated 
with the menopause. Non-PTRC. 
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Appendix III 
Table containing all targeted screening results. 
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM2938 Kidney disease 
Lev omepromazine UP 0.024  
Enalapril FN 0.001 LTC Above 
Hydrocodone UP Negative  
Codeine UP 0.16  
Codeine, 
glucuronide- 
UP Negative  
Morphine FN 0.04 LTC Below  
TIM2943 
Drow ning and 
heart disease 
Amlodipine UP 0.057  
TIM2945 
Traff ic 
(antemortem) 
    
TIM2946 
Cause of death 
not found; 
Drug addict 
Benzoylegonine UP Negative  
Clonazepam, 7-
amino- 
UP Negative 
Clonazepam 
metabolite 
Diazepam UP 0.039  
EDDP UP Negative  
Bromazepam FN 0.013 LTC Above 
Cocaine FN 0.001 LTC Above 
Haloperidol UP Negative  
Methadone UP 0.35  
Diazepam, 
demethyl- 
UP 0.028  
Clonazepam FN 0.056 
LTC Below  / 
metabolite 
present 
TIM2949 
Traff ic 
(antemortem) 
Cetirizine UP 0.12  
Diazepam, 
desmethyl- 
FN 0.002 LTC Above 
Paracetamol UP Negative  
Venlafaxine UP 0.46  
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM2949 
(continue) 
Traff ic 
(antemortem) 
(continue) 
Venlafaxine, O-
desmethyl 
UP 0.096  
Zolpidem 
metabolite 1 
UP Negative  
Zolpidem 
metabolite 2 
UP Negative  
Chlorprothixene, 
desmethyl- 
UP 0.073  
Chlorprothixene UP 0.17  
Zolpidem UP 0.16  
TIM2952 
Methadone 
poisoning 
Bromazepam UP 0.34  
EDDP UP Negative  
Methadone UP 1.5  
Mirtazapine UP 0.04  
Mirtazapine, 8-
hydroxy- 
UP Negative  
Mirtazapine, N-
desmethyl- 
UP Negative  
TIM2955 
Methadone 
poisoning 
Benzoylecgonine UP 0.11  
Cetirizine UP Negative  
Cocaine UP Negative  
Chlorprothixene, 
desmethyl- 
UP 0.057  
Dextromethorphan UP Negative  
EDDP UP Negative  
Hydroxizine UP 0.002  
Lidocaine UP Negative  
Methadone UP 0.46  
Morphine FN 0.034 
LTC Below  / 
related compound 
identif ied 
6-MAM- UP Negative 
Same properties 
as morphine 
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM2955 
(continue) 
Methadone 
poisoning 
(continue) 
Morphine, 
dihydro- 
UP Negative  
Noscapine UP Negative  
Papaverine UP Negative  
Paracetamol UP Negative  
Quinine UP Negative  
Solifenacin UP Negative  
Yohimbine UP Negative  
Chlorprothixene UP 0.13  
Codeine UP 0.01  
TIM2956 
Violence 
(antemortem) 
Benzoylecgonine FN 0.01 LTC Above 
Paracetamol UP Negative  
TIM2964 
Traff ic 
(antemortem) 
    
TIM2965 
Traff ic 
(antemortem) 
    
TIM2967 Lung disease 
Metoprolol UP 0.019  
Metoprolol, 
hydroxyl- 
UP Negative  
Primidone UP 3.0364  
Terbutaline UP 0.01  
TIM2968 Heart disease     
TIM2970 
Sexual assault 
(antemortem) 
Citalopram, 
desmethyl- 
UP 10  
Citalopram, 
didesmethyl- 
UP Negative  
Citalopram/ 
Escitalopram 
UP 7.2  
TIM2971 
Violence 
(antemortem) 
    
TIM2972 
Traff ic 
(antemortem) 
    
      
      
 Appendixes 
  
126 
Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM2976 
Methadone 
poisoning 
EDDP UP Negative  
Methadone UP 0.4  
Diazepam, 
desmethyl- 
UP 2.2  
Demoxepam FN 2.5 
LTC Below  / 
Parent drug 
present 
Promethazine FN 0.0005 LTC Above 
Oxazepam UP 0.017  
Paracetamol UP Negative  
Tramadol UP 0.51  
Tramadol, N-
desmethyl- 
UP Negative  
Tramadol, O-
desmethyl- 
UP 0.13  
Chlordiazepoxide UP 1.4 
Demoxepam 
parent drug 
TIM2978 
Methadone 
poisoning 
Citalopram/ 
Escitalopram 
UP 0.34  
Citalopram, 
desmethyl- 
UP 0.28  
Citalopram, 
didesmethyl- 
UP Negative  
Clonazepam, 7-
amino- 
UP 0.21  
Chlorprothixene, 
desmethyl- 
UP 0.08  
EDDP UP Negative  
Methadone UP 1.3  
Paracetamol UP Negative  
Quetiapine UP 0.15  
Chlorprothixene UP 0.092  
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM2982 
2nd degree burn 
and carbon 
monoxide 
poisoning 
Lidocaine UP Negative  
Quetiapine UP 0.006  
TIM2998 
Methadone 
poisoning 
Clonazepam, 7-
amino- 
UP 0.23  
EDDP UP Negative  
Methadone UP 0.46  
Nitrazepam, 7-
amino- 
UP 0.009  
Paracetamol UP Negative  
TIM3001 Choking 
Chlordiazepoxide UP 0.1 
Demoxepam 
parent drug 
Doxepine UP Negative  
Demoxepan FN 0.87 
LTC Below  / 
parent drug 
present 
Oxazepam UP 0.085  
Oxazepam, 
glucuronide- 
UP Negative  
Promathezine UP 0.009  
Promethazine, 
sulphoxide- 
UP Negative  
Diazepam, 
desmethyl- 
UP 0.84  
Amlodipine UP 0.033  
TIM3002 Heart disease 
Diazepam, 
desmethyl- 
FN 0.002 LTC Above 
Paracetamol UP Negative  
TIM3003 
Cause of death 
Not found. 
(High alcohol 
level) 
Diazepam, 
desmethyl- 
FN 0.013 LTC Above 
Chlorprothixene FN 0.0001 LTC Above 
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM3004 Internal bleeding 
Ketobemidone UP Negative  
Paracetamol UP Negative  
Roxithromycin UP Negative  
Tramadol UP 0.15  
Tramadol, N-
desmethyl- 
UP Negative  
Tramadol, O-
desmethyl- 
UP 0.05  
TIM3005 Heart disease 
Cinchonine UP Negative  
Hydroquinidine UP Negative  
Paracetamol UP Negative  
Propranolol UP 0.14  
Quinine UP 0.5  
Warfarin UP 0.61  
Citalopram FN 0.003 LTC Above 
TIM3006 
Traff ic 
(antemortem) 
    
TIM3010 Heart disease 
Cinchonine UP Negative  
Quinine UP Negative  
Sertraline UP 0.015  
Zopiclone UP 0.011  
Zopiclone, 
desmethyl- 
UP Negative  
TIM3012 
Assault victim 
(antemortem) 
Benzoylecgonine UP 0.014  
Cocaine FN 0.003 LTC Above 
Hydroxyzine UP Negative  
Lidocaine UP Negative  
Metronidazole UP Negative  
Morphine FN 0.035 LTC Below  
Remifentanil UP Negative  
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM3014 Liver disease 
Chlordiazepoxide UP 0.65 
Demoxepam 
parent drug 
Diazepam, 
desmethyl- 
FN 0.01 LTC Above 
Demoxepam FN 0.31 
LTC Below  / 
parent drug 
present 
Paracetamol UP 1.0  
TIM3017 
Methadone 
Poisoning 
Citalopram, 
desmethyl- 
UP 0.33  
Citalopram, 
didesmethyl- 
UP Negative  
Citalopram/ 
Escitalopram 
UP 1.2  
EDDP UP Negative  
Methadone UP 2.4  
Oxazepam UP 0.07  
Paracetamol UP 30  
TIM3018 Heart disease 
Amlodipine UP Negative  
Citalopram, 
didesmethyl- 
UP Negative  
Nortriptyline UP 0.17  
Risperidone, 
hydroxyl- 
UP Negative  
Amitriptyline UP 0.13  
Citalopram/ 
Escitalopram 
UP 0.32  
Citalopram, 
desmethyl- 
UP 0.19  
TIM3019 Burned 
Alfentanil UP Negative  
Atenolol UP Negative  
Citalopram/ 
Escitalopram 
UP 0.52  
Citalopram, 
desmethyl- 
UP 0.26  
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM3019 
(continue) 
Burned 
(continue) 
Citalopram, 
didesmethyl- 
UP Negative  
Midazolam UP Negative  
Paracetamol UP Negative  
Fentanyl UP Negative  
TIM3026 Heart disease     
TIM3027 
Violence 
(antemortem) 
Ibuprofen FN 5.0 Non-PTRC 
Paracetamol UP 1.0  
Tramadol UP 0.16  
Tramadol, O-
desmethyl- 
UP 0.057  
Tramadol, N-
desmethyl- 
UP Negative  
TIM3033 
Violence 
(antemortem) 
Nortriptyline UP 0.009  
Nitrazepam, 7-
amino- 
UP 0.036  
Amitriptyline UP 0.02  
Nitrazepam UP 0.046  
 
TIM3034 
 
Violence 
(antemortem) 
Lidocaine UP Negative  
Midazolam UP Negative  
Mono-
ethy lgly cinexy lidide UP Negative  
Paracetamol UP Negative  
Metronidazole UP Negative  
TIM3037 Internal bleeding Atropine UP Negative  
TIM3038 
Fat embolism 
syndrome 
Ciprofloxacin UP Negative  
Lidocaine UP Negative  
Morphine UP 2.5  
Oxycodone UP 0.004  
Oxycodone, 
desmethyl- 
UP Negative  
Paracetamol UP Negative  
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM3038 
(continue) 
Fat embolism 
syndrome 
(continue) 
Bupivacaine/ 
Levobupivacaine 
UP Negative  
Diazepam FN 0.005 LTC Above 
TIM3040 
Violence 
(antemortem) 
Benzoylecgonine UP 0.001  
TIM3041 
Violence 
(antemortem) 
Mirtazapine UP 0.043  
Mirtazapine, 8-
hydroxy- 
UP Negative  
Mirtazapine, N-
desmethyl- 
UP Negative  
TIM3044 
Traff ic 
(antemortem) 
Amfetamine UP 0.088  
Benzoylegonine UP 0.16  
Bromazepam FN 0.01 LTC Above 
Diazepam UP 1.1  
Fenoterol UP Negative  
Diazepam, 
desmethyl- 
UP 1.2  
Morphine FN 0.005 LTC Above 
Oxazepam UP 0.2  
Oxycodone, 
desmethyl- 
UP Negative  
Oxycodone UP 0.047  
Paracetamol UP Negative  
Temazepam UP 0.2  
TIM3045 
Morphine 
poisoning 
Benzoylegonine UP 0.18  
Cocaethylene UP Negative  
Cocaine UP 0.04  
Codeine UP 0.015  
Levamisole/ 
Tetramisole 
UP Negative  
Lidocaine UP Negative  
Morphine UP 0.12  
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM3045 
(continue) 
Morphine 
poisoning 
(continue) 
Noscapine UP Negative  
Amphetamine FN 0.002 LTC Above 
Papaverine UP Negative  
Paracetamol UP Negative  
Phenacetine UP Negative  
TIM3046 External bleeding 
Olanzapine UP 0.1  
Olanzapine, N-
desmethyl- 
UP Negative  
Risperidone, 
hydroxyl- 
UP 0.05  
TIM3051 
Cause of death 
not found; 
High levels of 
zuclopentixol 
Clonazepam, 7-
amino- 
UP 0.026  
Paracetamol UP 90  
Zuclopenthixol UP 0.032  
TIM3052 
Phenobarbital 
poisoning 
Benzoylecgonine UP 0,002  
Citalopram, 
desmethyl- 
UP 0,092  
Citalopram, 
didesmethyl- 
UP Negative  
Clonazepam UP 0,002  
Clonazepam, 7-
amino- 
UP 0,039  
Diazepam UP 0,11  
Diphenydramine UP 0,1  
Phenobarbital FN 82 Barbituric 
Methylphenidate UP 0,006  
Mirtazapine UP 1,7  
Mirtazapine, 8-
hydroxy- 
UP Negative  
Mirtazapine, N-
desmethyl- 
UP Negative  
Diazepam, 
desmethyl- 
UP 0,03  
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM3052 
(continue) 
Phenobarbital 
poisoning 
(continue) 
Oxazepam FN 0.004 LTC Above 
Paracetamol UP 1  
Promethazine UP 0,13  
Promethazine, 
hydroxydesmethyl 
UP Negative  
Promethazine, 
sulphoxide- 
UP Negative  
Temazepam UP 0,012  
Alprazolam UP 0,071  
Citalopram/ 
Escitalopram 
UP 0,18  
TIM3054 Shot in the head     
TIM3056 Internal bleeding 
Enalaprilat FN 0,014 LTC Above 
Metoprolol UP 0,02  
Metoprolol, 
hydroxy- 
UP Negative  
Enalapril FN 0,01 LTC Above 
TIM3057 Internal bleeding 
Acrivastine UP Negative  
Quinine UP Negative  
TIM3059 Traff ic     
TIM3060 
Traff ic 
(antemortem) 
    
TIM3061 
Traff ic 
(antemortem) 
Cinchonine UP Negative  
TIM3062 
Traff ic 
(antemortem) 
    
TIM3063 
Cause of death 
not found 
Paracetamol UP Negative  
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Appendix III  (continue)     
Case 
Police / 
RKA Report 
Compound UNIFI1.7TM LIMS (mg/Kg) 
FN 
evaluation 
TIM3064 
Inflammation of 
pancreas 
Aripiprazole UP 0,15  
Lamotrigine UP 0,9  
Olanzapine UP 0,001  
Olanzapine, N-
desmethyl- 
UP Negative  
Paracetamol UP Negative  
Terbutaline UP 0,016  
TIM3068 
Internal bleeding 
and Methadone 
poisoning 
Ambroxol UP Negative  
Bromhexine UP Negative  
Codeine UP 0,11  
Codeine, 
glucuronide- 
UP Negative  
Codeine, 
desmethyl- 
UP Negative  
EDDP UP Negative  
Hydrocodone UP Negative  
Methadone UP 1,9  
Paracetamol UP Negative  
Zopiclone UP 0,064  
Zopiclone, 
desmethyl- 
UP Negative  
TIM3069 Internal bleeding 
Amisulpride UP 0.26  
Losartan UP Negative  
 
 
